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SUMMARY 
The importance of two entero-endocrine hormones, namely GIP and 
GLP-1(7-36)amide, in a range of physiological and pathological states associated with 
hyperphagia, was investigated in rodents. The states investigated consisted of 
pregnancy, lactation, cold acclimation, modified suckling neonatal nutrition, 
insulinoma, streptozotocin diabetes and the genetic diabetic syndromes of oýJQk mice 
and BB rats. In addition, the ontogeny of the two hormones was monitored and the 
importance of the maternal diet to the physiological hyperinsulinaemia of the foetus 
investigated. 
Plasma and/or intestinal IR-GIP were shown to increase in all hyperphagic 
conditions with the exception of insulinorna. In all groups with increased basal plasma 
GIP concentrations, levels were reduced towards control values by an 18 hour fast. In 
the pathological states of insulinoma and streptozotocin, during suckling neonatal 
overnutrition and after two weeks of cold acclimation, the GIP response to acute 
glucose or fat stimulation was ex a`_gerated. However, following weaning the 
overnourished animals had normal plasma and intestinal GIP concentrations, and after 
five weeks cold acclimation the plasma GIP response to acute glucose stimulation was 
normalised. A strong correlation between hyperphagia and increased K cell stimulation 
was therefore concluded. GLP-1(7- 36)amide concentrations were monitored in the 
intestine. A relationship between intestinal GLP-1(7-36)amide concentration and 
hyperphagia was suggested from several of the studies which demonstrated an 
increased intestinal GLP-1(7-36)amide content and/or concentration. However, one of 
the most potent stimulators of GLP-1(7-36)amide concentration was undernutrition 
during the suckling period. Intestinal changes measured at this time persisted following 
weaning. The importance of insulin on normal K cell function was revealed by the 
pathological states of excessive or depleted insulin concentrations (insulinoma and 
streptozotocin diabetes respectively). The importance of a negative feedback 
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mechanism on K cell secretion was revealed in the streptozotocin study. This feedback 
was shown to operate on both postprandial carbohydrate and fat stimulation of the K 
cell. GLP- I (7-36)amide was shown to be a important component of the entero-insular 
axis in lean and ob ob mice, on a relative molar basis GLP-1(7-36)amide being more 
potent than GIP in stimulating insulin secretion. However, an in vitro gut sac 
incubation technique cast doubt on whether this hormone is a true incretin as it was not 
directly stimulated by nutrient absorption. In addition to the effects of GIP and GLP- 
1(7-36)amide on insulin homeostasis, the ontogeny and neonatal studies suggested an 
important role for these hormones in early neonatal development. It is suggested that in 
addition to their actions on the B cells of the pancreas these hormones may well be 
important, directly and through interaction with insulin, in adipose tissue metabolism. 
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Chapter 1 .0 
INTRODUCTION 
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1.1 The Control of Insulin Secretion 
Glucose, under normal physiological circumstances, is the main metabolic fuel 
of the body and is widely regarded as the primary stimulus for insulin secretion from 
the B cells of the pancreas. Using the in-vitro technique of incubating collagenase- 
isolated mouse islets it can be shown that a sigmoidal relationship exists between 
extracellular glucose concentration and insulin secretion (1/2V,,, ax) requiring 8mM 
glucose in the mouse and 6mM in the rat (Ashcroft et al., 1972). Metabolism of 
glucose is a necessary prerequisite for insulin secretion (Ashcroft, 1980). The B cells 
therefore function optimally over the normal physiological plasma glucose 
concentration range of these animals. 
Experiments in rats have demonstrated that normal, moderate, post-prandial 
increases in plasma glucose, from 4.0 to 6.6 mN1 over 20 minutes, are a significant 
stimulus for plasma insulin release. Intravenous infusion of glucose to mimic similar 
increases in plasma glucose have shown however that this physiologically normal 
increase in plasma glucose produces a very weak plasma insulin response (Louis- 
Sylvestre, 1978). It can therefore be concluded that although the B cell is functioning 
within the normal, narrow range of plasma glucose concentrations, this physiological 
rise in plasma glucose is not, on its oven, a potent stimulus for insulin secretion. 
Experiments in man using equal glucose loads orally and intravenously have shown 
similar results, a moderate insulin response to intravenous glucose, even when plasma 
glucose exceeds levels normally seen post-prandially (McIntyre et al., 1964). 
It is recognised that insulin biosynthesis and secretion is regulated by a complex 
interaction of circulating nutrients, neurotransmitters, paracrine agents and gut 
hormones. The role of the various secretagogues alters in importance under different 
physiological situations (Malaisse, 1972: Malaisse, 1988). The secretory response of 
the B cells is therefore modulated by a number of compounds. The B cell must have 
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the ability to not only detect these , ecretago` ues but also to integrate the information 
provided by each one. Evidence suggests that the concentration of glucose in the 
interstitial fluid surrounding islet cells is the principal regulator (or initiator) of insulin 
secretion but that neural and hormonal components of the entero-insular axis play a key 
role in modulating (potentiating) the secretory response to feeding (Morgan et al., 1988; 
Howell, 1990). 
1.2 The Entern-Insular Axis 
The term entero-insular axis was first defined by Unger & Eisentraut in 1969, 
as "the regulatory control exerted by the gastrointestinal tract on the endocrine 
pancreas. " The term encompasses neural sind hormonal actions as well as direct 
substrate stimulation of all cells within the islets of Langerhans. Its physiological 
importance is demonstrated by, the increased tolerance of an oral glucose load (McIntyre 
et al., 1964; Elrick et al., 1964; Louis-Svlvestre, 1978). 
1.2.1 A Historical Perspective of the Entern-Insular Axis 
In 1906, it was first suggested that oral administration of acid extracts of 
porcine proximal small intestine could modify the glycosuria of clinical diabetics 
(Moore et al., 1906). In the late 1920's and early 1930's, LaBarre and colleagues 
demonstrated that an endocrine factor, secreted from the gut, enhanced pancreatic 
insulin secretion. This factor was not the hormone secretin that they were currently 
investigating (LaBarre & Still, 1930). As a result of this work, LaBarre coined the 
term incretin to describe a humoral activity (or activities) of the gut that enhances 
endocrine secretions of the pancreas. Eight years later the idea of a duodenal hormonal 
control on the pancreas was rejected by Loew et a!., (1940). Their experiments with 
fasted dogs denied the existence of a hypoglycaemic factor in the duodenum. 
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The development of radioitnmunoassay (RIA), in the early 1960's (Yalow and 
Berson, 1960), stimulated new interest in the area of gut hormones as plasma insulin 
itself could now be measured. Insulin RIA demonstrated for the first time that orally 
administered glucose evokes a greater insulin response than comparable amounts of 
glucose given by the intravenous route (McIntyre et al., 1964; Elrick et al., 1964). 
This increased insulin response was initially ascribed to enhanced insulin production, 
not decreased insulin turnover (Lickley et al., 1975; McIntyre et al., 1970). 
Comparison of insulin and C-peptide responses to oral and intravenous glucose loads 
however, indicate that the incretin effect is the result of both an increased insulin 
secretion from the B cells and decreased hepatic extraction in normal subjects (Gibby & 
Hales, 1983; Hampton et al., 1986; Shuster et al., 1988). 
1.2.2 The Components of the Entero-Insular Axis 
The enteric signal of the entero-insular axis (EIA) responsible for augmentation 
of insulin release was initially presumed to be one or more gastrointestinal hormones 
(Creutzfeldt et al., 1970; Rehfeld, 1972). The EIA is now acknowledged to consist of 
a neural as well as an endocrine component. This neural component has largely been 
overlooked because endocrine factors are easier to manipulate and quantify. 
Increasingly it has been realised that many gastrointestinal peptides are present in both 
the central nervous system and the gastrointestinal tract and evidence is accumulating 
that many peptides may function as neurotransmitters. This has led to an increased 
interest in the neural arm of the ETA. The relative importance of the two branches of the 
EIA have been assessed in rats by sham feeding and atropine treatment (Berthoud, 
1984). From this study it was estimated that neurally mediated secretion accounted for 
at least 261-, and hormone mediated secretion at least 30%, of the total insulin response 
to a liquid test meal. 
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Pancreatic transplantation studies have produced conflicting results. Some 
studies have shown preservation of the i ncretin effect in pigs despite total loss of the 
neural component (Lindkaer-Jensen et al., 1976; Nauck et al., 1985). Other workers 
have shown complete abolition of the EI. ß (Jakob et al., 1970). The discrepancies may 
possibly be explained by differences in the methodology of the studies regarding the 
site of transplantation and venous drainage. In man, a study on diabetic patients who 
received a combined kidney and pancreas transplant following renal failure, showed a 
qualitatively preserved insulin response to oral glucose (Clarke et al., 1989). 
The importance of hormonal factors under transplantation circumstances may be 
overestimated, possibly due to their compensation for the denervation of the pancreas, 
and may therefore not reflect the normal physiological situation. 
Several candidate incretins have been proposed for the endocrine component of 
the EIA. 
1.2.3 Criteria for Incretin Candidates 
Several gastrointestinal hormones whose actions are endocrine in nature are able 
to stimulate insulin secretion in response to glucose and amino acids (Rushakoff et al., 
1990). In order to be considered an incretin several criteria must be met. These criteria 
are listed in Table 1.1. 
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Table 1.1 Criteria for Potential Incretin Candidates 
The hormone should be produced by gut epithelial cells and released in 
res onse to the ingestion of nutrients, especially glucose. 
Exogenous administration of a pure preparation of the hormone should 
augment insulin release at the concentrations that occur in vivo. 
Inhibition of hormone action by the use of agonists or a blocking antibody 
should reduce insulin secretion in response to oral nutrients. 
Receptors for the hormone should be present on pancreatic B cells. 
Several gut hormones have been studied as possible incretins, the evidence for 
the well established gut hormones has been reviewed by Krevmann & Bloom (1991), 
and Morgan (1992). Of the hormones characterised and found to be capable of 
promoting insulin secretion, the most interesting so far isolated are known by the 
acronyms GIP and GLP- I (7-36)amide. Until the discovery of GLP-1(7-36)amide 
during the early 1980's, GIP was widely regarded as the major endocrine component 
of the EIA. It was thought to be the peptide with the most potent insulin stimulating 
activity secreted in response to glucose (Creutzfeldt & Ebert, 1985). 
Each of these peptides will be considered separately for completeness. 
1.3 GIP 
The original name of this hormone was gastric inhibitory polypeptide as it was 
first characterised in terns of its gastric acid inhibitory properties. As the physiological 
functions of the hormone became established it was renamed, retaining the acronym, as 
glucose dependent insulinotropic polypeptide or glucose dependent insulin releasing 
polypeptide. It is a hormone belonging to the glucagon-secretin family and showing 
similarities of structure with secretin, glucagon and GLP-1(7-36)amide (Schmidt et al., 
1985). 
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1.3.1 A Historical Perspective of GIP 
GIP was discovered by Brown & Pederson in 1970 whilst investigating the 
effect of a porcine cholecystokinin-pancreozymin (CCK) preparation (prepared by 
Jorpes & Mutt, 1961) on gastric acid secretion in dogs. They observed that a 40% pure 
CCK preparation stimulated acid secretion more strongly than a 10% pure CCK 
preparation. From this it was hypothesized that either a stimulator of gastric acid 
secretion had been selectively concentrated, or a second inhibitory hormone was 
present in the 10% preparation which was removed on purification. Brown and co- 
workers had previously published that they could isolate, from a side fraction of the 
CCK purification, a polypeptide which was inhibitory for H+ secretion, pepsin 
secretion and motor activity in the antral and fundic pouches of dogs (Brown et al., 
1969). Sequence determination of the peptide showed an amino acid composition 
distinct from any known `astrointestinal peptide and so it was given the name gastric 
inhibitory polypeptide (Brown et al., 1970). 
With the purification of the peptide components of the 10% CCK preparation it 
became possible to study their effects on immunoreactive-insulin (IRI) levels. Studies 
in man and rats showed that 10% CCK enhanced IRI concentration in blood when 
glucose was simultaneously administered. Highly purified CCK at a corresponding 
dose rate failed to reproduce the insulinotropic effect (Brown et al., 1975). Subsequent 
infusion of porcine GIP with glucose demonstrated that the potentiating effect of 10% 
CCK on IRI rise, during an intravenous glucose infusion, is largely attributable to GIP. 
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1.3.2 Isolation and Purification of GIP 
Porcine GIP, as isolated and purified by Brown and colleagues (1970) was 
shown to be homogeneous by polyacrvlamide gel electrophoresis. It was initially 
characterised as a straight chain peptide of 43 amino acids with a calculated molecular 
weight of 5105 daltons (Brown & Dryburgh, 1971). It has since been demonstrated 
that this sequence determination was wrong by an extra glutamine residue after position 
29. Porcine GIP is now known to consist of 42 amino acid residues (Jörnvall et al., 
1981). 
Subsequently, both the bovine and human forms of GIP have been sequenced. 
Both have been shown to contain 42 amino acids. Species variations in amino acid 
content have been found. Porcine and human GIP differ at residues 18 and 34 (Moody 
et al., 1984; Carlquist, 1987). Porcine and bovine GIP's differ at residue 37 
(Carlquist, 1987). The physiological importance of these species variations remains to 
be established. No natural truncated forms of GIP have been found but a synthetic 
replicate of human GIP1_37 retains the biological activity of natural human GIP 
(Carlquist, 1987). 
1.3.3 Distribution of GIP within the Gastrointestinal Tract 
The cellular location and hence distribution of a hormone is established by 
immunolocalisation methods. GIP was first suggested to be located in the D1 cell of 
the duodenum and jejunum in dogs and man (Polak et al., 1973). Subsequent studies 
in man, pigs and dogs indicated that immunofluorescent GIP cells were ultrastructurally 
indistinguishable from the K cells (Buffa et al., 1975). The K cell was first identified 
histochemically in 1975, by Solcia and co-workers (Solcia et al., 1975). The D1 cell is 
not involved in GIP production. In mammals GIP-secreting K cells are located 
exclusively in the small intestine, being concentrated mainly in the duodenum and upper 
jejunum of man (Bloom & Polak, 1981). In the rat and mouse, however, the K cells 
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are as numerous in the ileum as in the upper small intestine (Solcia et al., 1989). In 
man, GIP release studies in response to glucose stimulation have confirmed the 
proximal small intestine to be the major, but not exclusive site of endogenous GIP 
release. Small quantities of GIP also being released by the distal small intestine 
(Thomas et al., 1977). This compares favourably with the distribution of GIP reported 
by the extraction studies on human tissue by Bloom & Polak (1981). 
1.3.4 The Molecular Forms of Immunoreactive GIP 
Immunoreactive GIP (IR-GIP) as detected by RIA can be separated on a 
molecular weight basis by gel filtration. In man, gel filtration of plasma or serum 
demonstrates three distinct peaks of immunoreactivity; one of high molecular weight 
which elutes in the void volume (V0) of the column, one of a molecular weight of 
approximately 8000 daltons and one of approximately 5000 daltons. The 5000 dalton 
peak corresponds with the elution position of synthetic porcine GIP (Brown et al., 
1979). Gel filtration of gastrointestinal mucosal extracts of porcine and human tissue 
fails to detect the VOIR-GIP but does detect a fourth peak of immunoreactivity eluting 
between the 8000 dalton peak and the void volume. This fourth peak has been 
suggested to be a prohormone of 5000 IR-GIP (Krarup, 1988). 
It has been shown that pre-treatment of serum (boiling or addition of 
concentrated urea) reduces the amount of VOIR-GIP and increases 5000 IR-GIP. On 
the basis of this it has been suggested that VOIR-GIP represents non-specific binding of 
5000 IR-GIP to large molecular weight serum proteins (Krarup, 1988; Jones et al., 
1987). VOIR-GIP may however represent interference of serum proteins alone as 
reactivity of antisera to 5000 IR-GIP is not paralleled by reactivity to VOIR-GIP. GIP 
itself, therefore, may not be involved in this non-specific binding (Krarup, 1988). The 
levels of VOIR-GIP are unaffected by ingestion of test meals, glucose or fat (Krarup et 
al., 1985; Krarup et al., 1987a). VOIR-GIP is a problem in assays as it has been 
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shown to vary substantially between plasma samples (Krarup et al., 1985). Sensitivity 
of the assay is therefore important to reduce the amount of plasma sample in the assay 
and thereby reduce the interference of VOIR-GIP. 
The 8000 IR-GIP is not believed to be a prohormone. Extraction and 
characterisation of this immunoreactive form from the porcine small intestine, has 
shown that it does not contain the complete amino acid sequence of 5000 IR-GIP (Otte 
et al., 1984). Pancreas perfusion studies have shown the 8000 IR-GIP not to be 
insulinotropic in nature (Krarup et al., 1987b). Following oral stimulation, 8000 IR- 
GIP has been reported to increase in one study (Krarup et al., 1987a), while previous 
work by the same group reported a very modest increase in 8000 IR-GIP after a meal 
with inconsistencies in the response detected by different antisera (Krarup et al., 1985). 
A number of different antisera have now been successfully raised against 
porcine GIP (Kuzio et al., 1974; Morgan et al., 1978; Sarson et al., 1980a). 
Unfortunately, whilst all the antisera recognise the three molecular components of 
plasma GIP, they differ considerably in their recognition of the relative amounts of the 
various forms present. All the antisera do, however, recognise the 5000 IR-GIP to be 
the major form. The cross reactivity of human plasma GIP with the various antisera 
available has been reviewed by Jorde et al. (1983). Characteristics of the various 
antisera have been reviewed by Krarup (1988). Differences in cross reactivity of 
porcine antisera with human GIP are due to the different binding regions available in 
the antisera. Most antisera raised against porcine GIP have binding regions between 
residues 15 to 42. Unfortunately this is the region of species variations in amino acid 
sequence. Whilst there is general agreement in the literature about GIP release patterns 
in response to the ingestion of nutrients in man, the absolute values measured differ 
according to the antiserum used (Jorde et (7l., 1983). One group have reported fasting 
values five times lower than those reported by other groups (Sarson et al., 1980a). 
This has led to some confusion in the early work on plasma GIP concentrations in 
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clinical situations. The characteristics of the antiserum raised at Surrey are discussed 
fully in the Methods Chapter. 
1.3.5 Stimuli for GIP Release from the Endocrine K Cell 
For GIP to be considered a peptide of the EIA it is essential that it is released 
into the circulation by the ingestion of secretagogues known to release insulin (Brown, 
1982). Intestinal perfusion studies in rats have shown that GIP is stimulated by 
monosaccharides which are actively transported by the sodium dependent hexose 
pathway (Sykes et al., 1980). The use of phloridzin, a ß-D-glucoside, has confirmed 
that absorption of the sugar is necessary for GIP secretion, not just the presence of the 
sugar in the intestinal lumen (Sykes et al., 1980; Creutzfeldt & Eben, 1977). Studies, 
in man and rats, with sugars which do not meet the structural requirements for active 
transport (an intact pyranose ring, a hydroxyl group at C6 and a hydroxyl group in the 
alpha position on C-, ) fail to stimulate GIP secretion (Sykes et al., 1980; Salminen et 
al., 1982). 
For mice, however, the situation is not so clear. Fructose stimulates GIP 
release in the obese hyperglycaemic mutant j2 mice (Platt et al., 1989). This may 
be explained by the metabolism of fructose (fructolysis) into glucose and lactate within 
the intestinal epithelial cell of these animals, or possibly the sodium-dependent glucose 
transporter is not an exclusive stimulus for GIP secretion in these animals. 
On a calorigenic basis, fat, in the form of triblycerides, is a more potent 11 
stimulator of GIP release than glucose (Jorde et al., 1983; O'Dorisio et a!., 1976; 
Brown et al., 1975, Falko et al., 1975). In contrast free fatty acids, mono and 
diglvicerides have demonstrated \': viable GIP responses (Ross & Shaffer, 1981; 
Williams et a!., 1981). The mechanism 
by which trig lycerides stimulate GIP is 
unknown, but for individual fatty acids it has been shown in mice that an increased 
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chain length and a greater degree of unsaturation enhance GIP release (Kwasow-ski er 
al., 1985). It has been suggested that differences in intracellular metabolism of fat may 
account for the different GIP responses (K%vasowski et al., 1985). As with sugars, 
absorption of fat into the epithelial cell is a necessary prerequisite for GIP release. In 
man, fat malabsorption syndrome due to chronic pancreatitis produces an impaired GIP 
response to an oral fat load. This can be partially restored by the provision of digestive 
pancreatic enzymes with the meal (Ebert & Creutzfeldt, 1980a). Coeliac patients have 
also been shown to have very poor GIP responses to a test meal, even though the 
number of immunofluorescent GIP cells in their small intestine was normal (Creutzfeldt 
et al., 1976). 
Intraduodenal administration, in man, of a mixture of amino acids (namely 
arginine, histidine, isoleucine, lysine and threonine) has been reported to produce a 
marked rise in GIP (Thomas et al., 1978). In contrast, in mice, individual amino acids 
produce modest and transient GIP increases with no difference in potency between the 
amino acids tested (Flatt et al., 1991). Protein is generally absorbed in man as di- and 
tripeptides by a sodium-dependent mechanism (Munck, 1981). Hence, the luminal 
concentration of amino acids produced by Thomis and co-workers in their study was 
far greater than that normally seen. Use of whole proteins (280g fillet steak or 45g of a 
meat extract) has failed to produce a significant elevation in serum GIP levels (Cleator 
& Gourley, 1975). The influence of di- and tripeptides on GIP secretion has yet to be 
investigated. 
On an individual nutrient basis, fats and carbohydrates are the major stimuli for 
GIP secretion. Nutrients however are rarely ingested alone but more usually in a 
complex mixed meal form. The interaction of nutrient stimulatory effects must also be 
considered. It has been suggested that amino acids may modify the GIP secretory 
response to a meal; corn oil-stimulated GIP release in dogs can be progressively 
inhibited by increasing doses of the amino acids alanine or arginine (Williams et al., 
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1981). The physical form of a meal can also influence the postprandial GIP response. 
If volume is standardised then the size of an oral glucose load correlates with 
postprandial plasma GIP levels in man (Hampton et al., 1986). Altering the 
composition of a solid meal (200-1200 kcal/meal), whilst maintaining its size also 
shows a linear relationship with postprandial GIP response (Service et al., 1983). 
Physical form, volume and energy content can all interact to alter gastric emptying 
(Low, 1991) and thus alter the GIP response. 
1.3.6 The Evidence for GTP as a Incretin 
The evidence for an insulinotropic role for GIP is inferred from studies where 
porcine GIP was infused into man and animals, and from the addition of porcine GIP 
to cell cultures. Many workers in the earlier studies failed to provide information on the 
purity of the hormone preparation used and the prevailing glucose concentration. In 
many of these studies the doses of GIP used were supraphysiological and the 
hyperglycaemic environment was in excess of normal postprandial increases (Dupre et 
al., 1973; Elahi et al., 1979). In 1984, the physiological importance of GIP was still in 
doubt (Sarson et al., 1984). More recent studies support the opinion of GIP as an 
insulin secretagogue in humans (Jones et al., 1987; Jones et al., 1989a; Kreymann et 
al., 1987; Rasmussen et al., 1990) and in animals (Flatt et al., 1984). Human synthetic 
GIP has been shown to potentiate insulin secretion at physiological concentrations 
(Kreymann et al., 1987) and to be more potent than porcine GIP (Füessl et al., 1988; 
Füessl et al., 1990). 
Immunoneutralisation of endogenous GIP indicates that for rats about 20% of 
the augmentation seen after the administration of intraduodenal compared with 
intravenous glucose can be attributed to GIP (Eben & Creutzfeldt, 1982; Eben et al., 
1983). When animals are unrestrained and not anaesthetised GIP antiserum greatly 
diminishes the incretin effect (Lauritsen er al., 1981). This discrepancy between the 
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studies is most probably due to differences in their methodology and the contribution in 
the neural component of the EIA. 
1.3.7 Stimulation of Insulin Secretion by GIP 
As mentioned in previous sections of this Chapter, GIP only stimulates insulin 
secretion under mild to moderate hyperglycaemic conditions. In rats, the degree of 
glycaemia required has been assessed as a plasma glucose concentration greater than 
5.5mM (Anderson et al., 1978). Glucose, in modulating the response of the B cells to 
the presence of GIP protects the organism from inappropriate hyperinsulinaemia 
leading to hypoglycaemia. 
For GIP to stimulate the B cells, receptors must be present capable of binding 
GIP. Evaluation of GIP receptors is difficult for two major reasons; the iodination 
methods used for GIP and the methods for isolating islets. Iodination of GIP produces 
a heterogeneous population of iodinated peptides and also changes in the GIP molecule 
resulting from the fact that iodination alters biological activity (Brown et al., 1982). 
However in 1976, it was reported that two hydrophobic amino acid areas in peptides of 
the glucagon family are probably important for receptor binding (Blundell et al., 
1976). In the GIP molecule the sequence regions 6-14, and 19-27, are the 
hydrophobic regions. Modification of Tyrl° by iodination and Met14 and Tyr25 by 
oxidation can therefore be expected to interfere with receptor binding. 
Cell isolation methods currently use collagenase to digest away extraneous 
material. Yet there is evidence that collagenase critically influences the GIP receptor 
(Brown, 1982). Some success has been obtained with hamster transplantable 
insulinoma cells because of the relatively high density of the binding sites. Studies 
have found two types of binding site. a sm; il1 population of high affinity sites, and a 
larger population of low affinity sites (Amiranoff et al., 1985). Binding of GIP to its 
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receptor was found to be specific, saturable and reversible. Glucagon did not alter 
binding of 1251-GIP to pancreatic B cells. 
Glucose is the main physiological stimulator of insulin secretion being 
metabolised by the B cells and so enhancing, adenosine triphosphate (ATP) production 
(reviewed by Hedeskov, 1980; Berggren et al., 1992). Sharp in 1979, reported that 
raising the cyclic adenosine mono-phosphate (cANIP) concentration of the B cell 
enhanced the effects of glucose on insulin stimulation. Other workers have since 
elucidated that GIP increases cAMP accumulation in the islets (Szecowka et al., 1982). 
GIP achieves this by activating adenylate cyclase in the plasma membrane, which is 
responsible for the conversion of ATP to cA IP (Flats & Bailey, 1991). The elevation 
of cAMP by GIP is insufficient to stimulate insulin secretion on its own, simultaneous 
glucose metabolism generating ATP is necessary for increased insulin secretion. In a 
recent study GIP was also suggested to activate another plasma membrane associated 
enzyme, phospholipase A-) (PLA2) (Lardinois ct al., 1990). This has not been studied 
by other workers. 
Early studies suggested that GIP did not stimulate glucagon secretion from the 
A cells of the pancreas at physiological concentrations (Brown et al., 1975; Pederson & 
Brown, 1978; Elahi et al., 1979). More recently GIP has been shown to enhance 
glucagon secretion under basal conditions (Kreymann et al., 1987; Kreymann & 
Bloom, 1991). Glucagon itself is known to stimulate insulin release in the same 
manner as GIP, activating adenylate cyclase and thus promoting an increase in cAMP 
(Schuit & Pipeleers, 1986; Berg gren et al., 1992). Glucagon and GIP therefore have a 
synergistic effect on glucose-induced insulin release (Berggren et al., 1992). 
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1.3.8 Inhibition of GIP Release from the K Cell 
Although there is no generally accepted mechanism, a negative feedback 
situation has been proposed. For a negative feedback role to be considered the 
substance, hormone or metabolite, must be liberated by GIP in response to nutrient 
absorption. It has been shown in man that the magnitude of the GIP response to fat 
absorption can be reduced by a simultaneous intravenous glucose load (Cleator & 
Gourley, 1975; Creutzfeldt et al., 1976; Crocket et al., 1976; Verdonk et al., 1980). A 
negative feedback control of insulin on fat stimulated GIP in normal subjects was first 
suggested by Brown et al. (1975). This feedback was clearly demonstrated by the 
infusion of exogenous insulin simultaneously with an oral fat load. Negative feedback 
on fat-stimulated GIP secretion has also been verified by Creutzfeldt et al. (1980) in 
patients with no endogenous insulin secretion i. e. insulin dependent diabetics. 
Creutzfeldt demonstrated in these patients that glucose-induced GIP secretion was not 
reduced by exogenous insulin infusion. In obese subjects however, exogenous insulin 
fails to reduce fat stimulated IR-GIP release (Creutzfeldt et al., 1978). 
The effects of glycaernia on GIP secretion have also been investigated (Verdonk 
et al., 1980) but it is difficult to isolate the effects of glycaemia from the effects of 
hyperinsulinaemia. Creutzfeldt et al. (1980) reported a slight suppressive effect of 
hyperglycaemia on fat-induced GIP secretion in the absence of insulin. Prolonged 
hyperinsulinaernia, possibly induced by glucose clamping, has been shown to reduce 
the effect of insulin on the K cell (Stockman et al., 1984) possibly by reducing the 
sensitivity of the K cell to insulin. 
The importance of a feedback system is acknowledged in order to protect the 
organism from inappropriate hyperglycaemia. If the K cells respond to the circulating 
insulin concentration, the question remains how the cell can distinguish fat stimulation 
from glucose stimulation. It has been suggested that the K cell does not respond to 
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insulin concentration directly but indirectly to the increased utilisation of glucose 
induced by insulin (Creutzfeldt et al., 1980). 
The importance of feedback on fat simulation of GIP for species that naturally 
consume a low fat diet is debatable and species differences in feedback mechanisms 
may exist. In contrast to the observations in man, a reduced fat attenuation of the GIP 
response to an intraduodenal glucose load has been reported in dogs (Sirinek et al., 
1978). One study has even suggested a role for C-peptide H in a feedback mechanism 
in rats (Dryburgh et al., 1980). To date no other workers have studied this. 
1.3.9 Other Metabolic Effects of GIP 
GIP has been shown to act synergistically with insulin to augment insulin 
dependent inhibition of liver glycogenolysis in both rodents and man (Hartmann et al., 
1986; Elati et al., 1986). In addition to its interactions with insulin, GIP also 
demonstrates independent direct physiological actions on adipose tissue metabolism. 
GIP possesses a strong antilipolytic action on glucagon stimulated lipolysis by 
selectively and competitively blocking the activation of adenylate cyclase by glucagon 
(Ebert & Brown, 1976). Activation of adipose tissue lipoprotein lipase in 3T3-LI cells, 
a mouse fibroblast cell line which resembles an adipocyte, by GIP (Eckel et al., 1978) 
is potentially an important mechanism for the clearance of triglycerides from 
chylomicrons after feeding. GIP has also been shown to stimulate fatty acid synthesis 
in certain deposits of rat adipose tissue (Oben et al., 1991c). All of these actions 
complement the incretin role of GIP. 
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1.4 GIP-1(7-36)amide 
Glucagon-like peptide-1 (GLP-1) a hormone from the same family as GIP is 
located in the small and large intestine. Two truncated forms of the hormone have been 
identified, GLP-1(7-37) and GLP-1(7-36)amide. Both truncated forms are equipotent 
insulinotropic hormones in the perfused rat pancreas (Weir et al., 1989; Suzuki et al., 
1989). Additionally it has been suggested that GLP-1 and GLP-2 (see Figure 1.1 and 
Section 1.4.2 and 1.4.3) may be neurotransmitters as both have been found to activate 
rat brain adenylate cyclase (Hoosein & Gurd, 1984). However, it is their potential 
involvement as incretins of the EIA which is reported here. 
1.4.1 A Historical Perspective of Gut Glucagon-Like Peptides 
In 1961, Unger and coworkers demonstrated that material present in extracts of 
canine and human intestine could cross react with antibodies directed towards the N 
terminal/central regions of the pancreatic glucagon molecule. This material failed to 
bind to antibodies directed towards the C terminal part of pancreatic glucagon (Unger et 
al., 1961; Moody, 1980). The term glucagon-like immunoreactivity (GLI) was 
proposed by Unger, to distinguish this material from pancreatic glucagon. Gut 
glucagon-like immunoreactivity was subsequently shown to be present in extracts of 
intestinal tissue from rats, dogs and humans (Unger, 1961; Unger, 1966; Samols et al., 
1966; Unger, 1968). 
Gut glucagon-like immunoreactivity was shown to be heterogeneous in nature 
(Samols et al., 1966). A classification system was developed on the basis of 
approximate molecular weight and reactivity of the hormone towards various glucagon 
antisera. It is now known that pancreatic glucagon and intestinal glucagon are products 
of tissue specific processing of the proglucagon hormone. A simpler nomenclature 
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system, based on proglucagon residues, has therefore been established (reviewed by 
Conlon, 1988). 
1.4.2 Isolation of GLP-1 (Prolucagon 72-108) 
Molecular biological advances during the 1980's, with the production of 
complementary DNA (cDNA) to messenger RNA (mRNA) for proglucagon, enabled 
the elucidation of the complete amino acid sequence of mammalian proglucagon. Lund 
and co-workers were the first to report that the preproglucagon gene from angler fish as 
well as encoding glucagon encodes another peptide with a high degree of homology 
with glucagon, glucagon related COON peptide (Lund et al., 1982). Their findings 
were confirmed by Bell and co-workers using a cDNA raised against hamster mRNA, 
they found not one but two peptides with an amino acid structure similar to glucagon, 
glucagon-like peptide-1 and glucagon-like peptide-2 (Bell et al., 1983b). It was later 
determined that preproglucagon mRNA in the pancreas, ileum and colon are identical 
and that identical transcription start sites are used in all three tissues (Mojsov et al., 
1986; Conlon, 1988). The diversity of peptides found in the gut and pancreas is 
therefore concluded to be due to tissue-specific post-translational processing (George et 
al., 1985; Mojsov et al., 1986; Orskov et al., 1986). Tissue specific processing of 
preproglucagon has been reviewed by Conlon (1988) and Drucker (1990). It is 
illustrated in Figure 2. Not all researchers in this area recognise such distinct tissue 
specific processing. Mojsov and coworkers report that the pancreas does contain some 
free GLP-1 (in the forms GLP-1(7-37) and GLP-1(7-36)amide) though the 
concentrations are far lower than those seen in the gut (M1ojsov et al., 1986). 
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Figure 1.1 Tissue Specific Processing of Preproglucagon in the Pancreas and 
Gastrointestinal Tract 
Preproglucagon 
A cell 
PANCREAS 
1_` 
Proglucagon 
L cell 
INTESTINE 
NH2 
Glicentin related 
pancreatic polypeptide 
Glucagon 
Hexapeptide 6` 
7', 
C terminal residue 
Modified from Conlon (1988). 
108 
Glicentin 33 
Oxyntomodulin 
69 
GLP-1 78 10 
GLP-1 (7-37) 
108 
126 
GLP-2 
158 
The co-existence of glicentin, GLP-1 and GLP-2 immunoreactivity within a 
single enteroglucagon cell secretory granule was reported by Vamdell et al. (1985). 
The L cell of the intestinal mucosa was reported to be the cellular localisation of 
enteroglucagon in 1976, (Moody et al., 1976). This was subsequently confirmed in 
the rat, dog and cat by Larsson & Moody (19S 1). 
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1.4.3 Isolation and Sequence Determination of GLP-1(7-36)amide 
GLP-1 (proglucagon 72-108) is a peptide of 37 amino acid residues. It is 
cleaved at residue 6, a single basic residue, to produce GLP-1(7-37). The C terminal 
glycine residue would be expected to give up its amino grouping to amidate the terminal 
arginine residue (Bradbury et al., 1982) producing GLP-1(7-36)amide. The truncated 
form of the peptide GLP-1(7-36)amide has been shown to be the major molecular form 
in intestinal tissue from rats, pigs and humans (Kreymann et al., 1987; Kreymann et 
al., 1988; Orskov et al., 1989). Perfused pancreas experiments in rats have enabled 
identification of the important amino acid residues for insulinotropic activity. 
Amidation of the C terminal residue had no significant effect on activity of the hormone 
in this capacity (Suzuki et al., 1989). Histidine at position 7 as a free terminal amino 
acid is important for insulinotropic activity (Suzuki et al., 1989). 
GLP-1 (prohormone 72-108) is an important peptide being found in all 
proglucagons isolated so far. The amino acid sequence is highly conserved across 
species being identical in rat (Heinrich et a!., 1984) hamster (Bell et al., 1983b) bovine 
(Lopez et a!., 1983) and human (Bell et a!., 1983a) preproglucagons. GLP-1(7- 
36)amide and GLP-1(7-37) also show a strong degree of homology at the amino 
terminal end of the molecule to glucagon. Fourteen out of twenty-nine comparable 
residues are the same (Varndell et al., 1985). 
The importance of GLP-2 is as yet unknown. No physiological role has yet 
been found and it is absent is some non-mammalian preproglucagons (Lund et al., 
1982). 
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1.4.4 Distribution of CGLP-1(7-36)amide within the Gastrointestinal Tract 
As mentioned previously in this Chapter, gut glucagon-like immunoreactivit - is 
located in the L cell of the intestinal mucosa. Extraction of intestines and determination 
of the distribution of a hormone is dependent on accurate identification of the intestinal 
regions. Within the small intestine, the distinction between duodenum, jejunum and 
ileum is important to make, yet few researchers accurately report where they determined 
the different regions to be. Extraction of intestines and determination of the distribution 
of GLP-1(7-36)amide in rats reveals that the highest concentrations are located in the 
terminal ileum and colon in both normal and diabetic animals (Kreymann et al., 1988). 
This report compares well with the distribution of but glucagon-like immunoreactivity 
reported by earlier workers. Low concentrations of glucagon-like immunoreactivity 
have been found in the duodenum and jejunum, with tissue concentrations rising 
progressively to a maximum in the lower ileum and colon in humans (Bloom & Polak, 
1978), primates (Bryant & Bloom, 1979), pigs (Holst et al., 1987) and the rat (Perez- 
Castillo & Blazques, 1980). In contrast, oxyntornodulin (pro(lucagon 33-69) another 
product of the L cell, has been shown to be more widely distributed throughout the 
intestine. Significant amounts of oxyntomodulin were found in the jejunum and 
caecum as well as the ileum and colon (Kervran et al., 1987). This discrepancy is 
almost certainly due to differences in identification and reporting of the areas of the 
small intestine. 
1.4.5 The Molecular Forms of lmmunoreactive GLP-1 (Prohormone 72-108) 
Gel filtration of porcine plasma for basal IR-GLP-1(7-36)amide, and 
postprandial IR-GLP-1(7- 36)amide, demonstrates that most of the IR-GLP-1 
measurable in plasma in the basal state is inactive. This is due to cross reaction of the 
antiserum with the inactive bound pancreatic form, pancreatic C terminal residue. 
Nutrient stimulation causes in increase in active, intestinal GLP-1(7-36)amide with a 
corresponding decrease in the pancreatic form (Orskov et al., 1987a). As a 
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consequence of this cross-reactivity of the antiserum, the apparent changes in 
circulating levels of IR-GLP(7-36)amide are small (Q rskov et al., 1987a). This has 
created problems with assay sensitivity and specificity. Very few research groups have 
successfully raised antisera to GLP- l (7-36)amide. Those that have, have found that 
their antisera cross-react with the parent GLP-1 molecule (prohormone 72-108) 
(Kreymann et al., 1987; George et al., 1985; Uttenthal et al., 1985; Orskov et al., 
1987a). Some antisera also cross-react with proglucagon C terminal residue peptide 
released from the pancreas (Q rskov et al., 1987b). 
1.4.6 Stimuli for GLP-l (7-36)amide Release from the Entero-Endocrine 
L-Cell 
GLP-1(7-36)amide immunoreactivity has been shown to be released into the 
circulation following a mixed meal or in response to an oral glucose load (Kreymann et 
al., 1987). Peak IR-GLP-1(7-36)amide response occurred 30 minutes after the 
administration of the test meal. 
The mechanism of GLP-1(7-36)amide secretion from the L cell has only 
recently received attention. One group of workers have published results from ileal 
loop perfusion studies in dogs (Shima et al., 1990). They investigated sugar 
stimulation of GLP-1(7-36)amide secretion and concluded that only actively absorbed 
sugars stimulate GLP-1(7-36)amide release. This confirmed previous observations of 
other workers that D-glucose is a stimulus for GLP-1 secretion in porcine ileum 
(Orskov et al., 1986) and in man (Krevmann et al., 1987). The study by Shima and 
co-workers was interesting as they reported that absorption and subsequent metabolism 
of the sugar was not responsible for GLP-1(7-36)amide release. The sugar had to meet 
specific stearic requirements to stimulate GLP-1(7-36)amide release. Disaccharides 
also stimulated GLP-1(7-36)amide release, but interestingly their effects appeared to be 
direct acting and not via their hydrolysis products. 
Page 2 
These results require confirmation but initially this seems a strange situation of 
hormone release in response to a nutrient stimulus which is still to all extents external to 
the body. Activation of a hormonal pathway for the stimulation of insulin secretion 
under these circumstances could well be dangerous. 
1.4.7 The Evidence for GLP- 1 (7-36)amide as an Incretin 
Initial investigators examining the incretin effect used full-length GLP-1 
(proglucagon 72-108). This was shown to have only a weak stimulatory activity upon 
insulin release in isolated islets (Schmidt et al., 1985), and in &ob mice (Bailey & 
Flatt, 1987). Truncated forms of GLP-1 (both GLP-1(7-37) and GLP-1(7-36)amide) 
are considered physiologically important incretins based on evidence from cultured islet 
experiments (Drucker et al., 1987; Hatt et al., 1990) and pancreas perfusion studies 
(Shima et al., 1988). Infusion studies in humans at physiological post-prandial 
concentrations have shown GLP-1(7-36)amide to be the most potent enhancer of 
insulin secretion yet identified (Kreymann et al., 1987). 
Pancreas perfusion studies have demonstrated that truncated GLP-1 shows 
glucose dependency for its action on insulin secretion (Shima et al., 1988). 
1.4.8 Stimulation of Insulin Secretion by GLP-1(7-36)amide 
As with the studies looking at B cell receptors for GIP, insulinoma cells have 
been utilised to investigate potential receptors and their characteristics for truncated 
GLP-1. Specific receptors have been found on rat insulinoma cells. Binding of 
GLP-1(7-36)amide has been found to be saturable and time dependent, (Orskov & 
Nielsen, 1988; Göke & Conlon, 1988). These receptors were highly specific being 
completely separate from ('lucagon receptors. Glucagon and GIP failed to influence the 
binding of GLP-1(7-36)amide. Receptors have also been reported in rat brain and lung 
membranes (Kanse et al., 1988). 
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Binding of GLP-1(7-36)amide to its receptor has been shown to increase cAMP 
concentration in a dose dependent manner via its activation of adenylate cyclase (Göke 
& Conlon, 1988; Göke et al., 1989; Drucker et al., 1987). GLP-1(7-36)amide 
therefore stimulates insulin in the same manner as GIP and glucagon. Unlike GIP, 
GLP-1(7-36)amide suppresses glucagon secretion (Kreymann et al., 1987; Fridolf et 
al., 1990a; Fridolf et al., 1990b; Yamato et al., 1990). This offers another method by 
which truncated GLP-1 can control postprandial glucose levels. Full length GLP-1 can 
bind to the truncated GLP-1 receptor but it is 200 times less potent than its truncated 
form (Göke & Conlon, 1988). 
1.4.9 Other Metabolic Effects of GLP-] (7-36)amide 
GLP-1(7-36)amide has been shown to directly stimulate fatty acid incorporation 
and fatty acid synthesis in adipose tissue (Oben et a!., 1991c). 
1.5 Comparison of GIP and GLP-1(7- 36)amide 
GIP and GLP-1(7-36)amide share 13 amino acid residues in common. They 
each show glucose dependency for their incretin effect and both stimulate insulin 
release by the adenylate cy lase system and cA"\1P synthesis. GLP-1(7-36)amide is on 
a molar basis four times as potent as GIP at stimulating insulin release, but it's 
circulating levels are much lower both in the basal and postprandial states (Kreymann et 
al., 1987). Both hormones also have direct metabolic actions on adipose tissue. 
GIP and GLP-1(7- 36)amide can interact with each other in a synergistic manner 
to stimulate cA: \1P (Fehmann et al., 1990a). GIP and GLP-1(7-36)amide can also 
interact with CCK-ti, one of a variety of truncated forms of cholecvstokinin (CCK) 
(Fehmann et al., 1990b; Zawalich, 1988). CCK-8 is a neural component of the EIA; it 
has the ability to augment insulin secretion in response to amino acid stimulation. 
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CCK-8 stimulates insulin secretion by means of an alternative secondary messenger 
system to that used by GIP and GLP-1(7-36)amide. CCK interacts with phospholipase 
C in the plasma membrane with the generation of diacylglycerol and inositol (1,4,5) 
triphosphate (Flatt & Bailey, 1991; Berggren et al., 1992). 
1.6 The Role of the ETA in Disease States 
Manipulation of the habitual diet has been demonstrated to modify basal and 
acute nutrient stimulated GIP secretion in rats (Hampton et al., 1983) and in humans 
(Ebert et al., 1979). GLP-1(7-36)amide levels have been reported to be increased in 
the large intestine in hyperphagic, streptozotocin diabetic rats (Kreymann et al., 1988). 
Circulating gut hormone levels are therefore of interest in disease states which 
are known to have a strong dietarN, link. The vast majority of studies have concentrated 
on IR-GIP levels due to it's earlier discovery. Investigations into GLP-1(7-36)amide 
levels are complicated by the lower circulating concentration of this hormone and it's 
fragility making assay sensitivity a problem. Gut glucagon-like immunoreactivity, as 
measured with N-terminal directed glucagon antisera, has been shown to be 
significantly elevated in coeliac disease (Bloom & Polak, 1981) and in obese patients 
following jejuno-ileal by-pass surgery (Sarson et al., 1980b). GLP-1(7-36)amide 
levels have been shown to be elevated in patients with postgastrectomy dumping 
syndrome (Kreymann et al., 1987). 
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1.6.1 Clinical Studies 
As yet no pathological condition has been found which is causally related to 
hyper- or hyposecretion of GIP. Changes in plasma circulating IR-GIP concentrations 
have however been described for many disease states (Sarson & Bloom, 1981). Table 
1.2, provides an outline of clinical studies concerned with changes in plasma GIP 
levels in insulin-dependent diabetes mellitus (IDDM), non-insulin dependent diabetes 
mellitus (NIDDM) and obesity. These three diseases have attracted considerable 
attention in this area, a correlation between GIP concentrations and insulin levels has so 
far not been proven. Interpretation of the results of the clinical studies is not aided by: 
the wide variation in study protocol used, the number of subjects, the provision of 
adequate controls, the nature of the provocative test, consideration of the influence of 
previous dietary habits and medicinal treatment of subjects. In addition to protocol 
differences, assays were performed using different RIA methods. The cross-reactivity 
of the porcine antisera to human GIP will also have influenced the results. Recent 
studies have attempted to control the possible variations in individual response by 
obtaining homogeneous subject groups and standardising the method used. 
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Table 1.2a Literature Review of Clinical Studies Investigating the Potential 
Involvement of GIP in Insulin Dependent Diabetes Mellitus 
uthor Year Nature of study 
Willms et al. 1978 Increased basal GIP. 
Reynolds et al. 1979 11 Patients with IDDM treated with insulin. Last insulin 
dose 4 hours before test. Basal GIP levels normal. Reduced 
GIP response to a lg/kg body weight glucose load. 
Creutzfeldt et al. 1980 0 patients insulin-treated for ?5 years. Body weight 
within 10% ideal. Insulin dose withheld night before test 
and CHO content of meal reduced by 50%. Increased basal 
IP levels and increased response to glucose load (100g 
glucose equivalent). Test repeated with simultaneous insulin 
infusion; again similar GIP response. 
Fat tolerance test (150ml suspension corn oil) with ii, 
glucose infusion gave similar increased GIP response. 
Krarup et al. 1983 15 patients. GIP response to standard meal (490 Calories; 
60% CHO, 26% fat, 14% protein) measured 7 days, 14 
lays and 3 months after diagnosis. Basal GIP levels normal 
n all 3 occasions and GIP response to the meal was 
reduced at all 3 time points. 
Service et al. 1984 5 patients. Normal basal GIP levels and normal response to 
a standard meal (6 Cal/kg ideal body weight, 50% CHO, 
30% fat, 201-1% protein). 
Krarup et al. 1985 15 subjects. GIP response to standard meal examined 7 
days, 14 days and 3,6,9,12 and 18 months after 
diagnosis. Standard meal same as in previous study. GIP 
response to the meal reduced on the first 4 occasions. GIP 
response subsequently normalised as B cell function 
eclined. 9 months after diagnosis no significant difference 
was found from GIP response of normal subjects. 
Intensive insulin treatment at the point of diagnosis caused a 
aster normalisation of GIP levels. 
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Table 1.2b Literature Review of Clinical Studies Investigating the Potential 
Involvement of GIP in Non-Insulin Dependent Diabetes Mellitus 
uthor Year Nature of study 
Brown et al. 1975 patients within 20% ideal body weight, treated by diet 
lone. Some previously treated by oral hypoglycaemic 
gents, discontinued 3 days before test. Basal GIP levels 
normal. In response to an oral glucose tolerance (50g) the 
GIP response was exaggerated. In response to a 66g 
'glyceride load incremental GIP response was greater but 
he integrated response was similar to the controls. 
oss et al. 1977 20 patients non obese, treated by diet alone (previously 
treated by use of oral hypoglycaemic agents stopped 1 week 
before test). Basal GIP levels normal, with an exaggerated 
GIP response to a 50g glucose load. 
Ebert et al. 1980b 141 patients - GIP response to a test meal was normal for 
18%%%, diminished for 27% and exaggerated for 55% of 
patients. GIP response to an oral glucose load (100g) was 
normal for 12%, diminished for 34% and exaggerated for 
54% of patients. 
Levitt et al. 1980 12 patients -6 with clinical evidence of autonomic 
neuropathy (AN) treated by diet and oral hypoglycaemic 
agents. Basal GIP levels normal. In response to a mixed 
heal (36.4g fat, 72g CHO and 43g protein) those patients 
without AN gave a normal GIP response. Patients with AN 
showed a significantly reduced GIP response at all time 
points. 
Salera et al 1982 14 patients (non obese) 15 patients (obese). Non obese 
patients had normal basal and acute stimulated GIP levels in 
response to 75g of glucose. Obese patients had normal 
basal GIP levels with increased response to 75g glucose. 
Elahi et al. 1984 10 patients, none had received insulin or oral hypoglycaemic 
agents. Hyperglycaemic clamp procedure used. Basal GIP 
levels markedly elevated. Glucose tolerance test (40g/m2 
body surface) incremental GIP response smaller than with 
control patients. 
Service et al. 1984 > normal weight and 5 obese patients. Normal basal GIP 
levels. Reduced GIP response to standard meal (50% CI lO, 
)0% fat and 20% protein). Reduced mean GIP response 
was due entirely to a reduced response in obese patients. 
Mazzaferri et al. 1985 19 Caucasian diabetics (lean and obese), 11 American Indian 
diabetics (obese). High fasting GIP levels and exaggerated 
GIP responses to nutrients seen. American indians had 
"onsistently greater GIP responses to tests. 
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Table 1.2b 
continued 
sei et al. 1986 patients, poorly controlled. Basal GIP levels normal. In 
response to a test breakfast (500kCal), a significantly 
increased GIP level at 20 minutes post prandially. 
guck et al. 196 14 patients, lean and moderately obese. Oral 
ypoglycaemics (taken by 5 patients) stopped 3 days before 
est. Oral glucose load (50g glucose + low molecular weih 
ligomers) and isoglycaemic iv glucose infusion performed. 
Mean basal GIP values and GIP responses to oral glucose 
were normal. The range of GIP responses was however 
wider in patients than controls. 
ones et al. 1986a 8 newly presented, previously untreated patients. Normal 
basal GIP levels. Glucose tolerance (75g), significantly 
elevated plasma GIP levels seen at 30 - 90 minutes. Meal 
olerance test (500kCal; 20% protein, 20% fat and 60% 
CHO) GIP response significantly higher in diabetic patients 
it several time points. This effect was independent of 
besitz'. 
roop 1989 27 patients (9 lean, 18 obese). Treated by diet alone. 
Liquid test meal given (625kCal; 85g CHO, 27g protein and 
1g fat). Basal GIP levels normal in diabetic patients. Lean 
diabetic subjects showed a reduced GIP response to the test 
heal. Obese diabetic subjects showed a similar GIP 
response to obese non-diabetic controls. 
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Table 1.2c Literature Review of Clinical Studies Investi ating the Potential 
Involvement of GIP in Obesity 
Author Year Nature of study 
reutzfeldt et al. 1978 125 obese subjects divided into 2 groups on the basis of 
heir glucose tolerance. 3 tests were performed on 3 groups 
f subjects; test meal (152g CHO, 30g fat and 36g protein), 
ral glucose load (100g) and oral triglyceride (150m1 corn 
il suspension). Basal fasting GIP levels significantly 
levated in obese patients. Obese patients gave a greater 
IP response to the mixed meal and oral fat. In response to 
ral glucose the GIP levels were normal in obese patients. 
illms et al. 1978 147 subjects (> 130% ideal body weight). Small groups of 
patients were subjected to an oral glucose load (100g) or a 
test meal (1031 Cal; 18g glucose, 14g maltose, 12g 
altotriose, 52g lactose, 56g oligosaccharides, 100ml cream 
nd 36g milk protein) or an oral triglyceride load (150m1 
orn oil suspension). Tests were administered before and 
after food restriction and in some cases starvation. 
Patients demonstrated increased basal levels and exaggerated 
GIP responses. These responses decreased significantly 
following food restriction and/or starvation. 
Lauritsen et al. 1980 12 morbidly obese patients given a 50g oral glucose load. 
GIP release was normal. 
Service et al. 1984 10 obese subjects, otherwise healthy. Solid/liquid meal (6 
a1/kg ideal body weight. ) given. No significant differences 
in post prandial GIP response seen. 
Jones et al. 1989b 17 obese subjects. Subjects were given an oral glucose 
olerance (75g) or a meal tolerance (500kCal; 20% protein, 
20% fat and 60% CHO) and an iv glucose test (75g). All 
subjects received at least 2 of the 3 tests. 
Fasting GIP levels were normal. Post prandial GIP levels 
were significantly greater in the obese subjects. Following a 
period of dietary restriction and weight loss there was no 
change in GIP levels. 
The awareness of the need to carefully control the study protocol has 
strengthened the evidence that a disordered entero-insular axis may be involved in the 
promotion of these three disease states. In insulin dependent diabetes a disordered 
entero-insular axis appears to be present in the short time between diagnosis and 
establishment of insulin therapy (Krarup et al., 1985). For non-insulin dependent 
diabetes and obesity, two disease states that often overlap, the abnormalities of the 
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entero-insular axis appear to be more fundamental. Weight loss in obese patients failed 
to normalise IR-GIP response to a test meal (Jones et al., 1989b). Abnormalities in IR- 
GIP secretion appear to be especially marked in obese individuals and obese non- 
insulin dependent diabetics. A strong association between GIP and insulin secretion 
was reported in obese American Indians as compared to the Caucasian population of 
America (Mazzaferri et al., 1985). Genetic components of obesity therefore influence 
the disorder of the entero-insular axis in both man and animals. GIP may therefore 
contribute to the apparent hyperinsulinaemia of obesity and non-insulin dependent 
diabetes under certain conditions. 
If a disordered entero-insular axis is involved in these disease states, GIP is 
only one incretin of the endocrine arm of this regulatory control mechanism and so the 
specific role of GIP in disease states may be difficult to isolate from concomitant 
changes in other endocrine, paracrine or neural factors. 
To date only two studies have been published investigating GLP-1(7-36)amide 
in non-insulin dependent diabetic patients (Hirota et al., 1990; Orskov et al., 1991). 
Both studies found a significantly exaggerated IR-GLP-1(7-36)amide response to a 75g 
glucose load without the simultaneous suppression of the pancreatic C-terminal 
polypeptide which contains the GLP-1 sequence. Further work is required to confirm 
these results. 
1.6.2 Animal Studies 
The difference in meal size and composition and the influence of preceding diet 
on GIP response are factors which can be controlled far easier in animal studies. The 
entero-insular axis has been clearly demonstrated in rats and shown to respond to 
nutrient stimulation in a similar manner to the response seen in man (Kikuoka et a!., 
1987). Rodents can he genetically and chemically m: unipulated to demonstrate 
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obesity/diabetes syndromes which are comparable with human disease states. Several 
of these syndromes and their influence on the EIA are reviewed by Bailey & Flatt (1988 
and 1991) and Bone (1991). 
Animals with hypoinsulinaemic diabetes fall into two categories; those which 
develop diabetes spontaneously and those for whom the diabetes is chemically induced. 
The BioBreeding (BB) rat develops diabetes spontaneously as a result of massive B cell 
destruction by an autoimmune process. Evidence from studies indicates that specific 
dietary constituents may be important for the expression of diabetes in susceptible BB 
rats (Danemann et al., 1986; Scott, 1988). Investigations into the EIA and more 
specifically the GIP levels in these rats has not been undertaken. In contrast, induction 
of hypoinsulinaemia diabetes by administration of a large dose of streptozotocin has 
been shown to be associated with elevated plasma GIP in the fed state. An exaggerated 
GIP response to acute nutrient stimulation has also been reported in animals treated 
with streptozotocin (Bailey et al., 1986b). 
Obesity-diabetes syndromes in animals have attracted more attention in this area 
of research. One extensively studied animal model is the genetically obese 
hyperglycaemic ob ob) mouse. The origins and characteristics of this animal are 
reported by Bailey et al. (1982). The model compares well with aspects of NIDDM in 
man. This is a spontaneously occurring syndrome with expression of the syndrome 
being influenced by environmental factors. Animals homozygous for the ob gene 
exhibit hyperphagia and severe obesity. Metabolically these animals are severely 
hyperinsulinaemic, hyperglycaemic and demonstrate insulin resistance (Bailey & Flatt, 
1986). There is also strong evidence for a disordered entero-insular axis involvement 
in this syndrome as these animals display intestinal K cell hyperplasia and 
correspondingly elevated plasma GIP levels (Flats et al., 1983; Flatt et al., 1984). The 
disorder of the entero-insular axis is likely to be an important contributor to the 
hyperinsulinaemia of this syndrome (Bailey & Flatt, 1988). Plasma IR-GIP levels are 
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particularly sensitive to dietary factors in these animals (Flats & Bailey, 1984; 
Kwasowski et al., 1985), and age related changes in plasma GIP parallel changes in 
plasma insulin (Flats et al., 1984). GIP levels are not responding purely to the 
hyperphagia in these animals as restricted feeding does not entirely normalise plasma 
GIP levels (Flatt et al., 1983). 
The diabetes-obese (dydb) mice, another spontaneous syndrome, also exhibit 
entero-endocrine cell hyperplasia, with increased intestinal GIP concentrations (Flatt et 
al., 1983; Bailey et al., 1986a). In contrast, the fatty Zucker (fVfa) rat, another 
spontaneous syndrome, has no change in GIP levels and only a moderate increase in 
insulin concentration (Morgan, 1979; Chan et al., 1984). However these animals are 
more sensitive to the actions of GIP. These animals show an increased GIP stimulated 
fatty acid incorporation into white adipose tissue (Beck & Max, 1986) and an increased 
sensitivity to the insulinotropic action of GIP (Chan et al., 1984). 
Clinical and animal work, while not being conclusive, does suggest the 
possibility of a relationship between insulin and GIP levels and therefore a role for the 
EIA in the development or promotion of certain disease states. Investigations into a 
role for the EIA in disease has largely concentrated on the incretin effect. Both GIP and 
GLP-1(7-36)amide however, are directly biologically active in white adipose tissue 
metabolism. A contribution to obesity-diabetes syndromes via this pathway is therefore 
a strong possibility which requires further attention. 
1.7 Rationale of Current Investigations 
The aims of this thesis are to increase the breadth and depth of knowledge of the 
roles of two potent incretin hormones, GIP and GLP-1(7-36)amide, in both 
physiological and pathological states. All the states investigated were strongly 
associated with hyperphagia. The biochemical nature of this hyperphagia was not 
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questioned, animals were deemed to be hyperphagic when a sustained, significant 
increase in food consumption was observed. All investigations were performed in 
rodents in order to control the habitual diet and thereby avoid any difficulties in 
interpretation of the results due to dietary influences. The pathological conditions 
investigated if not spontaneous were induced by accepted, well documented methods. 
Finally because GLP-1(7-36)amide has only relatively recently been identified, 
little is known of its importance in rats. Most of the evidence accumulated so far has 
been obtained from human and porcine studies. Little is known about the stimulus- 
secretion coupling of the L cell. Evidence that glucose stimulates its secretion has been 
obtained in humans and pigs by acute challenge experiments. To date only one study in 
dogs has reported stimulation of GLP-1(7-36)amide release by perfusion studies. An 
in-vitro stimulation procedure was utilised in rats to elucidate the nutrient requirements 
for GLP- I (7-36)amide release. 
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Chapter 2.0 
METHODS 
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The following provides an account of the general procedures employed in this 
thesis. Actual experimental protocol is included, where necessary, in the relevant 
experimental Chapters. 
2.1 Animals and their Housing Conditions 
All albino, Wistar rats used were obtained from the Rodent Breeding Unit, 
University of Surrey. Transfer of animals, from the breeding unit to the experimental 
unit, was performed at least 24 hours prior to caging the animals for the individual 
experiments. NEDH rats for the insulinoma study were obtained from the experimental 
unit directly. Obese hyperglycaemic Uý mice and lean homozygous (J±) litter 
mates were kindly donated by Dr C. J. Bailey, Dept. of Pharmaceutical Sciences, Aston 
University, Birmingham. 
Animals were generally caged under similar experimental conditions (4-6 per 
cage), with sawdust bedding. Pregnant and lactating animals were caged individually 
with a sawdust and straw bedding. A standard 12hr photoperiod (0700-1900hr) at 
22±2°C and 50% humidity was maintained. Food in the form of LAD1 (Biosure, 
Cambridge) and tap water were provided ad libitwun. The composition of the diet was: 
48% carbohydrate; 21.5% protein; 3.5% fat; 2.7% fibre; metabolisable energy 
14.2MJ/kg. Where necessary food was withdrawn 18 hours before a provocative test 
was performed. 
2.2 Administration of the Test Substances 
Oral tolerances were assessed by straight tipped gavage administration of test 
substances intragastrically. Animals were removed from the cage immediately prior to 
dosing and held securely throughout the procedure which was performed as quickly as 
possible to cause minimum stress to the animal. The oral glucose load consisted of 
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3.2g D-glucose/kg body weight (51.2kJ/kg body weight) (BDH Chemicals, Poole). 
The glucose was solubilised (40%w/v) in RO (reverse osmosis purified) water. 
The oral fat load consisted of 1.38g corn oil/kg body weight (51.2kJ/kg body 
weight) comprising on average 30% 18: 1 and 50% 18: 2 fatty acids (Paul & Southgate, 
1976). The fat was administered in an emulsion with RO water. The emulsion was 
produced by 30 seconds sonication with an ultrasonic generator (Dawe Instruments 
Ltd. ). 
Intraperitoneal glucose tolerance tests were also performed in the insulinoma 
and streptozotocin studies. In all studies the concentration and total volume of the 
solution was the same as for the intragastric tests (8ml/kg body weight). 
An insulin sensitivity test was performed, following an 18 hour fast, in the cold 
acclimation study and streptozotocin study. In all studies, porcine insulin (Actrapid- 
MC, Novo Industria, Copenhagen) was used at a dose of (lU/2ml) per kg body 
weight. 
2.3 Standard Procedures 
In all studies, food intake and body weight measurements were made on a daily 
or an alternate day basis as appropriate. Food consumption was taken as the difference 
between the amount of food provided and that left in the hopper 24 hours later. All 
animals were examined periodically for any signs of ill health. 
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2.4 Collection of Samples 
2.4.1 Plasma 
Blood samples were taken regularly, from control and test animals, from the cut 
tail tip. Animals were restrained during the procedure and every thought was given to 
avoid undue stress to the animal. 
All blood samples were collected on ice in heparinised (sodium heparin 
5001U/ml, BDH Chemicals Ltd, Poole) 250µl polyethylene microcentifuge tubes 
(Elkay Products Inc., Shrewsbury). Tubes were heparinised by filling them with 
heparin solution and leaving it in contact with the tubes. The heparin solution was 
removed by pipette immediately prior to taking the blood sample. Samples were 
collected and spun immediately using a Beckman microcentrifuge for 30 seconds at 
5000g. Plasma was immediately removed and aliquoted for glucose assay (10µ1), 
insulin assay (20µ1), and GIP assay (1O0µ1). Samples were then frozen and 
maintained at -20°C until assayed. Thawing and refreezing of samples was avoided. 
2.4.2 Tissues 
Animals were killed by cervical dislocation and the small intestines (from the 
base of the fundus to the ileocaecal junction) from both control and test animals were 
excised, cleaned of extraneous material and weighed. They were then immediately 
placed on dry ice and subsequently transferred to a -20°C freezer prior to extraction into 
acid ethanol. Pancreatic tissues from mob mice were also dissected and treated in a 
similar manner. 
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2.4.2.1 Extraction Procedure used for Tissue Extracts 
Tissues were extracted according to the method developed by Kenny (1955). 
Acidified ethanol solution (750m1 absolute ethanol; 250m1 RO water, 15m1 36% v/v 
HCl) was added to the frozen tissue at a dose of 5m1/g wet weight in a universal glass 
tube. Pancreatic tissue from Qob mice was extracted at lOml/g wet weight. Tissues 
were then cut to yield small pieces prior to sonication for 15 seconds with an ultrasonic 
generator (Dawe Instruments Ltd. ). All procedures were performed in a cold tray at 
4°C or by packing the sample tubes in ice. The resulting homogenate was subsequently 
incubated at 4°C for 24hrs prior to centrifuging (Beckmann J6) at 2500 rpm for 10 
minutes. The supernatant was decanted and aliquoted into disposable tubes and frozen 
to -20°C for storage. 
2.5 Plasma GIP RIA 
This assay was developed by Morgan et a!. (1978) and has subsequently been 
refined. Alterations were made where necessary, in the volume of plasma used and 
antiserum dilution, but the method was essentially unchanged. 
2.5.1 Iodination of GIP 
The method of iodination used was described by Kwasowski (1986) using the 
chloramine T (N-chloro p-methyl benzenesulphonamide) method of Greenwood & 
Hunter (1963). 
Pure porcine GIP (originally a gift from Professor J. C. Brown, Vancouver, 
Canada and kindly provided by Dr. L. Morgan, University of Surrey) was used for the 
production of 125I-GIP. A stock supply of porcine GIP dissolved in phosphate buffer 
(pH 7.5,0.4M) at a concentration of 5µg GIP per 10µ1 buffer was used. Aliquots 
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(10µl) of this solution were stored in plastic auto-analyser cups (Sterilin) at -20'C until 
required. The iodination procedure was carried out in a small volume and so great care 
was taken to ensure the small volume of sample was not disturbed from the bottom of 
the cup. The auto-analyser cup containing l0µl of GIP solution was allowed to 
equilibrate to room temperature before uncapping. The cup was then clamped and the 
lid carefully removed taking care not to disperse the small amount of solution around 
the sides of the cup. 
A solution of chloramine-T (BDH Chemicals Ltd., Poole) in phosphate buffer 
(15µg in 10µI, pH 7.4,0.4M) and a solution of sodium metabisulphite (BDH 
Chemicals Ltd., Poole) in phosphate buffer (40µg in 20µl, pH 7.4,0.4-N1) were 
prepared immediately prior to iodination. 
To the IOpI of GIP solution was added 1mCi (10µl) of 125I-sodium iodide 
(IMS30, Amersham International, Buckingham). Chloramine-T (10µ1 of the 
15µg/10µ1 solution) was then added to the reaction vessel and the solution was 
carefully mixed for 15 seconds by alternate drawing up and expulsion of the reaction 
mixture into the pipette tip previously used to introduce the chloramine-T. The reaction 
was halted by the addition of 2Oµ1 of the sodium metabisulphite solution. The reaction 
products were immediately diluted with 200µl of a protein buffer: 0.1M sodium acetate 
pH 5.0, containing 0.5% (w/v) human serum albumin, HSA Fraction V, Sigma 
Chemical Co., Poole) and 500 KIU/ml aprotinin (Novo, Denmark). 
The separation of reaction products was achieved by simple gel permeation 
chromatography. The reaction products were transferred to a 1.1x15 cm disposable 
polyethylene column (\Vright/Amican provided by Dr. P. Kwasowski, University of 
Surrey) containing a matrix of superfine Sephadex G15 (Pharmacia LKB 
Biotechnology, Upsala, Sweden) which had been swollen at 4'C overnight in the 
protein buffer. The column was poured and equilibrated with the protein buffer prior to 
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the start of the iodination procedure. The column was eluted with the protein buffer. 
Fractions of approx 0.45m1 (10 drops/fraction tube) were collected on a LKB Ultrorac 
7000 fraction collector in disposable tubes. Approximately 24 fractions were collected. 
A pool of protein buffer 1-2cm in height was continuously maintained at the top of the 
column during the collection. 10µl of each fraction were transferred, by pipette, into 
disposable tubes and these aliquots and their pipette were counted for 10 seconds in a 
LKB 1260 Multigamma II. 
Two peaks of radioactivity were obtained, the first containing the iodinated 
peptide, the second the free iodine. The highest fraction on the descending limb of the 
first peak was aliquoted (20µ1 aliquots) into LP3 tubes and stored at -20°C until 
required. The stability of the tracer was usually in the order of 6 to 8 weeks. 
A typical elution profile of the iodination of porcine GIP is seen in Figure 
2.1.0. It can be seen that approx 83% of total radioactivity measured is incorporated 
into the antigen peak (fractions 5-1? ). This varies within successful iodinations from 
70-85% of the total radioactivity. 
Figure 2.1.0 Typical Elution Profile of Iodinated Porcine GIP 
from a Sephadex G 15 Column 
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2.5.2 Affinity Purification of Iodinated GTP 
Iodinated porcine GIP was affinity purified on a column provided by Dr. P. 
Kwasowski. The column basically consisted of a partially purified IgG cut from a low 
avidity anti-porcine GIP antisenim covalently bound to an activated silica bed. Anti- 
porcine GIP IgG was partially purified by precipitation from serum with ammonium 
sulphate solution (50% w/v). The purified IgG was then covalently linked to 
approximately 1g of 100µm diameter porous activated silica beads, with a pore 
diameter of lnm, using glutaraldehyde. The beads were then washed thoroughly in RO 
water and stored in a polyethylene column (1 .lx]5 cm) under carbonate/bicarbonate 
buffer pH 9.8 (sodium carbonate 1.59g/1 and sodium hydrogencarbonate 2.93g/1 with 
sodium azide 0.2g/l). By this method immunologically active 125I-GIP could be 
separated from immunologically damaged 125I-GIP. Affinity purification of 125I-GIP 
was carried out immediately prior to its use in the assay. 
Affinity purification was carried out at room temperature in a radioactivity 
designated area. The column was clamped, allowed to settle, and cleaned with RO 
water (20m1) and then equilibrated with 20m1 (in 4x5m1 aliquots) of GIP assay buffer 
(0.04M phosphate buffer, pH 6.5, containing 0.5% w/v human serum albumin and 
500 KIU/ml aprotinin). One or more of the 20µl aliquots of iodinated hormone were 
reconstituted to a total volume of 3mls with the assay buffer and layered on the column 
with a disposable pipette. The column was then topped up with assay buffer and 
capped. Continuous mixing of the column for 30 minutes at room temperature was 
performed using a rotormixer. After 30 minutes the column was reclamped, allowed to 
settle and then the buffer and damaged label allowed to run off. The silica bed was 
rewashed with 20ml (4x5ml) of RO water. Finally the bound labelled hormone was 
eluted by the addition of 5>l nil of 0.5ý, ý v/v hydrochloric acid, pH 1.3. Affinity 
purified hormone was collected in a 5ml -, Liss vial that 
had been previously washed 
with assay buffer. The vial once full, was transferred to a cold tray at 4C. The 
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affinity column was further washed with 2x5ml RO water and then filled with 
carbonate/bicarbonate buffer (pH 9.8), stoppered and stored at 4°C. 
Affinity purification waste (a 100µ1 aliquot), the empty fraction tube(s), and 
100µ1 of affinity purified hormone were then counted in the 1260 Multigamma II for 30 
seconds. A typical profile of proportional radioactivity is 30% affinity purified 
hormone, 40% waste and 30% still adsorbed to the original fraction tube. The problem 
of large amounts of radioactivity remaining in the fraction tube has very recently been 
addressed by the use of polyethylene tubes and dilution of fractions with lml assay 
buffer at the time of iodination prior to freezing. 
Assessment of specific activity of the label was performed by self displacement. 
Standard curves were set up with increasing amounts of purified label present. The 
specific activity was in the order of 240-278 nCi/ng as estimated by calculating the 
concentration of IR-GIP in increasing amounts of labelled GIP added to the assay 
(Walker, 1977). 
2.5.3 Preparation of Porcine GIP Standards 
Pure porcine GIP was weighed on a microbalance (Perkin Elmer Autobalance) 
and dissolved in 0.1NI formic acid containing 0.14M lactose, 0.04M HSA, 11mM citric 
acid, 6mM cysteine hydrochloride and 1600 KIU/ml aprotinin. 100µl aliquots 
(containing ing/µl porcine GIP) were freeze dried in glass vials to a constant vacuum. 
The vials were then stoppered without release of the vacuum and stored at -20'C until 
use. Aliquots were only defrosted once before use, and any remaining standard was 
discarded. 
Page 44 
2.5.4 Charcoal Stripped Senior 
Pooled fasting human serum was used to produce the charcoal-stripped serum 
(CSS). Charcoal (GSX, Sigma) was added to the pooled serum (20g charcoal/100mis 
serum). The mixture was stirred overnight (18 hours) at 4°C and then centrifuged 
(6000g for 30 minutes). The supernatant was then repeatedly filtered (Filtrox W-Steril 
Filters, H. Erben Ltd., Ipswich), under water suction, until all finings were removed 
and a pale coloured serum obtained. Aliquots (5m]) of CSS were stored at -20°C. 
New batches of CSS and standards were always tested against the previous 
batch in the routine assay procedure and with quality controls to ensure reproducibility 
of results between assays. 
2.5.5 Antibody 
All assays were performed with rabbit anti-porcine GIP antiserum 
(RIC34/1 11J). The immunization procedure and characteristics of this assay are 
reported in Morgan et al. (1978). Comparison of this antibody with other published 
assays is reported by Jorde et al. (1983) and Krarup (1988). In brief, the rabbit was 
immunised with a GIP/ovalbumin `glutaldehyde conjugate. The antiserum is very 
specific, showing less than I% cross reactivity with: glucagon, VIP, secretin, 
pancreatic polypeptide, insulin or C-peptide. The antiserum recognises the 3 major 
molecular species of IR-GIP. 
2.5.6 Quality Controls 
Pooled postprandial and fasting plasma samples from rats covering the range of 
GIP concentrations measured in the standard curve were aliquoted and stored at -20'C. 
Each pool was assayed to determine the hormone concentration present (n=12 aliquots 
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per pool). Each quality control plasma was included (2 aliquots per pool) in the assays 
and the hormonal values obtained used to calculate within assay variation and between 
assay variation. 
2.5.7 Assay Procedure 
The GIP assay system employed was a 4-day equilibration assay. Antibody 
bound antigen was separated by immunoprecipitation using a donkey anti-rabbit 
gamma-globulin antibody. 
The protocol for the assay is given in Table 2.1. 
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Table 2.1 Protocol for Plasma GIP Assay 
T ubes routinely set u 
eagents Total Non- Zero Standards Sample Sample Quality 
dded (µl) Counts specific NSB control 
Binding 
(NSB) 
Day 1 
Assay 
buffer 300 200 100 300 200 200 
Charcoal 100 100 100 
tripped 
plasma 
Standard 100 
Sample 100 100 
Antiserum 100 100 100 100 
plasma 100 
All tubes vortex mixed and incubated 24 hrs 4'C 
2 Day 
1-GIP 100 100 100 100 100 100 100 
All tubes vortex mixed and incubated 48 hrs 4° 
Dav 4 
Normal 50 50 50 50 50 50 
abbit 
serum 
Donkey 50 50 50 50 50 50 
anti-rabbit 
anima 
globulin 
14% PEG 100 100 100 100 100 100 
All tubes vortex mixed and incubated 4 hrs 4°C prior to separation of the bound 
and free phases 
The diluent assay buffer used throughout the assay was 0.4M phosphate buffer 
pH 6.5, stored as a stock solution with 0.02% sodium azide. This stock was diluted 
1: 10 prior to use with RO water (giving 0.04N I phosphate buffer) and 0.5% HSA (w/vi 
and 500 KIU/ml aprotinin (Novo, Denmark) were added. 
Assays were set up in a cold tray at 4°C, all solutions being refrigerated before 
use. All standards were run in triplicate with samples being run necessarily only as 
single tubes. Non specific binding (ESB) tubes for samples were prepared using 
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pooled sample plasma and run at regular intervals in the assay. Therefore, each animal 
did not have its own NSB data. The NSB of sample plasma and CSS was always 3- 
6% of total binding. 
In the setting up of the assay repeated volumes of buffer, label and antisera 
were added using a repeating multivolume pipette (Multipette 4780, Ependorf, 
Hamburg). In this assay the antiserum was used routinely at an initial dilution of 
1: 6000. The standards were set up in triplicate, by serial dilution, to cover the range 
25-800 pmol/1. 
Affinity purified labelled GIP was always added at a dilution giving 
approximately 7000-7500 cpm/100µ0. Separation of the bound phase was achieved 
using a donkey-anti-rabbit y-globulin antiserum, 5Oµ1/tube, at an initial titre of 1: 32 
(Guildhay Antisera, Guildford). Normal rabbit serum ('SRS) (Sigma) at an original 
titre of 1: 135 was added to increase the subsequent size of the bound precipitate, 
(50. l/tube). Following the addition of NRS and the second antibody 100µI of 14% 
polyethelene glycol (PEG, theoretical molecular weight 6000) was added to accelerate 
the reaction. The incubation period in the presence of the second antibody was 4 
hours. Tubes were then centrifuged, (20min, 2500rpm (1200-1300g) Beckmann J6 
centrifuge). The resulting supernatant ww as aspirated from each tube using a water 
pump. The bound 125I-GIP remaining in the tube was then counted in a LKB 1260 
Multigamma H. The parameter group for the assay was loaded from the permanent 
memory. The samples were loaded on the 12 hole counting racks in the order specified 
by the coding of the parameter setting. The Multigamma II was linked to a computer 
and data analysed and plotted using a spline function (% label bound against log 
concentration) best line fitting program. Unknown sample values were then 
automatically read off the standard cure. 
A typical standard curve for the assay is shown in Figure 2.1.1. 
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Figure 2.1.1 Typical Standard Curve for the Plasma GIP Assay 
Each point rcprescnts mcan+SD for n=6 observations 
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Serial dilutions of mouse and rat plasma demonstrated parallelism with the 
standard curve (Figure 2.1.2). 
Figure 2.1.2 Standard Curve Demonstrating Parallelism Between Porcine 
1R-GIP and IR-GIP in Rat and Mouse Plasma Pools 
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2.5.8 Assessment of the Plasma GIP Assay 
The sensitivity of the plasma GIP assay was determined in three ways. When 
calculated as the concentration of GIP equivalent to twice the standard deviation of the 
binding at zero the result was 2lpmol/l. The approximate estimate of sensitivity given 
by the amount of unlabelled antigen required to produce a 10% fall in the binding at 
zero was 37.1 pmol/l. 
Intra-assay coefficient of variation was 2.5% at 27pmol/1; 4.7% at 134pmo1/1 
and 8.5% at 402pmol/l. Inter-assay coefficient of variation was 2.9% at 28.1pmo1/1; 
5.6% at 133pmol/l and 10.2% at 406 pmol/l. 
In Chapter 5, the serially sampled mob mice plasma GIP assay was run with 
only 20µl of plasma per assay tube. The initial incubation volume in these tubes was 
maintained by adding an extra 80µl of assay buffer to all sample tubes. Charcoal 
stripped serum was not added to the standard tubes as the plasma effects of 20µl in 
400µ1 are insignificant. The shortfall in Volume of the standard tubes was made up 
with an extra 100µl of assay buffer. Subsequently all ob ob plasma GIP results were 
multiplied by a factor of 5, to correct for the difference in plasma volume used. The 
sensitivity of the standard curve was modified by the alterations in assay protocol. 
Twice the standard deviation of the binding at zero was 35pmol/1 and a 10% drop from 
zero binding was 5lpmol/1. Inter-assay coefficient of variation was 7.3% at 31pmolIl: 
13.2% at 92pmol/I and 21% at 387 pmolll (n=12). Intra-assay coefficient of variation 
was 5.9% at 29pmol/l; 10.9% at 90pmol/I and 20% at 370pmol/1 (n=4). 
2.5.9 GTP Assay for Tissue Extracts 
The assay for the measurement of IR-GIP in acid ethanol tissue extracts was 
modified from the plasma GIP assay procedure. The assay was essentially maintained 
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but CSS was no longer required, this being replaced by 1O0µl of assay buffer. The 
protocol is shown in Table 2.2. The standard curve was run in triplicate (Figure 2.4). 
Samples were run in duplicate. Serial dilutions of tissue extracts showed parallelism 
with the standard curve (Figure 2.4) and extracts were subsequently assayed at 1: 100- 
1: 200 times original dilution with assay buffer. 
Table 2.2 Protocol for Tissue Extracts GIP Assay 
T ubes routinely set u 
eagents 
" dded (µl) 
Total 
Counts 
Non- 
specific 
Binding 
(NSB) 
Zero Standards Sample 
NSB 
Sample Quality 
control 
Day 1 
ssay 
buffer 
400 300 200 300 200 200 
Standard 100 
Sample 100 100 
ntisenim 100 100 100 100 
extracts 
100 
All tubes vortex mixed and incubated 24 hrs 4°C 
av 2 
1251-GIP 100 100 100 100 100 100 100 
All tubes vortex mixed and incubated 48 hrs 4°C 
Dav 4 
Normal 
rabbit 
serum 
50 50) 50 50 50 50 
onkey 
anti-rabbit 
gamma 
globulin 
50 50 50 50 50 50 
141-1r' PEG 100 100 100 T 100 100 100 
All tubes vorte\ nixed and incubated 4 hrs 4'C prior to separation of the bound 
and free phases 
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Figure 2.1.3 
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The limit of detection (2xSD from zero) was 28.6 pmol/1. The sensitivity of the 
assay assessed as a 10 drop from zero binding was 56.7pmol/1. Intra-assay 
coefficient of variation was 8.3c at 57pmol/l; 3.4% at 297pmo1/1 and 2.6% at 
790mo1/1. Interassay coefficient of variation was 9.2% at 60pmo1/1; 4.6% at 312pmoVi 
and 3.4% at 786pmo1/1. 
2.6 GLP-1(7-36)amide RIA 
Development of a sensitive, precise RIA to GLP-1(7-36)amide is difficult 
because the circulating concentrations of this hormone are so low. Kreymann et al. 
(1987) reported fasting levels in the order of 30-50 pmol/1. To date all the assay 
procedures reported (Orskov cr al., 1987a; Uttenthal et al., 1985; George et al., 1985: 
Kreymann et al., 1987) utilise extraction methods to concentrate the peptide levels prior 
to assay. When serially sampling rat plasma, sample volumes of >100gl are not 
possible for any one experiment. To date no research group has been capable of 
Typical Tissue Extract GJP Standard Curve 
Values arc mean - SD for n=6 observations. 
Rirallelism he .An porcine IR-GIP and IR-GIP in tissue extracts from insulinoma-bearing, streptozotocin diabetic and pregnant rats is also 
demonstrated. Values arc means of 6 samples. 
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measuring circulating concentrations of GLP-1C, -36)amide in serial samples taken from 
rats and other small laboratory rodents. 
2.6.1 Iodination of GLP-] (7-3f )amide 
Synthetic human GLP-1(7-36)amide was purchased from Peninsula 
Laboratories Europe Ltd., St. Helens. The iodination procedure was exactly the same 
as that used for porcine GIP. A typical elution profile of iodinated GLP-1(7-36)amide 
is seen in Figure 2.1.4. In comparison to GIP iodination, it can be seen that a lower 
percentage of the iodine was incorporated into the GLP-1 molecule, typically 50-60% 
for a good iodination. This is due to less tyrosine residues in the amino acid sequence 
of GLP-1(7-36)amide for iodination. 
Figure 2.1.4 Typical Elution Profile of Iodinated Human GLP-1(7-36)amide 
from a Sephadex G15 Column 
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2.6.2 Affinity Purification of Iodinated GLP-1(7-36)amide 
An affinity column for the purification of labelled GLP-1(7-36)amide was 
provided by Mr. R. Elliott, University of Surrey. This column was similar to the GIP 
column and the procedure for purification identical. 
2.6.3 Preparation of Human GLP- I (7-36)amide Standards 
Human GLP-1(7-36)amide standards were produced in exactly the same way as 
the GIP standards. 
2.6.4 Production of GLP-l (7-36), mide Antiserum 
GLP-1(7-36) amide, like porcine GIP, is on its own a poor immunogen. It 
therefore requires to be linked to a larger and therefore more immunogenic protein to 
promote a stronger immune reaction in the host animal. Numerous reagents are 
available to couple small proteins (haptens) to larger proteins. Two traditional methods 
were used to produce conjugates of GLP- I (7-3f )amide and bovine serum albumin 
(BSA, Fraction V, Sigma, Poole). 
2.6.4.1 GLP-] (7-36)amide-BSA Conjugation with Carbodiimide 
This method was modified from that first reported by Goodfriend et al. (1964). 
Conjugation procedure: 
200 µg of synthetic, human GLP-1(7-36)amide (Bachem, Sweden) was 
dissolved in 200µl of RO water. To the peptide solution, bovine serum albumin 
(fraction V 450µb in 200µl RO wIter) was added. 
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1-ethyl-3-(3'-dimethylaminopropyl)-carbodiimide (560µg/lml of RO water) was then 
added dropwise whilst stirring. This gave an initial peptide: protein: ethyl-CDI ratio of 
1: 0.067: 42 as suggested by Rehfeld et al. (1972). The reaction mixture was gently 
stirred at 20°C for 18 hours (overnight). The resultant slightly opalescent solution was 
dialysed against 4x11 RO water at 20°C. 
The GLP-1(7-36)amide-BSA conjugate solution was adjusted to 2ml volume 
with RO water and stored in 0.5ml aliquots at -20°C until required. 
2.6.4.2 GLP-l (7-36)amide-BSA Conjugation with Glutaraldehyde 
This method was derived from that reported by Reichlin et al. (1968). 
Conjugation procedure: 
Conjugation was carried out immediately prior to immunization of the animals. 
GLP-1(7-36)amide (I 00p in l(X)µl RO water) was mixed with a BSA solution 
(170µg in 50µl RO water). To this was added 150µ1 of a 1: 10 dilution of an original 
25% aqueous solution of glutaraldehyde (Glutaraldehyde Grade 2, Sigma, Poole). The 
reactants were thoroughly mixed by pipette and allowed to rest at room temperature for 
60 minutes. 
2.6.4.3 Immunization Procedure 
Rabbits were the preferred host animal for immunization. Four young, female, 
half lop rabbits were obtained (Ranch Rabbits Ltd, Crawley Down) and caged at the 
Breeding Unit, University of Surrey. On the day of priming, each rabbit was calmed 
with 0.1ml of Hipnorni. Each rabbit was bled by the ear vein prior to immunization 
and approximately 1 (hml of blood per rabbit was collected and allowed to clot. Serum 
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obtained from this retracting clot was stored at 4°C with sodium azide (0.117c w, /v) and 
used in subsequent assays to assess non-specific binding of the antiserum. 
Two rabbits were immunized with the carbodiimide linked conjugate and two 
with the gluteraldyhyde linked conjugate. Each rabbit received 0.5m1 of the conjugate 
(assuming total conjugation of the peptide, a dose equivalent to 50µg 
GLP-1(7-36)amide) which was initially mixed with 100µ1 of BCG (BCG Vaccine BP, 
BNF, Intradermal). Immunoden solutions were thoroughly emulsified with marcol 
(two volumes marcol: one volume aqueous immunogen) prior to injection. 
Immunization was carried out intradennally at 30 to 40 sites (approximately 50µl 
emulsion/site) in the subscapular region. 
Monitoring of the immunological response and subsequent boosting of the 
animals was carried out by Mr. R. Elliott and Dr. L. Morgan. After several months 
successful antiserum dilution curves with reasonable titres were obtained from 3 of the 
4 rabbits. One bleed from a rabbit, immunized 130 days previously, with a 
glutaraldehyde conjugate was kindly donated by Dr. L. Morgan and Mr. R. Elliott. 
This rabbit (coded G2) had produced the most marked immunological response to the 
primary immunization, but had subsequently died (approx 150-200 days post 
immunization) through undetermined causes before any immunization boosts had been 
administered. 
For comparative purposes Professor J. J. Holst (Institute of Medical 
Physiology, Copenhagen, Denmark) kindly donated an antiserum raised against 
GLP-1(7-36)amide by his research group (Antiserum Code No 2135). The 
characteristics of this antiserum are reported in Orskov et al. (1987a). Briefly this 
antiserum was raised in rabbits against a GLP-1(7-36)amideBSA carbodiimide 
conjugate. It cross reacts 100% with synthetic GLP-l(1-36)amide but not with GLP-2 
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or glucagon. It also cross reacts, showing a high affinity for the large C-terminal 
proglucagon pancreatic polypeptide. 
2.6.4.4 Comparison of Antisera and Assay Development 
Antiserum 2135, was provided as a purified antiserum (50µg) freeze dried. 
The antiserum was reconstituted in 50µl phosphate buffer (0.04M, pH 6.5) at 4'C and 
then further diluted with phosphate buffer to give 1: 100 dilution of the original 
solution. This was aliquoted (]00µl aliquots) into disposable tubes, capped and stored 
frozen at -20°C. Thereafter thawing and refreezing of aliquots was avoided. 
Antisenim G2 (15.5.89) was not purified from the original serum obtained at 
that bleed time. The serum was maintained at -4°C with 0.11Io vow/v sodium azide. 
GLP-1(7-36)amide and GIP are very similar hormones in many respects, 
therefore, for convenience it was decided to investigate and develop a GLP-1 assay 
under the normal assay conditions used successfully for GIP. 
The initial assessment of the antisera was made by investigating the titre of the 
antisera by means of antiserum dilution curves. 
Production of Antisenim Dilution Cun-es 
For each antiserum, duplicate tubes were set up containing 2O0µl assay buffer 
(0.04 M phosphate buffer, pH 6.5, containing 0.5% w/v human serum albumin and 
500 KIU/ml aprotinin). In addition, 100µ1 of iodinated GLP-1(7-36)amide (affinity, 
purified and diluted to approx 7000 cpm/100pl) was added to each tube. Antiserum 
2135 (100µl ) was added at an initial dilution of 100,1000,2000,4000,8000 16000 
and 32000 times in assay buffer. Antiserum G2 (15.5.89) was diluted initially 125. 
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250,500,1000,2000,4000 or 8000 times, again in assay buffer. Phase separation of 
tubes was achieved by adsorption (iml/tube) using dextran coated charcoal. A 20% v/v 
solution of 5% w/v Dextran T-70 coated charcoal (Sigma) in phosphate buffer pH 6.5, 
0.04M. 
Dilution curves of pooled normal rabbit serum were also run over the range 
appropriate for each antiserum to check the non-specific binding of the tubes under 
these experimental conditions. The resultant mean antiserum dilution curves are given 
in Figure 2.1.5. 
Figure 2.1.5 Mean Antiserum Dilution Curves for Antisera 21 35 and G2 
Values arc means of n=4 observations. 
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The maximum binding of affinity Purified, iodinated GLP-1(7-36)amide with 
excess antibody was typically 70-80%. The titre of each antiserum was therefore taken 
to be the initial dilution that would bind 35% of the added label under the conditions of 
the assay. Antiserum 2135, therefore, had a titre of an initial dilution of 1: 10,000, 
comparing favourably with the titre reported by Orskov et al. (1987a) and G2 
(15.5.89) had a titre of 1: 2000. 
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Production of Standard Curves 
The assay procedure is given in Table 2.3. 
Table 2.3 Protocol for Tissue Extract GLP-1(7-36)amide Assay 
T ubes routinely set u 
eagents Total Non- Zero Standards Sample Sample Quality 
added (µl) Counts specific NSB control 
Binding 
(NSB) 
Day 1 
ssay 400 300 200 300 200 2(X) 
buffer 
Standard 100 
Sample 100 100 
Antiserum 100 100 100 1(X) 
C tissue 100 
extract 
All tubes vortex mixed and incubated 24 hrs 4°C 
Da 2 
1251- 100 100 100 100 100 100 100 
LP 1 
(7- 
36)amide 
All tubes vortex mixed and incubated 48 hrs 4°C 
Dav 4 lmmuno reci station procedure 
ormal 50 50 50 50 50 50 
abbit 
r 
serum 
Donkey 50 50 50 50 50 SO 
anti-rabbit 
gamma 
globulin 
14% PEG 100 100 100 100 100 10 
All tubes vortex mixed and incubated 4 hrs 4°C prior to separation of the hound 
and free phases 
Alternate Adsorption procedure 
av 4 
Dextran 1000 1000 1000 1000 1000 1000 
: oated 
charcoal 
All tubes incubated 20 minutes 4°C prior to separation of the bound and free 
phases 
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The assay conditions were the same as for the tissue extracts GIP assay. 
Antisera were run at their half-maximum binding titre dilutions as mentioned 
previously. In addition to charcoal separation of phases the double antibody procedure 
was also tested at the same dilution used for the tissue GIP assay. In total four 
standard curves were run, two using antiserum 2135 and two using antiserum G2 
(15.5.89). The results are given in Figure 2.1.6. 
Figures 2.1.6 Assessment of Two Different Methods for the Separation of 
Phases 
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From the standard curs. es it can be seen that higher binding of label to antiserum 
was recorded using the second antibody method of separation. This would therefore 
allow lowering of the initial antiserum dilution, to maintain the 35% titre, producing a 
more sensitive assay. The initial antiserum dilution was therefore adjusted to 1: 12000 
(for antiserum 2135) and 1: 2500 (for G2) and imnaunoprecipitation became the method 
of choice for separation of the bound and free label. Typical assay standard curves are 
shown in Figure 2.1.7. 
As a consequence of the heightened sensitivity of the assay obtained using an 
immunoprecipitation method of phase separation, reducing the second incubation time 
from 48 to 24 hours was investigated. However reducing the time course of the assay, 
while maintaining the reaction at 4°C, greatly reduced its sensitivity (data not shown) 
and therefore the idea was abandoned. 
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Figure 2.1.7 Typical Standard Curves for Human GLP-1(7-36)amide 
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Values are mean and standard deviation for 6 replicates 
Antisenim 2135 
50 
40 
30 
0 
GA 
20 
ZR 10 
0 
Antiserum G2 
40 
,0 
30 
c 
Z 
O 
20 
10 
0 
Assessment of Specificity of the Antisera 
n G2 
Specificity was assessed by investigating the cross reactivity of the antisera with a 
range of gastrointestinal hormones, glucagon and the synthetic parent molecules, GLP- 
1(7-37) and GLP-1(1-36)amide (all hormones were obtained from Penninsula). These 
ntiserum 2135 
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hormones were incubated individually with the antiserum in the standard assay 
procedure over a range of concentrations; 150 pg/ml to 50ng/ml in the case of GLP- 
1(7-37); 2.5-1000ng/ml for glucagon, GLP-2, human GIP, VIP, secretin, somatostatin 
and motilin. The results are given in Table 2.4. 
Table 2.4 Demonstration of Specificity of the Assay 
Percentage cross reactivity with hormone 
Hormones Tested Antiserum 2135 Antiserum G2 
LP-1(7-37) 87% <1% 
LP-1(1-36)amide 100% 100% 
LP-2 <1% <1% 
VIP <1c'C <1% 
Human GIP <1% <1% 
Somatostatin <1% <1% 
Secretin <1 % <1% 
Motilin <1% <1% 
luca on <1% <1% 
From the results it can be speculated that antiserum 2135, as Orskov et al. 
(1987a) described, is a sideways looking antiserum binding towards the N terminal of 
the GLP-1(7-36)amide molecule. This antiserum is therefore unable to distinguish 
between the original and the truncated forams of the molecule. G2 (15.5.89) on the 
other hand must have a binding region towards the C-terminal region involving or 
consisting of the final amidated arginine residue of the molecule. 
Serial dilutions of intestinal extracts from several experiments were run in order 
to show parallelism with the standard curve (Figure 2.1.8) and from these serial 
dilutions quality control tissue samples were obtained to subsequently monitor the 
assay. 
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Figure 2.1.8 Demonstration of Parallelism of Tissue Extracts with Human 
IR-GLP-1(7-36)amide Standard Curve 
Values are mean ± SD for n=6 observations 
Parallelism between human IR-GLP-1(7-36)amide and IR-GLP-1(7- 36)amide 
in tissue extracts from streptozotocin diabetic, insulinoma-bearing and 
neonatal rats is also demonstrated. Values are means of 6 samples. 
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Having established the differing specificities of the two antisera, the 
characteristics of the assay were established with the running of several standard curves 
and quality control intestinal extracts. Antiserum G2 had a sensitivity of 18pmoU1 
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(2xSD from zero) or 30pmol/l (10% reduction in zero binding). The intra-assay 
coefficient of variation was 3.117c at 24pmolfl; 9.2% at 538pmo1/1 and 15.7% at 
1365pmol/1. The interassay CV was 5.7% at 25pmol/1; 8.6% at 549pmo1/1 and 16.6ce 
at 1343pmo1/1. Antisenm 2135 had a sensitivity of 22pmo1/1 (2xSD from zero) or 
34pmo1/1(10% reduction in zero binding). The inter- and intra-assay CV were very 
similar to those obtained with antiserum G2. 
In order to prove no additional interference from other hormones in the tissue 
extracts, gel filtration of extracts was performed. 
2.6.5 Gel filtration of Intestinal Extracts 
Prior to gel filtration, extracts (? ml aliquots) were necessarily dried down to 
remove the acid ethanol. Aprotinin (5(10 KIU/ml) was added as a precaution to the 
extracts prior to removal of acid ethanol. Extracts were blown dry under nitrogen at 
room temperature for 30 minutes to evaporate the ethanol and then transferred to 
polypropylene centrifuge tubes (Falcon) and placed in a rotary evaporator for 2 hours 
until all liquid was evaporated and a yellow precipitate remained. The precipitate was 
reconstituted in 2ml 0.5, N I acetic acid for subsequent gel filtration. 
Gel filtration was performed by modification of the method of Holst et al. 
(1987). A single jacket blass column (1.5cmxlOOcm) was clamped above a fraction 
collector. The whole apparatus was prepared and maintained at 4°C. The column was 
packed with Sephadex G50, fine grade (Pharmacia LKB Biotechnology, Upsala, 
Sweden). The Sephadex was previously swollen for 24 hours at 4'C in an excess of 
0.5M acetic acid (40g/1). The column was packed manually in a single action with the 
Sephadex slum'. It was then allowed to settle for 4 hours and equilibrated with 2 litres 
of 0.5M acetic acid. Flow rate was adjusted to 30ml/hour. The Sephadex bed settled 
to a height of 68cm providing a total bed volume of 481cm3. A reservoir of eluent was 
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maintained at the head of the column bed by means of a peristaltic pump. Fractions of 
2m1 volume were collected by means of a fraction collector (LKB Ultrarack 7000). 
The column was calibrated by means of gel filtration standards (Sigma). In 
addition, cyanocobalamin (Vit B12, Sigma) was run as a low molecular weight marker. 
Standards were run at the concentrations advised, varying from 2mg to 5mg/ml in 
0.5M acetic acid. 10% glycerol was added to all standard solutions to aid loading of 
sample. Standards were loaded over 72 hours in 3 separate runs; dextran blue was run 
in isolation followed by albumin, cytochrome C and cyanocobalamin, and finally 
carbonic anhydrase and aprotinin. The maximum sample volume loaded at any one 
time was 2ml. Samples were loaded onto the bed surface under the reservoir of eluent 
by means of a fine (lmnm dianmeter) polyvinylchloride tube attached to the loaded sample 
syringe. The calibration cur\'e obtained is shown in Figure 2.1.9. Kav is a partition 
coefficient relating the volume eluted from the start of sample application to the elution 
peak (Ve) minus the elution volume for the excluded component (Vo) to the total 
volume (external and internal) available (Vt). Kav=(Ve-Vo)(Vt-Vo). 
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Figure 2.1.9 Calihration Curve of Gel Filtration Matrix 
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The total volume of the packed bed was established using a 4mg/ml solution of 
copper (II) sulphate. All coloured compounds were seen to progress through the 
column as strong horizontal bands. Eluted fractions were monitored spectro- 
photometrically, in quartz cuvettes, at 280nm using a Uvicon Spectrophotometer. 
Fractions collected from the subsequent gel filtration of intestinal extracts were 
frozen to -80°C and freeze dried (Edwards Freeze Dryer) until a constant vacuum was 
maintained. Subsequently some fraction tubes were seen to contain white crystalline 
powder others were seen to be empty. All tubes were reconstituted to 2mls volume 
with assay diluent on the day of assay and assayed, as per GLP-1 assay procedure, at 
an initial dilution of 1: 10 and 1: 40. All extracts were assayed with both GLP-1(7- 
36)amide antisera. 
Figure 2.2.0, demonstrates the typical gel filtration profile obtained with 4 
intestinal extracts from experimental rats. In addition intestinal and pancreatic extracts 
of oh ob mice were also filtered. These results will be given in Section 5.3.4.1. 
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Figure 2.2.0 Typical Gel Filtration Profile of Small Intestinal 
IR-GLP-I (7-36)amide Extracts of Wistar Rats 
Vo is the void volume of the column; CC is the elution maximum of cytochrome 
C; GLP-l (7-36)amidc is the elution maximum of a human standard preparation 
previously run through the column; B12 is the elution maximum of 
cyanocobalamin. Kav was defined in Section 2.6.5. 
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In conclusion, the two antisera appear to detect similar levels (within 15% error) 
of IR-GLP-1(7-36)amide in intestinal extracts. Therefore in subsequent studies, due to 
the limited supply of Antiserum 2135 only Antiserum G2 was used to measure 
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intestinal IR-GLP-1(7-36)amide levels. The results indicate that GLP-1(7-37) is 
present in intestines in negligible amounts and that rapid conversion to the amidated 
form must be the normal procedure. 
2.7 Plasma Insulin RTA 
Insulin was measured, again by RIA, using a method modified from Albano et 
al. (1972), as described by Flatt & Bailey (1981). 
2.7.1 Insulin Standard 
A crystalline mouse/rat insulin standard, (Novo Industria, Copenhagen), was 
reconstituted to l mg/ml in 0.4NI phosphate buffer, (pH 7.4). 150µl aliquots were 
frozen to -20°C and maintained at this temperature until use. On the day of assay the 
standard was defrosted and diluted to give a top standard of 20ng/ml, in 0.04M 
phosphate buffer (1: 10 dilution of stock 0.4: ß'I phosphate buffer) pH7.4, containing 
0.5%w/v bovine serum albumin and 500KIU/ml aprotinin. This top standard was 
serially diluted with buffer to give a final range of standards from 0.039-20ng/ml. 
2.7.2 Iodinated Insulin 
Iodinated bovine insulin (3µCi/5ml) manufacturers specific activity of 
50pCi/4g, was supplied by Amersham International, Buckingham. This was stored at 
4°C and diluted 1: 20 with assay buffer at the time of assay giving a concentration of 
125I-insulin of 1 nz/ml. 
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2.7.3 Quality Conrrc)l Plasma 
Quality control pooled plasmas' were obtained from fasted and fed (3.2 
glucose/kg body weight) rats, aliquoted and frozen to -20°C. Duplicates of each pool 
of plasma were run in each assay to check within and between assay variation. 
2.7.4 Antiserum 
The antiserum used (Flats & Bailey, 1981) was raised in guinea-pig against 
crystalline porcine insulin, (Antiserum P2,4/11/76). Antiserum was stored at -20'C, 
in 100µl aliquots of a]: I (X) dilution in phosphate/albumin buffer. At the time of assay 
one aliquot was diluted to 45m1 with assay buffer giving an initial dilution of 1: 45,000. 
This titre of antiserum gave a maximum binding of labelled insulin of 35%. 
2.7.5 Assay Procedure 
The protocol for the insulin assay is given in Table 2.5. 
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Table 2.5 Protocol for Prisma Insulin Ass: iv 
Tubes routinely set up 
eagents Total Non- Zero Standards Sample Quality 
dded (µl) Counts specific control 
Binding 
('TSB) 
Day 1 
ssay 
fluent 300 200 100 180 180 
Standard 100 
Sample 20 
Antiserum 100 100 100 100 
QC plasma 20 
All tubes vortex mixed and incubated 24 hrs 4° C 
Dav 2 
1251- 100 100 100 100 100 100 Insulin 
All tuhes vortex mixed and incubated 48 hrs 4°C 
Dav 4 
Dextrin 1000 1000 1000 1000 1000 
coated 
charcoal 
All tribes incubated 20 minutes 4°C prior to separation of the bound 
and free phases 
All procedures werc performed at 4°C in a cold tray and all solutions 
refrigerated prior to use. Standard tubes were run in triplicate. Samples were 
necessarily run individually. The assay is an equilibrium reaction over 4 days, the first 
24 hours being the incubation of the antiserum with the unlabelled antigen, without the 
presence of labelled antigen. 
Separation of phases was achieved by adsorption using dextran, (T-70), coated 
charcoal, (a 1: 5 dilution of 0.5ýc dextran T-70 stock 5% charcoal [Sigma] solution). 
The solution being diluted with phosphate buffer pH 7.4,0.04M. 
Page 71 
Charcoal stripped serum was not run in the assay as 20µ1 of plasma in an initial 
incubation volume of 300µ1 does not contribute significantly to non-specific effects and 
negates the one potential problem with the assay method in that charcoal separation is 
relatively sensitive to non-specific effects. 
The sensitivity of the assay as assessed by 2xSD from zero binding was 
0.087ng/ml and assessed by a 10% drop in zero binding was 0.105ng/ml. Quality 
control plasmas' indicated that the intra-assay coefficient of variation was 4% at 
0.197ng/ml; 8.4% at 1.320ng/ml; 7.7% at 5.610ng/ml and 3.1% at 10.75ng/ml. The 
inter-assay coefficient of variation was 5.1 at 0.203ng/ml; 8.4% at 1.41ng/m1; 9.2'/-c 
at 5.72ng/ml and 5.1 % at 1 O. 49ng ml. 
2.8 Plasma Glucose Assay 
Glucose was assayed by an automated glucose oxidase procedure using a 
Beckman Glucose Analvser 11 (Stevens, 1971) 
The analyser utilises the principle that when glucose is oxidised by glucose 
oxidase the rate of oxygen utilisation is proportional to the glucose concentration. 
glucose oxidase 
ß-D-glucose + 02 )Glucuronic acid + H202 
To prevent the H-, O, from yielding back any oxygen to the solution two 
peroxide-dependent reactants are present. 
The rate of 0, utilisation is monitored by an oxygen electrode, located within 
the side of the reaction vessel, which responds to the concentration of 
O2 in the reaction 
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solution. The electrode compares the rate of use of an unknown sample, with that of a 
standard glucose solution of 8.3 mnol/l. 
Procedure 
The machine is calibrated to provide a repeatable digital oxygen display reading 
of 23.5 with a freshly aerated supply of Beckmans Glucose Reagent at 37'C. Aeration 
is achieved by shaking the bottle of reagent 2-3 times with 2-3 charges of air. 
Calibration with the standard glucose solution (8.3rnmol/l) (Beckman Glucose 
Standard) is then performed by introduction of 10µl standard solution using a 
microman pipette (Gilson) into the reaction cup of the analyser. Glucose reagent is 
already present in the reaction cup and so the reaction proceeds immediately. The 
reaction solution is mixed by alternate drawing up and expulsion of the solution from 
the pipette used for glucose standard introduction. The pipette is subsequently removed 
and a reading noted from the digital display. The analyser automatically goes through a 
wash cycle to ensure fresh reagent is available for the next aliquot of standard. 
Once calibrated, the glucose concentration of 10µl samples of defrosted plasma 
can be measured. The analyser will theoretically recover within ±3% of the nominal 
value of glucose standards up to 25mmol/I. For samples which exceeded this value the 
procedure was repeated using 5µl samples rather than diluting the sample prior to 
analysis. This was especially important for the streptozotocin diabetic rats and the 
mob mice which suffer severe hyperglycaemia. Wherever possible all samples from a 
single study were analysed in one run. The precision of glucose standards within runs 
had a standard deviation (SD) of 0.1 mM for 20 replicates and from day to day analysis 
the SD was 0.2mM. 
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2.9 Data Handling. and Statistical Analysis 
Normal distribution of the data were confirmed using Kolmogorov-Smirnov's 
one sample goodness of fit test. Variances, where necessary, were stabilised by 
transforming the data to L, oglo. Data obtained from sequential sampling of blood over 
a specific time period were assessed by means of repeated measures analysis of 
variance. Variables of feeding regime and in the case of the cold acclimated animals the 
environmental temperature were considered in the analysis. 
Descriptive data for three or more treatment groups was obtained using one-way 
analysis of variance followed by a range test. Where group sizes were equal Duncan's 
multiple range test at the 0.05 and 0.01 significance level was used. Where group sizes 
were unequal Scheffe single range test was used, at the 0.05 and 0.01 significance 
level, Scheffe being exact for unequal group size. 
Descriptive data for two treatment `croups were obtained using two-tailed 
Student's unpaired or paired t-test at the 0.05 and 0.01 significance level as 
appropriate. Differences over time in an individual group were assessed by Student's 
unpaired t-test at the same significance levels. 
Incremental responses were calculated by subtracting response at time 0 from 
response at time 30. Integrated responses were calculated by measuring responses 
(rl... r) at discrete time intervals (tl... tn) and calculating the area under the graph minus 
the basal area (rixtn). Integrated response was calculated as the sum of the integrated 
responses between all adjacent discrete measurements, and the final sum divided by 
two to give the final expression as (mmol/1). hr-1, (ng/ml). hrl, or (pmol/1). hrl. One- 
way analysis of variance followed by Duncan's multiple range test were employed to 
assess siýgnificsince between three groups. Student's unpaired t-test was employed to 
assess significance bemcen two groups. 
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Chapter 3.0 
BASAL AND NUTRIENT STIMULATED PLASMA IR-GIP 
AND INTESTINAL ENTERO-ENDOCRINE FUNCTION IN 
PHYSIOLOGICAL STATES ASSOCIATED WITH 
HYPERPHAGIA 
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The following studies all concern physiological states associated with short- 
term hyperphagia. The degree of the hyperphagia varies as does the underlying cause 
of the increased food intake. The aims in all five studies were to investigate whether 
normal K cell secretory function was modified by the increased physiological stresses 
of changing the environmental conditions and/or food availability or reproductive 
status. Each study will be considered separately and overall conclusions will be 
discussed at the end of this Chapter. 
3.1 The Effects of Pregnancy and Lactation upon Basal and Nutrient 
Stimulated Plasma IR-GIP and Intestinal IR-GIP and 
IR-GLP-1(7-36)amide 
3.1.1 Introduction 
Pregnancy in humans is a physiological state where food intake, both in terms 
of the quantity of food consumed and its nutrient composition, is acknowledged to be 
modified (Durnin, 1987). Glucose homeostasis is also known to be modified, fasting 
plasma glucose concentrations being reportedly decreased (Lind et al., 1973), or 
maintained (Kühl, 1975) in the presence of a substantially increased plasma insulin 
concentration (Kühl, 1975). An increased plasma insulin response to an oral glucose 
load has been described in late pregnancy (Kühl, 1975; Hornnes et al., 1978). In 
contrast, the incretin effect has been reported to be reduced in late pregnancy (Hornnes 
et al., 1979). Two groups of researchers have investigated whether this is due to 
modification of GIP secretion. Plasma IR-GIP levels measured during late pregnancy 
and early post partum have shown a reduced IR-GIP response to nutrients during the 
later stages of pregnancy (Hornnes et al., 1979; Jenssen et al., 1988; Hornnes et al., 
1978). The two research groups differ in their findings as to whether basal fasting GIP 
levels are modified by pregnancy. This is perhaps due to their experimental design 
which utilised different times postpartum to obtain control values. Use of non- 
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pregnant age matched control subjects suggests a reduction in plasma IR-GIP 
concentration at 36 weeks of gestation (Berseth et al., 1990). 
Animal experiments dealing with pregnancy and lactation are mainly concerned 
with protein energy malnutrition and its effect on the viability of the offspring. 
Hyperphagia during pregnancy and lactation in rats has been noted (Cole & Hart, 1938; 
Campbell & Fell, 1964; Larralde et al., 1966; Craft, 1970). Gastrointestinal 
physiology has been shown to be modified in pregnancy and lactation as a result of the 
hyperphagia (Boyne et al., 1966; Craft, 1970). To date no studies have been reported 
on the incretin effect in animals during pregnancy or lactation. However, we have 
previously shown modified intestinal IR-GIP concentrations in the small intestines of 
mice under conditions of altered reproductive status (Knapper et al., 1989, unpublished 
work). 
The aims of this stud' were to look at how pregnancy and lactation in the rat 
could potentially alter the normal functioning of the GIP secretory cells in both the basal 
state and in response to acute nutrient stimulation. Small intestinal concentrations of 
IR-GIP and IR-GLP- l (7-3f )amide were also measured in late pregnancy and at the 
height of lactation for comparative purposes. 
3.1.2 Methods 
3.1.2.1 Animals and their Treatment 
Thirty virgin, female, albino \Vistar rats were used in this study. The origin of 
these animals was discussed in Section 2.1. The test animals (n=18) were mated 
overnight and then caged individually once pregnancy was confirmed, by external 
examination on day 8. Pregnancy was allowed to proceed without intervention and on 
day 22 post coitus the animals were allowed to litter naturally. Litter sizes were 
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standardised within 24 hours of birth to n=10, normal litter size for this colony being 8- 
10 animals. The housing conditions and dietary provision for the animals were 
discussed in Section 2.1. 
3.1.2.2 Experimental Procedure 
Food intake and body weight measurements were monitored on alternate days 
as described previously (Section 2.3). Plasma, for the analysis of basal glucose, IR- 
insulin and IR-GIP levels, was obtained at regular intervals during pregnancy and 
lactation from 6 test and 6 control animals and treated as stated previously (Section 
2.4.1). On day 21 of pregnancy and day 16 of lactation acute nutrient response tests 
were performed. These consisted of an oral glucose tolerance challenge (51.2 kJ/kg 
body weight) or an oral fat challenge (51.2 kJ/kg body weight). The exact nature of 
these tests has been described previously' (Section 2.2). Pilot studies, using non-fasted 
animals (so as not to cause undue stress of the animals at such a late stage of their 
pregnancy) revealed problems with dosing fed hyperphagic animals and large 
individual variations in response to the test. No animal littered early and all produced 
successful litters (7-21 offspring) on day 22 of gestation. Due to the problems of 
dosing the animals it was decided to fast the animals for 18 hours prior to the acute 
nutrient tests. Following fasting and ,, in acute nutrient challenge only 7 of a total 
number of 12 pregnant rats produced successful litters (ranging in size from 10-17 
animals). The remaining 5 animals cannibalised their offspring immediately after 
parturition. These animals were immediately withdrawn from the study and replaced 
by 5 new rats of a similar age with litters of a similar age for use during the subsequent 
tests. In all subsequent acute nutrient tests the responses from the original rats (n=7) 
and the replacement rats (n=5) were statistically indistinguishable. 
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In addition to the basal and nutrient stimulated measurements, on day 20 of 
pregnancy and on day 21 of lactation, small intestines were excised from a group of 
control (n=6) and test (n=6) rats as previously described (Section 2.4.2). 
3.1.3 Results 
3.1.3.1 Body Weight and Food Intake 
Mean body weight results have been calculated for every 2-3 days of the study. 
The results are shown in Figure 3.1.1. 
Repeated measures analysis of variance revealed that body weight increased 
significantly in both the control and test animals over the study period (p<0.01). The 
rate of change in body weight was however greater in the test animals (repeated 
measures between group difference, p<0.01). Analysis of individual time points 
revealed that the pregnant animals became significantly heavier than age matched 
controls at 13 days post coitus (p<0.01). The large fall in body weight at the end of 
pregnancy was due to the effects of fasting the animals prior to the acute nutrient 
tolerance tests and parturition. A smaller, transient fall in body weight was also seen in 
the control animals at this time due again to the effects of the experimental procedure. 
Immediately following parturition body weights of control and test animals 
were similar. Body weight increased in the test animals as lactation became established 
and the demands of the offspring increased. Differences in body weight between the 
two groups became significant at several time points. From day 16 post partum 
onwards mean body weight gain in the lactating animals levelled off and started to 
decline slowly. By the end of lactation there were no significant differences in body 
weights between the two groups. 
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Figure 3.1.1 The Effect,, of Pregnancy and Lactation on the Body Weight of 
Wistar Rats 
Values are expressed as mean+_SEM for groups of 6 rats. Parturition 
occurred day 22 post coitus. Symbols (*, **) indicate values significantly 
different from control values at that time point when assessed by Student's 
unpaired t-test, *=p<0.05; **=p<0.01. 
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Mean food intake is summarised graphically in Figure 3.1.2. 
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Figure 3.1.2 The Effects of Pregnancy and Lactation on the Food 
Consumption of Wistar Rats 
Values are expressed as mean±SEM for groups of 6 rats. Parturition 
occurred day 22. Symbols (*, **) indicate values significantly different from 
control values when assessed by Student's unpaired t-test, *=p<0.05; 
**=p<0.01. From day 24 onwards the differences between the two groups 
were always statistically significant, p<0.01 (symbols not shown). 
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It can clearly be seen that although pregnant animals are hyperphagic (maximum 
food consumption 1.5 x control animals intake) lactating animals consume significantly 
greater quantities of food, (maximum food consumption 3.6 x control animals intake). 
The repeated measures analysis of variance within group difference was p<0.01. The 
fall in food intake day 20-22 in the pregnant animals is due to fasting for 18 hours and 
parturition. During lactation, maximum food intake was seen on days 33-37 post 
coitus (days 12-16 post partwn). Food intake then started to fall as weaning 
approached but the animals still demonstrated a clear degree of hyperphagia at this 
stage. 
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3.1.3.2 Basal Levels of Plasma Glucose, IR-Insulin and IR-GIP 
During Pregnancy and Lactation in Wistar Rats 
The mean results for plasma glucose, IR-insulin and IR-GIP are shown in 
Figure 3.1.3. Blood was sampled on the same days post coitus and post partun. 
Samples were run in a single assay. Control values during pregnancy and lactation 
were similar (means within 1 SD of each other) and so the control data were pooled to 
give one result. 
Fed plasma samples were obtained at 3 time points during gestation (post 
coitus) and lactation (post parturn) on days 8,15 and 20, to obtain basal measurements 
and to maintain familiarity of the animal with the handling and experimental procedure. 
Mean plasma glucose levels were significantly suppressed at all time points during 
pregnancy (p<0.01) in relation to levels seen in age-matched control and lactating 
animals. In comparison, plasma insulin levels were elevated significantly during the 
later stages of gestation. Lactating animals showed a tendency towards lower basal 
insulin levels but this trend never achieved significance. 
Plasma IR-GIP values were significantly elevated during lactation in 
comparison to pregnant values and on day 15 postpartum the mean IR-GIP values of 
the lactating animals were significantly greater than both the control and pregnant 
animals. Control animals had IR-GIP values intermediate to the pregnant and lactating 
animals at all time points. 
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Figure 3.1.3 The Effects of Pregnancy and Lactation on Plasma Glucose, 
Plasma IR-Insulin and Plasma IR-GIP in Wistar Rats 
Values are expressed as mean±SEM for groups of 12 (control) or 6 
(pregnant or lactating) rats. Symbols (*, _*) indicate values significantly 
different from the two other groups when assessed by one-way analysis of 
variance followed by Scheffe range test, *=p<0.05; **=p<0.01. Symbol 
(0) indicates a value significantly different from one other group at that 
time point when assessed by the same procedures, 0=p<0.05. 
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3.1.3.3 Acute Nutrient Stimulation Tests 
Two acute nutrient stimulation tests were performed, an oral glucose tolerance 
test and an oral fat tolerance test. 
3.1.3.3.1 Oral Glucose Tolerance Test 
This test was performed on day 21 of pregnancy and again on day 16 of 
lactation. All plasma samples were assayed in a single assay and because the control 
values obtained at both stud' times were similar (mean values within 1 SD of each 
other) the control data has been pooled and is represented as one graph. The results are 
displayed graphically in Figure 3.1.4. 
All three groups of animals gave clear responses to the oral glucose challenge. 
Fasting for 18 hours significantly lowered the plasma glucose concentration in the 
pregnant animals (p<O. Ol ). Repeated measures analysis of variance revealed 
differences between the groups (p<0.01). These differences were shown to be 
between the lactating animals and the control animals, lactating animals having a 
superior glucose tolerance compared to the control animals. Pregnant animals had a 
similar tolerance to the control animals. Integrated glucose responses are given in Table 
3.1.1, and confirm the improved glucose tolerance during lactation. 
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Figure 3.1.4 The Effects of Oral Administration of Glucose (51.2kJ/kg Bcýdy 
Weight) on Pregnant or Lactating Wistar Rats 
Animals were fasted for 18 hours prior to the test. Values are expressed as 
mean±SEM for groups of 6 (pregnant and lactating) or 1" (control) rats. 
Symbols (*#) indicate values significantly different from the two other 
groups when assessed by one-way analysis of variance followed by Scheffe 
range test, **=p<0.01. Symbols (0,00) indicate values significantly 
different from one other group when assessed by the same procedures, 
0=p<0.05; 00=p<0.01. 
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Table 3.1.1 Integrated Plasma Glucose, IR-Insulin and IR-GIP Responses to an 
Oral Glucose Challenge (51.2kJ/kg Bodv Weight) in Pregnant or 
Lactating Wistar Rats 
Values are expressed as mean±SEM for groups of 12 (control) or 6 (pregnant or 
lactating) rats. Symbol (*) indicates a value significantly different from the two 
other groups when assessed by means of one-way analysis of variance followed by 
Scheffe range test, *=p<0.05. Integrated responses were calculated as described in 
Section 2.9. 
Study Group Integrated Plasma Integrated Plasma Integrated Plasma 
Glucose Response IR-Insulin IR-GIP Response 
(mmol/1). hrl Response (pmol/1). hrl 
(n ml). hr-1 
Control Rats 188.5±17.5 53.4±10.4 5620.8±1377.2 
Pregnant Rats 255.2±25.9 142.1±25.9* 4748.3±1786.7 
Lactating Rats 94.0±21.2* 46.1±7.7 6055.2±1628.8 
The pregnant rats had an elevated fasting plasma insulin concentration in 
comparison to the other two groups (p<O. OI ). This elevated insulin concentration was 
further stimulated by the glucose challenge and the integrated insulin response of the 
pregnant animals (minus fasting values) was significantly greater than the response of 
the other two groups (Table 3.1.1). The lactating animals with their superior glucose 
tolerance did not show a modified insulin response. 
Fasting plasma IR-GIP levels were similar between all three groups as were 
their responses to the glucose challenge. 
3.1.3.3.2 Oral Fat Tolerance Test 
This test was performed on the same day as the oral glucose tolerance using a 
different group of animals. The results are illustrated in Figure 3.1.5. 
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Figure 3.1.5 The Effects of Oral Administration of a Corn Oil Suspension 
(51.2kJ/k2 Body Weight) on Pregnant or Lactating 
Wistar Rats 
Animals were fasted for 18 hours prior to the test. Values are expressed as 
mean±SEM for groups of 6 (pregnant and lactating) or 12 (control) rats. 
Symbols (*, **) indicate values significantly different from the two other 
groups when assessed by one-way analysis of variance followed by Scheffe 
range test, *=p<0.05; **=p<0.01. Symbol 0 indicates a value significantly 
different from one other group when assessed by the same statistical 
procedures, 0=p<0.05. 
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An 18 hour fast significantly lowered plasma glucose concentration in pregnant 
rats (p<0.05). Oral fat administration had a modest yet significant lowering effect on 
the glucose level of the pregnant animals. Plasma IR-insulin concentrations were 
unaffected by the oral fat load. Differences between the three groups when assessed by 
repeated measures analysis of variance were identified by one-way analysis of variance 
to be due to the hyperinsulinaemia of the pregnant animals which was not modified by 
fasting or the test procedure. Fasting removed differences in basal IR-GIP levels 
between the groups. All groups gave a positive IR-GIP response to the fat load and 
there was no significant difference between the responses of the three groups. 
3.1.3.4 Small Intestinal Entern-Endocrine Function in Pregnant and Lactating 
Wistar Rats 
Hyperphagia of 7 days duration during pregnancy and of 17 days duration 
during lactation had significant effects on intestinal wet weight (Figure 3.1.6). 
Figure 3.1.6 The Effects of Pregnancy and Lactation on Small Intestinal Wet 
Weight in Wistar Rats 
Values are expressed as mean±SEM for groups of 6 (pregnant or lactating) 
or 12 (control) rats. Symbol (**) indicates a value significantly different 
from the two other groups when assessed by one-way analysis of variance 
and Scheffe range test, **=p<0.01. 
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Intestinal wet weights were not expressed on a body weight basis because the 
pregnant animals body weight reflects foetal weight and not the true weight of the dam. 
This is evident from the normalisation of the body weight of these animals so soon after 
parturition. The rank difference in mean intestinal weight (lactating>pregnant>control 
rats) reflected the degree of hyperphagia observed in the test groups. 
The effect of pregnancy and lactation with concomitant hyperphagia on the 
content and the concentration of IR-GIP and IR-GLP-1(7-36)amide in the small 
intestine is shown in Figures 3.1.7 and 3.1.8. 
Pregnancy with its concomitant hyperphagia had marked effects on the total 
content and concentration of IR-GIP in the small intestine. Lactation with its 
concomitant hyperphagia increased the total amount of IR-GIP in the small intestine to a 
similar extent as pregnancy but did not significantly alter the concentration of IR-GIP 
when increased wet weight of the small intestine was taken into account. 
Again it was the pregnant animals which showed the greatest change in 
intestinal content and concentration of IR-GLP-1(7-36)amide. Intestines from pregnant 
and lactating animals had a higher extractable content of GLP-1(7-36)amide than 
control intestines (p<0.01). When wet weight of the intestine was taken into account 
the pregnant animals were the only group with an increased IR-GLP-1(7-36)amide 
concentration. 
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Figure 3.1.7 The Effects of Pregnancy and Lactation on Small Intestinal 
IR-GIP in Wistar Rats 
Values are expressed as mean±SEM for groups of 12 (control) or 6 
(pregnant or lactating) rats. Symbol (**) indicates a value significantly 
different from the two other groups when assessed by one-way analysis of 
variance followed by Scheffe range test, **=p<0.01. Symbol (00) indicates 
a value significantly different from control values when assessed by the 
same procedures, 00=p<0.01. 
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Figure 3.1.8 The Effects of Pregnancy and Lactation on Small Intestinal 
JR-GLP-I (7-36)amide in Wistar Rats 
Values are expressed as mean±SEM for groups of 12 (control) or 6 
(pregnant or lactating) rats. Symbol (**) indicates values significantly 
different from the two other groups when assessed by one-way analysis of 
variance followed by Scheffe range test, **=p<0.01. Symbols 
(0,00) indicate values significantly different from the control value when 
assessed by the same procedures, 0=p<0.05; 00=pp<0.01. 
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3.1.4 Discussion 
This study supports the observation of pregnancy and lactation being 
hyperphagic states. The hyperphagia associated with lactation was far greater than that 
seen during pregnancy, confirming previous reports (Campbell & Fell, 1964; Larralde 
et al., 1966; Craft, 1970; Cripps & Williams, 1975). In the present study, food 
consumption increased steadily throughout pregnancy, reaching a maximum level at 
50% greater than the control rats intake. During lactation food intake peaked on day 16 
postpartum at approximately 260% greater than control rats. These results confirm the 
observations of Cripps & Williams (1975). 
Basal measurements of glucose, IR-insulin and IR-GIP indicate pregnancy in 
rats to be a hyperinsulinaemic condition, with a corresponding decrease in plasma 
glucose. Similar findings have also been reported in some clinical studies (Hornnes er 
al., 1979). Lactating animals differed from control rats at the height of lactation only in 
their mean plasma IR-GIP levels, which reflected the degree of hyperphagia observed 
in these animals. It is interesting to note that with the severe hyperphagia present in 
these animals, the plasma glucose and IR-insulin levels were normal. This would 
suggest that milk production imposes a strong demand for glucose. Blood glucose 
levels have been reported to be lowered in lactation (Bliss et at., 1990) and this was 
proposed to be due to the increased nutrient needs for milk production and loss from 
the maternal body (Burnol et al., 1986). Plasma insulin has been reported to be 
decreased (Jones et al., 1984) and contrastingly increased (Stutter-Dub et al., 1974) 
during lactation. An elevated insulin concentration would make it difficult for the 
mammary gland to obtain sufficient glucose for milk production. The results of this 
study suggest that hyperphagia stimulates GIP release but because of the glucose drain 
of milk production insulin secretion is not augmented. Increased stimulation of the K 
cell has no long term effects and the degree of stimulation is still related to the amount 
of food consumed. The glucose challenge revealed no exhaustion or over stimulation 
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of the K cell. The importance of the increased plasma IR-GIP concentration remains to 
be determined. Humans have been shown to secrete GIP in milk at a constant rate for 
the first six months of life (Berseth et al., 1990). Whether this is also true for rats 
remains to be established. 
An 18 hour fast of the pregnant animals gave a milky appearance to subsequent 
plasma samples obtained during the acute studies. This is believed to be the result of 
the so called accelerated stanution of pregnancy (Herrera et al., 1969). The milky 
appearance is due to the raised plasma levels of triglycerides and ketone bodies which 
occur possibly as a means of sparing glucose and amino acids for foetal growth 
(Freinkel et al., 1971). This had no untoward effects on the assay procedures. Fasting 
the pregnant animals failed to reduce the insulin levels back to control values suggesting 
that the hyperinsulinaemia is of hormonal rather than dietary origin. 
Lactating animals are very sensitive to food withdrawal. An 18 hour overnight 
fast leads to virtual complete inhibition of milk production (Munday & Williamson, 
1981; Bussmann et al., 1984; Mercer & Williamson, 1986; Page & Kuhn, 1986). The 
physiological basis for this is not completely understood. Insulin is known to be 
involved in switching on lipo`genesis and glucose extraction (Jones et a!., 1984; Page & 
Kuhn, 1986). It has also been suggested that a gastrointestinal factor, a peptide, as yet 
unidentified but known to be insulin dependent in its actions may also be involved in 
switching on mammary glucose uptake (Page, 1989). The lactating animals were not 
therefore in a lactating state at the start of the acute tests. Whether the dose of glucose 
was sufficient to stimulate milk production can only be speculated. Experimentally, 
there was no option but to administer the oral challenge tests to fasted animals. When 
animals are hyperphagic to such a large degree there is a breakdown in their normal 
pattern of food intake, although a diurnal variation in milk secretion and food 
consumption is still present (Grigor & Thompson, 1987). It is therefore very difficult 
to oral dose an animal which already has a distended stomach due to its increased food 
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consumption. In addition, in such a small group of animals (n=6) individual variation 
in basal levels of glucose, IR-insulin and IR-GIP may well mask the response to the 
acute challenge. The lactating animals only differed from the control animals in their 
plasma glucose response to the oral glucose challenge. This indicates that the 
hyperphagia, even though severe, had no long term effects in these animals. 
The oral glucose tolerance test revealed that glucose tolerance was not 
significantly improved in the pregnant state in spite of the prevailing hyperinsulinaemia, 
suggesting some degree of resistance to the actions of insulin. Insulin resistance has 
been well documented in clinical studies (Bleicher et al., 1964; Kühl, 1975; Hornnes et 
al., 1978). The pregnant animals had an exaggerated insulin response to the glucose 
load in comparison with the lactating and control rats. This increased insulin response 
to glucose in late pregnancy is well documented clinically (Lipson & Sharp, 1978). 
Plasma IR-GIP responses to glucose or fat were not significantly modified by 
the states of pregnancy or lactation and basal levels were not significantly modified by 
pregnancy. Clinical studies in contrast have shown a moderately reduced secretion of 
GIP in response to acute glucose or mixed meal administration when compared to the 
postpartum response (Hornnes et al., 1979; Jenssen et al., 1988). This may be a true 
species difference but this is unlikely however as the rat's digestive system has a very 
similar form and function to that of humans (Neil & Kesel, 1984). The enteroinsular 
axis of rats and humans also responds to nutrients in the same way and to a similar 
extent (Kikuoka et al., 1987). Pregnancy in humans is a time of moderately increased 
food intake (Dumin, 1987), not like the hyperphagia seen in rodents. Perhaps in the 
rat, the demands of an increased food intake cause sufficient stimulation of the K cell to 
override any other stimuli, possibly the insulin feedback, which would aim to reduce 
GIP secretion. 
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Conditions associated with hyperphagia have been shown to produce 
hypertrophic changes in the small intestine (Dowling, 1967). In lactation, the increased 
intestinal weight reported has been attributed to a secondary effect of the increased food 
intake (Campbell & Fell, 1964). The same is probably true in pregnancy. However, a 
contributory effect of hormonal change cannot be ruled out. Hypertrophy of all layers 
of the rat small intestine occurs during the later stages of pregnancy and lactation 
(Cripps & Williams, 1975). GIP and GLP-1(7-36)amide are both mucosal hormones. 
Changes in intestinal weight during pregnancy and lactation may not therefore bear a 
direct relationship to changes in mucosal hormone levels as the muscle layers of the 
intestine contribute to intestinal weight to a greater extent than changes in mucosa 
(Cripps & Williams, 1975). Both pregnancy and lactation produced a marked increase 
in intestinal IR-GIP and IR-GLP-1(7-36)amide content. This increase was not purely 
the result of hyperphagia as the increase was greater during pregnancy. When the 
hormonal content was expressed on a gram wet weight of intestine basis, the pregnant 
animals were the only group to show an increase in both IR-GIP and IR-GLP-1(7- 
36)amide. 
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3.2 The OntoLcn\' of Entero-Endocrine Small Intestinal Function 
3.2.1 Introduction 
In rats, as in all mammals, at birth there is an abrupt shift from the continuous, 
intravenous feeding of simple molecules, via the placenta, to an intermittent, enteral 
feeding regime which is necessarily of a more complex nature. This dietary change is 
accompanied by extensive functional and structural changes in the gastrointestinal tract 
(Henning, 1986) together with adjustments in intermediary metabolism (Duff & Snell, 
1982; Jones & Rolph, 1985; Bassett, 1989). During intrauterine life, the foetus 
depends on glucose as its primary energy fuel. Amino acids are too valuable to 
catabolise for energy and fats (in the form of free fatty acids) are poorly transferred 
across the placenta. A newborn rat, as a consequence of this situation, has no white 
adipose tissue deposits and very low triglyceride storage in brown adipose tissue 
(Girard et al., 1973). The primary energy source of the neonatal rat at birth is 
glycogen. During suckling, the primary fuel of the neonate is fat. The majority of the 
fat being in the form of medium chain and long chain triglycerides (Grigor et al., 
1986). At weaning, there is another abrupt nutritional change for the neonatal rat to 
contend with. The high fat milk diet is replaced by a high-carbohydrate, low-fat solid 
diet (laboratory diet composition was given in Section 2.1). 
All these nutritional changes occur within a short space of time. The effects 
which these changes have on the entero-endocrine K and L cells of the rat intestine are 
unknown. The aim of this study was to monitor the small intestine and plasma, by 
means of precise RIA, for the two hormones GIP and GLP-1(7-36)amide to determine 
their ontogeny and to plot changes in their development with changes in nutritional 
status of the aninmal. 
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3.2.2 Methods 
Fourteen Wistar albino time-mated, pregnant rats of an initial body weight of 
200-250g, were utilised in this study. Small intestines were excised from foetal rats or 
neonates (on days 10,14,17,19,20, and 21 of intrauterine life and days 1,2,3,7, 
10,14,17,20,22,23,25,31,38, and 45 of life) and treated as described in Section 
2.4.2. For the excision of foetal intestines dams were sedated with ether anaesthesia 
immediately prior to cervical dislocation. The dam was opened along the midline of the 
body and the womb exposed. The number of foetus was noted and each foetus was 
excised from its protective sac, wiped to remove amniotic fluid and the intestines 
exposed and excised. For very young foetuses intestines were excised as a whole 
(small and large intestine) due to poor discrimination of the two areas. Foetal rats were 
removed from a single mother at one time point unless the number of foetuses was less 
than six, when two or more dams would be sacrificed as appropriate. From day 14 
post coitus it was also possible to obtain blood samples for plasma glucose, IR-insulin 
and from day 17 for IR-GIP assay. These samples were collected by cervical 
decapitation of the foetus and collection of blood in a heparinised Pasteur pipette. 
Plasma was treated as described in Section 2.4.1. 
All dams were allowed to litter naturally (on day 22 post coitus) and litters were 
redistributed within 24 hours of birth to provide each dam with the normal size litter for 
this colony (8-10 offspring/dam). Neonates were sacrificed randomly and litters 
redistributed where necessary to maintain the normal litter size. Abrupt weaning was 
carried out on day 2-1 post partuun. On this day offspring were sex separated, recaged 
in groups of 6 and provided with normal laboratory diet and water ad libitwn (Section 
2.1). 
Page 97 
3.2.3 Results 
Body weight and intestinal weight are given in Figures 3.2.1 and 3.2.2 
respectively. 
Figure 3.2.1 Body Weight During Late Foetal and Neonatal Life of Wistar 
Rats 
Parturition occurred day 0. Abrupt weaning occurred day 22. Minus figures 
on the x axis indicate intrauterine life. Values are mean±SEM for a 
minimum of 6 animals at each time point. 
80 
p 60 
tb 
40 
20 
0 
Days Postpartum 
Body weight gain showed a steep increase throughout the study. 
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Figure 3.2.2 Small Intestinal Weight of Wistar Rats During Late Foetal and 
Neonatal Life in Wistar Rats 
Parturition occurred day 0. Abrupt weaning occurred day 22. Minus figures 
on the x axis indicate intrauterine life. Values are mean±SEM for a 
minimum of 6 animals at each time point. 
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Intestinal weight gain showed a sigmoidal development over time. This graph 
indicates that maximum rate of growth occurred within the first four weeks of life. 
3.2.3.1 Ontogeny of Basal P1: i mma IR-GIP 
In addition to IR-GIP, plasma glucose and IR-insulin were also assayed to 
provide additional information on plasma glucose homeostasis. A small amount of 
plasma could be obtained from day 14 of gestation onwards by decapitation of the 
foetus, but only from day 17 onwards was there sufficient for IR-GIP assay. Plasma 
glucose concentrations during late foetal and neonatal life are illustrated in Figure 3.2.3. 
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Figure 3.2.3 Plasma Glucose During Late Foetal and Neonatal Life in Wistar 
Rats 
Parturition occurred day 0. Abrupt weaning occurred day 22. Minus figures 
on the x axis indicate intrauterine life. Values are mean±SEM for a 
minimum of 5 animals at each time point. Symbol (**) indicates 
a significant difference when assessed by Student's t-test, **=p<0.01. 
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Repeated measures analysis of variance revealed highly significant changes in 
plasma glucose with time (p<0.01). Following parturition (day 0) there was a rapid 
and significant (p<0.01) fall in plasma glucose due to the removal of placental nutrition. 
Glucose levels started to rise over the first few days of life as lactation became 
established in the dams becoming significantly increased by day 3 of extrauterine life. 
During suckling, glucose levels were maintained at lower levels of normal than the 
levels seen after weaning (p<0.01 achieved on day 21 post-partum). 
Page 100 
-10 0 10 20 30 40 50 
Figure 3.2.4 Plasma IR-Insulin During Late Foetal and Neonatal Life in 
Wistar Rats 
Parturition occurred day 0. Abrupt weaning occurred day 22. Minus figures 
on the x axis indicate intrauterine life. Values are mean±SEM for a 
minimum of 5 animals at each time point. Symbol (**) indicates values 
significantly different from day -9 when assessed by Students unpaired t-test, 
**=p<0.01. 
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Plasma IR-insulin showed significant changes over time when assessed by 
repeated measures analysis of variance (p<0.01). There was a rapid rise in plasma 
IR-insulin from day 17-20 of intrauterine life. Insulin levels were significantly 
increased (p<0.01) from day 17-21 of intrauterine life compared with day 14. 
Maximum IR-insulin levels were seen on day 20 of foetal life. A second short-term 
rise in plasma IR-insulin was seen immediately after weaning, but this was not 
significant in comparison to the post weaning levels seen. Post-weaning basal IR- 
insulin levels were slightly higher than those seen during the suckling period. 
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Figure 3.2.5 Plasma IR-GIP During Late Foetal and Neonatal Life in \Vistar 
Rats 
Parturition occurred day 0. Abrupt weaning occurred day 22. Minus figures 
on the x axis indicate intrauterine life. Values are mean±SEM for a 
minimum of 5 animals at each time point. Symbol (**) indicates p<0.01 
when assessed by Student's t-test. 
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Repeated measures analysis of variance revealed significant changes with time 
(p<0.01) in plasma IR-GIP concentration. Plasma IR-GIP levels started to rise prior to 
birth (a significant increase in plasma IR-GIP levels was seen from day 17 to day 19 of 
intrauterine life). Plasma IR-GIP levels increased at a more rapid rate over the first 
week of extrauterine life. Levels were significantly elevated during the suckling period 
from day 3 onwards. Basal IR-GIP levels were lower after weaning. 
3.2.3.2 Ontogeny of Intestinal 1R-GTP and IR-GLP- 1 (7-36)amide 
Total extractable immunoreactive GIP and GLP-1(7-36)amide are illustrated in 
Figure 3.2.6. 
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Figure 3.2.6 Small Intestinal IR-GIP and JR-GLP-1(7-36)amide Content in 
Late Foetal and Neonatal Wistar Rats 
Parturition occurred day 0. Abrupt weaning occurred day 22. Minus figures 
on the x axis indicate intrauterine life. Values are mean±SEM for a 
minimum of 5 animals at each time point. Symbol (**) indicates a 
significant difference from day 20 when assessed by Student's unpaired t-test, 
**=p<0.01. 
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A repeated measures analysis of variance program revealed significant increases 
in both IR-GIP and IR-GLP-1(7- 36)amide with time (p<0.01). IR-GIP and 
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IR-GLP-1(7-36)amide demonstrated a similar pattern of development in the small 
intestine. A steady increase in total intestinal content occurred over the first three weeks 
of extrauterine life. Large increases in both hormones occurred between days 20 and 
22 of extrauterine life (p<0.01) corresponding to the weaning period. Following 
weaning there was a consistant increase in IR-GIP and IR-GLP-1(7-36)amide content. 
Figure 3.2.7 Small Intestinal IR-GIP and IR-GLP- 1 (7-36)amide 
Concentration in Foetal and Neonatal Wistar Rats 
Parturition occurred day 0. Abrupt weaning occurred day 22. Minus figures 
on the x axis indicate intrauterine life. Values are mean±SEM for a 
minimum of 5 animals at each time point. Symbol (**) indicates p<0.01, 
when assessed by Student's unpaired t-test against values on day 17. 
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Significant changes in intestinal IR-GIP and IR-GLP-1(7-36)amide 
concentrations were seen over the ages studied when assessed by repeated measures 
analysis of variance (p<0.01). As with the plasma results, intestinal IR-GIP 
concentrations started to rise prior to birth; a significant increase was seen from day 17 
- day 19 post coitus (p<0.01). The level continued to rise and maximum intestinal 
IR-GIP concentration was seen at day 1 of extrauterine life. Intestinal concentrations 
fell from day I of extrauterine life and were statistically indistinguishable from 
intrauterine levels by day 3 of extrauterine life. A second smaller and again transient 
decrease (p<0.01) followed by an increase (p<0.01) occurred at 10-14-17 days of 
extrauterine life. 
GLP-1(7-3f )amide concentration in the intestine was first detected above the 
sensitivity limits of the assay on day 17 of intrauterine life. Intestinal IR-GLP-1(7- 
36)amide concentration was significantly increased from day 17-21 of intrauterine life 
(p<0.01). Maximum intestinal IR-GLP-1(7-36)amide was seen on day 2 of 
extrauterine life. High IR-GLP-1(7-36)amide concentrations were maintained for the 
first seven days of extrauterine life. 
3.2.4 Discussion 
The fall in plasm i glucose after birth has been reported previously (Gain & 
Watts, 1976). It is believed not to be serious if the birth is normal and the offspring are 
left in their normal environment with their mother. Plasma glucose during late 
intrauterine life was maintained in the presence of very high plasma insulin levels. In 
this study plasma insulin started to rise on day 19 of gestation and achieved its highest 
value on day 20. Similar results were reported by Schulze et al. (1977). It has been 
suggested that the foetal hyperinsulinaemia is necessary to increase protein synthesis in 
specific tissues (Johnson et al., 1990). The fact that plasma glucose is maintained 
while plasma insulin levels rise led W, itts and colleagues to question whether foetal 
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insulin was in fact biologically active. Asplund (1972) has suggested that rats develop 
a glucose-sensitive type of insulin secretory mechanism during the first days of 
extrauterine life which is modulated by postnatal feeding. Later workers have reported 
that the foetal rat can respond to a glucose challenge by secreting insulin and the degree 
of insulin response increases as pregnancy proceeds (Kervran et al., 1979). This 
suggests that the intrauterine increases in both IR-GIP and IR-GLP-1(7-36)amide seen 
in this study could be involved in the rise in IR-insulin prior to birth. 
The profile of basal plasma IR-GIP over the first few weeks of life has not 
previously been reported for rats. The reason for an increase in IR-GIP prior to birth 
which achieves basal levels normally seen in adult rats is unknown. If the K cell is 
being stimulated enterally than it can only be by the amniotic fluid which is believed to 
be swallowed to maintain electrolyte balance and to exercise the developing 
gastrointestinal tract. Foetal absorption of glucose from amniotic fluid has been 
described in rats at 19 days post coitus (Reusens et al., 1980). However, the nutrient 
absorption from amniotic fluid is believed to be negligible. 
The increase of basal IR-GIP levels which are maintained during the suckling 
period are suggested to be the result of a high fat milk diet and the increased frequency 
of food consumption observed during the first 2-3 weeks of extrauterine life. A recent 
study in humans has shown that GIP is present in human milk at a concentration 259- 
of the normal basal plasma values (Berseth et al., 1990). Whether this is also true for 
rats remains to be established. The neonatal period is characterised by a lactose and fat 
rich diet containing triglycerides, galactose and glucose which in adults are known to 
stimulate the release of IR-GIP. Plasma IR-GIP levels had risen almost two fold by 
day 3 post partutm from values at birth. It is possible that this delayed rise in IR-GIP is 
due to the establishment of lactation and the production of true milk. However Kühl et 
a!. (1982) reported that neonatal pigs at 72 hours of age produced no significant GIP 
response to oral triglyceride infusion or oral glucose indicating an immaturity of the 
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entero-insular axis. Certainly by 6 days of age pre-term human babies have a 
functional GIP response to milk (Lucas et al., 1980). A study on full-term human 
infants has reported a functional entero-insular axis at 2 day of age (King et al., 1977). 
GIP has been shown to induce insulin secretion in 3 day old perfused rat pancreas 
(Bataille et al., 1977) suggesting that the entero-insular axis may well be functional at 
an early age in rats. 
Intestinal weight increased maximally with extensive changes in digestive 
capacity and dietary composition at 3-4 weeks of life (Henning, 1986). Ontogeny and 
distribution of IR-GIP in rat small intestine was first reported by Gespach et al. (1979). 
In the present study, IR-GIP increased in the intestine prior to birth supporting the 
observed rise in plasma GIP and the development profile reported by Gespach and 
coworkers (1979). GIP secreting, K cells have been observed by Moxey & Trier 
(1977) in the small intestine of human foetus at 12 weeks of gestation. The reason for 
this early development is unknown. The sharp peak in intestinal IR-GIP concentration 
observed on day 1 post partum has been reported to be due to an increase in duodenal 
GIP, which reaches maximum concentrations day 1 to day 14 postpartum (Gespach et 
al., 1979). Gespach and fellow workers did not report any subsequent changes in 
concentration unlike that seen between days 14 and day 20 postpartum in this study. 
The main increase in IR-GIP content of the small intestine occurred during the third 
week of life when adaptation from a milk to a solid diet was occurring. Ontogeny of 
IR-GIP appears to be related to fuel disposal over the first few weeks of life. 
The onto`eny of IR-GLP-l (7-36)amide has only previously been inferred from 
the study of intestinal cell culture using non-specific glucagon antisera (Brubaker, 
1987; Brubaker & \'ranic, 1987). However, it was recently shown that mRNA for 
glucagon could be detected in the ileum during foetal life (Taylor et al., 1990; Jin et al., 
1990). Taylor and coworkers reported mRNA was detectable from day 18 of gestation 
onwards and Jin and coworkers reported day 14 as the earliest time for detection. 
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Proglucagon synthesis was seen to proceed in the same way as GIP by Jin et al. 
(1990). In the present study, the development of IR-GLP-1(7-36)amide showed a 
similar pattern to that of GIP. Total content increased maximally at 3 weeks of age as 
with GIP. Interestingly IR-GLP-1(7-36)amide only became detectable at 20 days post 
coitus, and levels only rose significantly above basal following birth. Unlike GIP, 
IR-GLP-1(7-36)amide was then maintained at these elevated concentrations for the first 
week of life. The importance of these rapid increases in GIP and GLP-1(7-36)amide 
can only be speculated at. Certainly they are not stimulating insulin levels as the 
environment is normoglycaemic. However, as discussed in Sections 1.3.9 and 1.4.9, 
GIP and GLP-1(7-36)amide both have direct biological effects on white adipose tissue 
and since rats are born with very little adipose tissue, rapid deposition of fat is essential 
for future survival. Insulin cannot play a significant role in fat deposition at this time 
because of the need to stimulate glycogen breakdown and gluconeogenesis. Suckling 
is a time of net gluconeogenesis for rats. The importance of GIP and GLP-1(7- 
36)amide in stimulating adiposity may therefore be of greater importance at this time 
than their role in entero-insular communication. In suckling pigs, plasma levels of the 
two hormones have been shown to increase rapidly in fasted pigs allowed to suckle at 
the mother (Oben et al., 1991 a). Both GIP and GLP-1(7-36)amide have been shown 
to directly stimulate fatty acid synthesis and incorporation, in a dose dependent manner, 
at different adipose sites (Oben et al., 1991c). Pigs are similar to rats in that they are 
born with very low triglyceride levels and no white adipose tissue deposits. 
GLP-1 is a product of the intestinal L cell. Rats are born with an immature 
intestine. Enteroglucagon, another product of the L cell has been suggested by some to 
be a trophic factor in intestinal development (Jacobs et a!., 1981; Watanabe et al., 
1990). More recently it his been suggested to be an antitrophic factor (Gregor et al., 
1990). The increase in intestinal GLP-l(7-36)amide and the maintenance of high levels 
during the first week of life may simply be due to control of small intestinal growth 
during this time period. 
Page 108 
To conclude, plasma and intestinal GIP levels start to rise prior to birth as does 
intestinal IR-GLP-1(7-36)amide concentration, at a time when hyperinsulinaemia is 
present under basal glucose concentrations. Is this hyperinsulinaemia led by the foetus 
or is there some stimulus from the mother that promotes it? The importance of maternal 
diet to this hyperinsulinaemia was assessed by the following study. 
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3.3 Evaluation of the Origin of Foetal Hvperinsulinaemia 
3.3.1 Introduction 
Pilot investigations for the pregnancy and lactation study indicated that the 
removal of the mother's food supply 24 hours prior to parturition was not conducive to 
successful littering and raising of offspring. The ontogeny study revealed that around 
this time foetal rats become hyperinsulinaemic. It therefore raised the question whether 
the unsuccessful production of litters was a severe stress response of the dam, or 
possibly a more physiological problem, due to the interruption of the maternal nutrient 
supply, limiting final development of the foetus. The aim was to investigate whether 
the normal hyperinsulinaemia of late foetal life was affected by removal of the maternal 
diet. 
3.3.2 Methods 
Five, time-mated, pregnant rats were caged individually under normal 
experimental conditions on day 15 post coitus. Although this was a small number of 
rats, the numbers of offspring produced were 16 for the fed group and 23 for the fasted 
group. From day 17 of gestation, normal lab chow was replaced with a powdered diet 
comprising: 21.5% casein; 3.5% sunflower oil; 48% sucrose; 6.8% cellulose; 1% 
vitamin mixture; 4% mineral mixture; metabolisable energy 14MJ/kg. This was 
supplied to all rats ad libitum. Food intake was monitored daily. On day 19 food was 
removed from 3 of the rats for a period of 18 hours. On day 20 all rats were killed by 
cervical dislocation following light anaesthesia with ether. Foetuses were excised from 
the dam following exposure of the womb as described in Section 3.2.2. Body weight 
and liver weight of each foetus was noted and plasma collected for glucose, IR-insulin 
and IR-GIP determination as indicated in Section 2. -1.1. 
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3.3.3 Results 
Body weights of the pregnant rats over the 5 days of study showed a gradual 
increase over the period of food intake. Animals fasted 18 hours showed an average 
loss of 18±4g body weight (mean±SD) over the fasting period. Food intake was 
reduced in all 5 animals once transferred to the powdered diet (Figure 3.3.1). 
Figure 3.3.1 Food Consumption of Pregnant Wistar Rats Before and After 
Transfer to a Powdered Diet 
Values are mean±SEM for n=5 unless otherwise stated. The powdered diet 
was introduced on day 17. Three of the rats were fasted on day 19. Symbol 
(**) indicates a significant difference from day 17 when assessed by 
Student's paired t-test, **=p<0.01. 
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As can be seen the powdered diet was less acceptable to the rats than the pellet 
diet as mean food intake fell significantly on its introduction (p<0.01). 
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No significant difference was observed in body weight between the two 
groups. 
Figure 3.3.3 Liver Wei(0ht of Foetuses From Fed and 18 Hour Fasted 
Pregnant Wistar Rats 
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Liver weight was measured to indicate `glycogen deposition; no significant 
difference was observed between the two `roues. 
Body Weight of Foetuses From Fed and 18 Hour Fasted 
Pregnant \Vistar Rats 
Values are mean--SL- N1. Foctuses were excised on day 20 of gestation from 
5 pregnant rats; 2 in the fed state and 3 after an 18 hour fast. The number of 
foetuses is indicated on the graph. 
Values are mean±SENI. Foetuses were excised on day 20 of gestation from 
5 pregnant dams; 2 in the fed state and 3 after an 18 hour fast. The number 
of foetuses is indicated on the graph. 
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Figure 3.3.4 Plasma Glucose, IR-Insulin and IR-GIP Concentration in 
Foetuses From Fed and 19 Hour Fasted Pregnant Wistar Rats 
Values are mean±SEM. Foetuses were excised on day 20 of gestation from 
5 pregnant rats; 2 in the fed state and 3 after an 18 hour fast. The number of 
foetuses is indicated on the graph. 
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Fasting the pregnant rats for 18 hours had no significant influence on foetal 
plasma glucose, IR-insulin or IR-GIP concentrations. 
3.3.4 Discussion 
Insulin has been implicated as a foetal growth factor. Growth of the foetus has 
been seen to occur at a rapid rate in late gestation (Battaglia & Meschia, 1986). 
Destruction of endogenous insulin by streptozotocin administration causes severe foetal 
growth retardation in lambs (Philipps et al., 1991). Transuterine insulin injection in 
rats at day 19 gestation has been shown to decrease protein accretion (synthesis) and 
thereby reduce turnover (Johnson et al., 1990). The hyperinsulinaemia of foetal rats is 
particularly effective at stimulating protein synthesis in brain, liver and heart (Johnson 
et al., 1990). The increase in plasma insulin in foetal rats correlates well with glycogen 
storage in the liver of the animals (Gain & Watts, 1976). Rats are born with very 
distended livers due to the glycogen stores being their only metabolic fuel to see them 
through the first hours of life. No difference in liver weight or any of the other 
parameters included in this study was observed. 
The results of this small study indicate that short term removal of the maternal 
diet during late pregnancy has no untoward effects on foetal hyperinsulinaemia, the 
cause of which is unknown. The reason for the compromised littering of the dams in 
the pregnancy study must therefore have been a stress response of the mother, even 
though food was returned to them at least 24 hours prior to parturition. 
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3.4 The Influence of Over- and Undernutrition on IR-GIP and 
IR-GLP-1(7-36)amide Development in the Small Intestine of Neonatal 
Wistar Rats 
3.4.1 Introduction 
It was apparent from the ontogeny study reported in this Chapter (Section 3.2) 
that high plasma levels of IR-GIP persist during suckling in neonatal rats. These high 
levels of IR-GIP fail to augment insulin secretion due to the normal glucose levels 
present as the result of a high fat, low carbohydrate diet. Clinical studies have shown 
that bottle fed neonates have exaggerated IR-GIP and IR-insulin responses to nutrients 
when compared to breast fed infants (Lucas et al., 1980). It therefore remains to be 
answered whether this difference persists after weaning. 
Manipulation of litter size is a procedure which has been utilised previously to 
look at enzyme induction during neonatal life (Duff & Snell, 1982). Alteration of litter 
size alters the body weight curve of neonates because of the difference in the degree of 
adiposity achieved by offspring rather than accelerating growth (Widdowson & 
McCance, 1961). 
The aims of this study were to investigate whether over- and undernutrition 
would alter the intestinal development of GIP and GLP-1(7-36)amide. Additionally, 
the influence of altered neonatal nutrition on IR-GIP and IR-insulin responses to an oral 
glucose tolerance test were investigated, both during suckling and after a period on the 
weaned diet. 
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3.4.2 Methods 
3.4.2.1 Animals and their Housing 
Twelve pregnant, Wistar albino rats at 19-20 days of gestation were used in this 
study. The origin of these animals was discussed in Section 2.1. Rats were caged 
individually under normal experimental conditions (Section 2.1) and allowed to litter 
normally. All dams littered within 18 hours of each other. All offspring were removed 
within a short time after birth and randomly reallocated to mothers to provide the 
following sized litters: 
2 
3. 
3.4.2.2 
Six litters where the number of offspring per dam was 4. 
These litters were considered to be overnourished. 
Two litters where the number of offspring per litter was 10. 
These litters were considered to be normally nourished. 
Three litters where the number of offspring per litter was 16. 
These litters were considered to be undernourished. 
Experimental Procedure 
Body weights of offspring were monitored on alternate days. On day 17 post 
partum, an oral glucose tolerance test (51.2kJ/kg body weight) was performed on 18 of 
the animals (6 rats from each treatment group). Animals were fasted for 18 hours prior 
to the test. The exact nature of the test was given in Section 2.2. Small intestines were 
collected from 6 offspring from each study group on the same day as described in 
Section 2.4.2. The remaining rats were redistributed within their original groups to 
maintain the litter sizes. 
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On day 22 post partum, the offspring were abruptly weaned. Animals were 
separated according to sex, caged in pairs and allowed access to normal laboratory diet 
and tap water ad libitum. On day 42 postpartum, an oral glucose tolerance test was 
repeated on the same 18 animals. The dose of glucose used was the same, 51.2kJ/kg 
body weight. On conclusion of the test, animals were allowed access to food and after 
a period of 6 hours they were culled by cervical dislocation and their small intestines 
removed as described previously. 
3.4.3 Results 
3.4.3.1 Body Weite 
Body weights are given for the 3 treatment groups over the period of study in 
Figure 3.4.1. 
Figure 3.4.1 
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The Effects of Over- and Undernutrition During the Suckling 
Period on the Body Weight of Wistar Rats 
Values are expressed as mean±SEM for groups of 6 rats. Abrupt weaning 
occurred day 22 post partum. Symbols (*, **) indicate the first time point at 
which the body weights of pups from the various litters became 
significantly different when assessed by one-way analysis of variance and 
Duncan's range test, *=p<0.05; **=p<0.01. 
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The body weights of pups in the 3 study groups became significantly different 
from day 3 postpartum onwards (ovemourished>normal>undernouri shed). These 
differences persisted even after weaning onto normal laboratory diet. Following 
weaning, food intake between the three study groups was similar. 
3.4.3.2 Oral Glucose Tolerance Test 
The two tests at 17 days and 42 days post partum will be considered together 
(Figures 3.4.2,3.4.3,3.4.4). 
Analysis over time revealed that at 17 days of age all three study groups had a 
significantly superior glucose tolerance when compared with their response at 42 days 
of age (P<0.01). Both the over- and undernourished groups had a lower fasting 
plasma glucose value when compared with the control group of normally nourished 
animals. As a result of their lower fasting values, their maximum glucose concentration 
at 30 minutes was also lower. Incrementally the rise in plasma glucose over the first 30 
minutes was similar for all three groups at 17 days of age (Table 3.4.1). 
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Figure 3.4.2 The Effects of Over- and Undernutrition During the Neonatal 
Period on the Plasma Glucose Response to an Oral Glucose 
Tolerance Test (51.2kJ/kg body weight) 
Animals were fasted 18 hours prior to the test. Values are expressed as 
mean±SEM for groups of 6 rats. Symbol (**) indicates significant 
differences between two of the three groups when assessed by one-way 
analysis of variance and Duncan's range test, **=p<0.01. 
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Table 3.4.1 Incremental Plasma Glucose Response to an Oral Glucose 
Tolerance Test (51.2kJ/kg body weight) in Over- and 
Undernourished Neonatal Wistar Rats at 17 Days of Age 
Values are expressed as mean±SEM for groups of 6 animals. The 
incremental response was calculated as described in Section 2.9. 
Study Group Incremental (0-30 minutes) Plasma 
Glucose Response mmolA 
Over Nourished Rats 5.17 ± 0.53 
Control Normally Nourished Rats 5.20 ± 0.28 
Under Nourished Rats 5.52 ± 0.99 
At 42 days of age there was no significant difference between any of the three 
groups at any time point. 
The improved glucose tolerance during suckling was not accompanied by an 
increased insulin response (Figure 3.4.3). At 17 days of age the overnourished 
animals had significantly higher fasting plasma insulin values than the undernourished 
animals and this difference was also present 120 minutes after the glucose 
administration. Fastinn plasma insulin levels were significantly higher at 17 days of 
age, compared with 42 days of age for all groups, (p<0.05). 
The undernourished animals actually gave a significantly lower plasma IR- 
insulin response at 17 days of age (compared with 42 days of age), despite 
improvement of glucose tolerance (p<0.01). 
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Figure 3.4.3 The Effects of Over- and Undernutrition During the Neonatal 
Period on the Plasma IR-Insulin Response to an Oral Glucose 
Tolerance Test (51.2kJ/kg by weite 
Animals were fasted 18 hours prior to the test. Values are expressed as 
mean±SEM for groups of 6 rats. Symbol 0, indicates a significant 
difference between two of the three groups when assessed by one-way 
analysis of variance and Duncan's range test, 0=p<0.05. 
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Figure 3.4.4 The Effects of Over- and Undernutrition During the Neonatal 
Period on the Plasma IR-GIP Response to an Oral Glucose 
Tolerance Test (51.2kJ/kg body weight) 
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Animals were fasted 18 hours prior to the test. Values are expressed as 
mean±SEM for groups of 6 rats. Symbols (00) indicate significant 
differences between two of the three groups when assessed by one-way 
analysis of variance and Duncan's range test, 00=p<0.01. 
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Fasting plasma IR-GIP levels were elevated at 17 days of age in all groups 
(p<0.01). Repeated measures analysis of variance revealed differences in the plasma 
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IR-GIP response of the three groups at 17 days. This difference was identified by one- 
way analysis and range tests to be due to the exaggerated IR-GIP response of the 
overnourished animals. Fasting plasma IR-GIP concentrations and the acute IR-GIP 
responses to the glucose load were similar for all three groups on day 42. 
3.4.3.3 Intestinal Measurements of IR-GIP and IR-GLP-1(7-36)amide 
Intestinal wet weight measurements of the three treatment groups are 
summarized in Figure 3.4.5, and total intestinal IR-GIP content is summarized in 
Figure 3.4.6. 
No significant differences were present in intestinal weight between the three 
groups at either 17 or 42 days of age. 
Page 123 
Figure 3.4.5 The Effects of Neonatal Over- and Undernutrition on Intestinal 
Wet Weight in Wistar Rats 
Values are expressed as mean±SEM for groups of 6 rats. 
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Figure 3.4.6 The Effects of Neonatal Over- and Undernutrition on Total 
Intestinal IR-GIP Content in Wistar Rats 
Values are expressed as mean±SEM for groups of 6 rats. Symbols (*, **) 
indicate values significant]y different from the other two groups when 
assessed by means of one-way analysis of variance and Duncan's range test, 
*=p<0.05; **=p<0.01. 
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Total extractable IR-GIP was significantly greater in the overnourished animals 
at 17 days of age (p<0.01). By 42 days of age this difference was reversed and total 
IR-GIP content was sig nific intly lower in the overnourished rats (p<0.05). 
Page 125 
The relative concentration of intestinal IR-GIP is shown in Figure 3.4.7. 
Figure 3.4.7 The Effects of Neonatal Over- and Undernutrition on Intestinal 
IR-GIP Concentration in Wistar Rats 
Values are expressed as mean±SEM for groups of 6 rats. Symbol (") 
indicates a value significantly different from the other two groups when 
assessed by means of one-way analysis of variance and Duncan's range test, 
*=p<0.05. 
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When wet weight of the intestine was used to give the relative concentration of 
intestinal IR-GIP, the overnourished rats had a higher concentration of intestinal IR- 
GIP at 17 days (p<0.05). By 42 days of age this difference was no longer apparent. 
Intestinal GLP-1(7-36)amide can be considered in the same way. 
Figure 3.4.8 The Effects of Neonatal Over- and Undernutrition on Total 
Intestinal IR-GLP-1(7-36)amide Content in Wistar Rats 
Values are expressed as mean±SEM for groups of 6 rats. Symbol (0) 
indicates a value significantly different from the normal group when 
assessed by means of one-way analysis of variance and Duncan's range test, 
0=p<0.05. 
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At 17 days of age total intestinal GLP-1(7-36)amide content was increased in 
both the over- and undernourished groups (p<0.05). By 42 days of age the three 
groups had similar total IR-GLP-1(7-36)amide levels. 
Figure 3.4.9 The Effects of Neonatal Over- and Undernutrition on Intestinal 
IR-GLP- I (7-3f )amide Concentration in Wistar Rats 
Values are expressed as mean±SEM for groups of 6 rats. Symbol (0) 
indicates a value significantly different from the normal group when assessed 
by means of one-way analysis of variance and Duncan's range test, 
0=p<0.05. Symbol (*) indicates a value significantly different from the two 
other groups when assessed by the same methods of analysis, *=p<0.05. 
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At 17 days of age intestinal IR-GLP-1(7-36)amide concentrations were 
significantly increased in both the overnourished and undernourished groups. By day 
42, the concentration of GLP- 1(7-36)amide had increased in normal rats beyond that of 
the overnourished rats but the undernourished rats still had a significantly higher GLP- 
1(7-36)amide concentration when compared with the overnourished rats. 
3.4.4 Discussion 
From about 14 days of age, neonates become more active and towards weaning 
they start to nibble at the laboratory chow provided for the dam. One possible reason 
for this may be the decline in food intake by the mother resulting in reduced milk 
production. As a result of this, the oral glucose tolerance test was performed at 17 days 
of age rather than just prior to weaning of the animals. During the suckling period, 
plasma IR-GIP was elevated both when fasted and in response to an acute glucose 
challenge for all groups. Glucose tolerance was improved. However, in spite of the 
prevailing modest hyperglycaemia and elevated IR-GIP levels, the insulin response was 
not augmented beyond that seen in the weaned animal. Intestinal IR-GIP was elevated 
only in the overnourished animals during suckling, as was IR-GLP-1(7-36)amide. By 
42 days of age, all measured parameters were normalised in the overnourished animals. 
It can therefore be concluded that overnutrition during the neonatal period transiently 
augments the function of the endocrine GIP secreting cell. The elevated fasting IR-GIP 
level is presumed to be due to the high fat diet consumed by the offspring. Milk 
contains triglycerides, glucose and galactose (in the form of lactose), nutrients all 
known to stimulate GIP secretion in adults. Undernutrition had no effect on intestinal 
IR-GIP concentrations. It did, however, result in elevated intestinal IR-GLP-1(7- 
36)amide concentrations by 17 days of age. These results were not normalised 21 days 
after weaning, 
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The observation that insulin secretion was not increased during suckling but 
glucose tolerance was improved has also been reported in human neonates (King er al., 
1977). The results suggest that the increased plasma IR-GIP concentration is not 
augmenting insulin secretion at this time, in spite of the moderate hyperglycaemia 
present. The importance of the biological roles of GIP and GLP-1(7-36)amide in white 
adipose tissue stimulation have been suggested previously (Section 3.2.4). The 
newborn rat has 0.5-1 % body fat at birth and this increases to 8-12% by 18 days of age 
(Haggarty et al., 1987). The importance of GIP and GLP-1(7-36)amide in fat 
deposition is at present unknown, it can be suggested that the action of these hormones 
on fat metabolism may be important at this stage of neonatal development. 
Undernutrition of rats resulted in a lower rate of body weight gain. To what 
extent malnutrition could have been present in the rats cannot be evaluated. The distal 
small intestine is however very sensitive to malnutrition (Hamilton et al., 1983) and rats 
are born with an under developed gastrointestinal tract (Henning, 1986). 
Enteroglucagon, another product of the GLP-1(7-36)amide secreting cell, has been 
suggested to be a trophic factor for intestinal development (Jacobs et a!., 1981; 
Watanabe et al., 1990). More recently enteroglucagon has been suggested to be an 
antitrophic hormone (Gregor et al., 1990). The increase in GLP-1(7-36)amide in 
undernourished animals may therefore have no specific role itself and may be a 
consequence of requirements for other hormones sequenced on the same proglucagon 
molecule. 
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3.5 The Effects of Cold Acclimation, with and without Concomitant 
Hyperpha ia, upon Basal and Nutrient Stimulated Plasma IR-GIP and 
Intestinal 1R-GIP and IR-GLP- I (7-36)amide 
3.5.1 Introduction 
Animals exposed to low environmental temperatures (experimentally usually 
5'C) demonstrate increased metabolism in order to maintain body temperature (Jansky, 
1973). Initially shivering thermogenesis is the primary means of heat production. 
With prolonged cold exposure (greater than three weeks), non-shivering thermogenic 
mechanisms (primarily due to brown adipose tissue metabolism) increase in 
predominance and ultimately replace shivering to maintain heat production (Nedergaard 
et al., 1982). This adaptive process is known as cold acclimation. The changes in 
vascularity and appearance of brown adipose tissue (BAT) which occur during cold 
acclimation have been fully reviewed by Smith & Horwitz (1969) using rat 
interscapular BAT. Activation of BAT is considered to result from increased adrenergic 
activity during cold exposure (Helle et al., 1980). 
In order to meet the increased energy demands of cold stimulated 
thermogenesis, hyperphagia occurs to avoid compromising body weight gain too 
severely (Cottle & Carlson, 1954). In 1980, Rothwell & Stock suggested that 
prolonged hyperphagia may produce an adaptation in the dietary induced thermogenic 
response. It was proposed that animals were capable of increasing their ability to 
respond calorigenically to noradrenaline. On the basis of this, it has been suggested 
that cold exposure and hyperphagia could be synergistic in the development of cold 
adaptability, possibly through activation of the sympathoadrenal system (Tulp et al., 
1982). Prevention of hyperphagia, during cold adaptation, by restricted feeding has 
produced conflicting results. After two weeks cold exposure, Johnson et al. (1981) 
reported that pair feeding (with warm control rats) limited BAT hypertrophy (despite 
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similar sympathetic innervation). Other research groups, using a three week study 
period, have reported no influence of pair feeding on BAT hypertrophy (Kuroshima & 
Yahata, 1985; Puerta & Abelenda, 1987). BAT primarily utilises free fatty acids as its 
main metabolic substrate. These free fatty acids are imported from white adipose tissue 
and also obtained directly from lipolysis liberating free fatty acids stored within BAT. 
Restricted feeding would perceivably limit substrate availability to BAT. The reported 
lack of influence of restricted feeding on BAT hypertrophy in some studies has led to 
suggestions that under these conditions ketone bodies may form part of the substrate 
for BAT (Wright & Agius, 1983). 
As stated previously, BAT is activated by increased adrenergic activity during 
cold exposure. Fasting (48 hours) however, reduces the responsiveness of the 
sympathetic nervous system and the adrenal medulla to acute cold exposure (Avakian & 
Horvath, 1981). Therefore, other components are involved in activation of BAT in 
cold environments. Glucagon has been implicated as a potent stimulator of BAT in 
cold exposed rats (Howland, 1986). Increased plasma glucagon concentrations have 
been reported by several research groups during cold exposure (Kuroshima et al., 
1978; Edwards & Howland, 1986). Correspondingly cold acclimation is known to 
increase glucose turnover and to lower plasma insulin concentrations by as much as 
50% (Beck et al., 1967; Vallerand et al., 1983). This fall in insulin levels is sufficient 
to reverse the hyperinsulinaemic, glucose intolerant effects of a hyperphagic cafeteria 
diet (Vallerand et al., 1986). The increase in plasma glucagon therefore results from a 
decrease in insulin secretion removing the suppressive action of insulin on the A cells 
of the pancreas, (Curry & Curry, 1970; Edwards & Howland, 1986). The fall in 
plasma insulin has been reported to be due to acute cold exposure as it is rapidly 
abolished by re-exposure to a warm environment (Vallerand et al., 1983). Other 
research groups disagree, reporting slow and progressive sequential changes in insulin 
levels and thus implicating cold acclimation to be involved in the fall of plasma insulin 
concentrations (Edwards & Howland, 1986). 
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The effects of cold acclimation on glucose homeostasis and insulin secretion are 
therefore well documented. The possible interactions of cold acclimation and 
hyperphagic effects on the entero-insular axis have not been considered. This study 
proposed to investigate this area of research by monitoring plasma IR-GIP 
concentrations during the period of cold acclimation and intestinal IR-GIP and IR-GLP- 
1(7-36)amide after six weeks of cold acclimation. The protocol involved two cold 
exposed study groups; one food restricted (to the level of intake of the thermoneutral 
control age matched rats) and one allowed to feed ad libitum. This procedure allowed 
monitoring of the influences of hyperphagia induced by cold exposure and the effects 
of cold exposure not attributable to hyperphagia on entero-endocrine function. 
3.5.2 Methods 
3.5.2.1 Animals and their Treatment 
Thirty male, Wistar albino rats (180-190g body weight) were utilised. The 
origin and handling of the animals is discussed in Section 2.1. The rats were 
maintained for one week at 22±2°C under normal experimental conditions, caged in 
groups of 3 or 4 (Section 2.1). This time allowed the rats to become familiar with the 
procedures of handling, weighing etc. During this week, one group of rats per 
treatment were randomly selected and bled to obtain basal measurements for plasma 
glucose, IR-insulin and IR-GIP as described in Section 2.4.1. On day 7, the animals 
were allocated to one of the following treatment regimes: 
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1. Thermoneutral exposure (22±2°C) with ad libitum feeding, two groups of six 
animals. 
2 Cold exposure (4±1 °C) with ad libitum feeding, two groups of seven animals. 
3 Cold exposure (4±1°C) with food restricted to the level of consumption of 
thermoneutral control rats, one group of seven animals. 
The rats were caged in groups of 3 or 4 with the aim of reducing the initial 
stress of cold exposure. The nature of the diet provided throughout the study is 
described in Section 2.1. All animals were allowed free access to tap water, and a 
standard 12 hour photoperiod (0700-1900 hours light) was maintained for both warm 
and cold treated animals. In view of the reported inter-relationship between feeding 
pattern and endogenous lipogenesis/lipolysis cycle in rats (Le Mangen, 1983) cold 
exposed pair fed animals were provided at 1600 hours daily with an amount of food 
eaten by thermoneutral control rats on the previous day. The pair-fed rats rapidly 
consumed the food provided. All experimental procedures were performed at 0900- 
1200 hours. 
3.5.2.2 Expejn ental Procedures 
Body weight and food intake were monitored daily as described in Section 2.3. 
This allowed the opportunity of regularly inspecting the health of the animals. Plasma 
samples for the basal measurements of plasma glucose, IR-insulin and IR-GIP were 
obtained at weekly intervals, from all three treatment groups, as described in Section 
?. 4.1. 
Acute nutrient response tests were performed 14 days and 35 days after the start 
of cold exposure (i. e. during and after completion of the process of cold acclimation), 
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following an 18 hour fast of the rats. Pilot studies, using non-fasted animals so as not 
to interfere with the process of cold acclimation, revealed problems with the dosing of 
hyperphagic animals. Individual animal variation in response to the test under these 
conditions was so great that interpretation of the results was difficult. Pair fed rats 
could not be fasted for 18 hours without altering their feeding time and so they were 
excluded from the acute tests. The acute challenges utilised were an oral glucose 
tolerance test (51.2 kJ/kg body weight) and an oral fat tolerance test (51.2 kJ/kg body 
weight). The exact nature of these tests is described in Section 2.2. 
An insulin sensitivity test was performed on day 42 of cold acclimation using 
porcine insulin (Actrapid MC, Novo Industria, Copenhagen), at a dose of (IU/2m1) per 
kg body weight, diluted in 0.9% (w/v) saline and adjusted to pH 3.5. 
At the end of the experiment (day 42), small intestines were isolated from the 
rats and treated in the manner described in Section 2.4.2. In addition the interscapular 
fat pad of each animal was removed and the BAT carefully dissected from adherent 
white adipose tissue and skeletal muscle. The wet weight of interscapular BAT was 
subsequently determined. 
3.5.3 Results 
3.5.3.1 Body weilt ht and Food Intake 
Daily food intake for the three study groups is depicted graphically in Figure 
3.5.1. 
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Figure 3.5.1 Food Consumption of the Three Study Groups Demonstrating 
the Extent of Hyperphagia in Cold Exposed Ad Libittun Fed 
Wistar Rats 
Values are expressed as mean±SEM for groups of 6 (warm control), 7 (cold 
ad libitum fed) and 7 (cold pair fed) rats. Animals were exposed to the cold 
from day 7 onwards. Symbol (**) indicates values significantly different 
from the other two study groups at that time point and subsequent time 
points when assessed by one-way analysis of variance and Duncan's 
multiple range test. ** =p<0.01. 
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Repeated measures analysis of variance revealed a significant effect of 
environmental temperature on feeding pattern (p<0.01). One-way analysis of variance 
and range testing revealed that the cold ad libitum fed rats became hyperphagic 
(p<0.01) on day 13 of the study (6 days after cold exposure began). Food intake in 
these rats increased over the following 24 hours and then remained relatively stable at 
approximately 1.5 times greater than normal intake for the duration of the study. 
Dietary chow stored at 5°C gained weight due to water adsorption from the 
damp environment at a rate of lOg/lOOg food over a 24 hour period. This weight gain 
was not compensated for in the experimental procedure as it only affected the cold ad 
libitum fed group. All food in the hopper of the cages was removed and replaced with 
fresh chow every 24 hours to ensure the continuing acceptability of the diet and to 
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prevent mould spoilage. As a consequence of this water adsorption the increased food 
intake following cold exposure was probably underestimated. 
Figure 3.5.2 
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The Effects of Cold Acclimation With and Without Concomitant 
Hyperphagia on the Body Weight of Wistar Rats 
Values are expressed as mean±SEM for groups of 6 (warm control) or 7 
(cold acclimated ad libitum fed) and 7 (cold pair fed) rats. Animals were 
exposed to the cold from day 7 onwards. Symbols (**) indicate values 
significantly different from the other two groups at that time point when 
assessed by one-way analysis of variance and Duncan's multiple range test, 
**=P<0.01. 
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Body weights significantly increased during the 6 week study in all three 
groups as indicated by repeated measures analysis of variance (p<0.001). The rate of 
growth correlated in each of the three groups not only with the feeding regime but also 
with the environmental temperature. One-way analysis of variance followed by 
Duncan's range test revealed significant differences in the body weight of the cold 
exposed ad libitum fed group and the warm control animals after 6 days of cold 
exposure. This difference did not persist; two days after the body weight difference 
became significant, the cold exposed animals became hyperphagic and exhibited catch 
up growth to the extent that differences in mean body weight were no longer significant 
by day 15 of the study. 
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The cold pair fed animals surprisingly never lost weight. They continued to 
develop but at a slower pace than the other two groups. Their mean body weight was 
decreased (p<0.01) compared with the other two groups after 9 days of cold exposure 
(day 16 of the study). Body weight of this group remained significantly depressed 
from that point onwards. 
3.5.3.2 Basal Plasma Glucose, IR-Insulin and IR-GIP during the process of 
Cold Acclimation 
The mean results of basal plasma glucose, IR-insulin and IR-GIP values are 
shown in Figure 3.5.3. 
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Figure 3.5.3 The Effects of Cold Acclimation With and Without Concomitant 
Hyperphagia on Plasma Glucose, IR-Insulin and IR-GIP 
Values are expressed as mean ±SEM for groups of 6 (warm control) or 7 
(cold ad libiiwn fed) and 7 (cold pair fed) rats. Symbols (*, **) indicate 
values significantly different from the other two study groups when assessed 
by one-way analysis of variance followed by Duncan's multiple range test 
*=p<0.05; **=p<0.01. Symbols (0,00) indicate values significantly 
different from one other study group when assessed by the same methods of 
analysis, 0=p<0.05; 00=p<0.01. 
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Repeated measures analysis of variance revealed significant differences in 
plasma glucose concentration with environmental temperature (P<0.01), but no 
significant influence of feeding regime. Upon exposure to the cold, plasma glucose fell 
slightly in both cold treated groups. This fall became significant in pair fed animals 
after 10 days of cold exposure (day 17 of the study) but was never below the normal 
basal range for rats. As cold acclimation progressed plasma glucose concentrations of 
both cold treated groups became significantly elevated in comparison to warm control 
rats. Values remained elevated until the conclusion of the study. 
Both environmental temperature and feeding regime significantly affected basal 
plasma insulin concentrations over time (p<0.05 and p<0.001, respectively). Both 
cold exposed treatment groups demonstrated a significant initial fall in plasma insulin 
levels after 3 days of cold exposure (p<0.01). In the cold ad libitum fed animals, this 
was followed by a return to increased insulin levels comparable with those seen in the 
warm control animals. Pair-fed animals, however, had reduced basal insulin levels 
throughout the study (p<0.01). 
Basal plasma IR-GIP levels were significantly influenced by environmental 
temperature and feeding reimen over the time course of the study (p<0.05 and 
p<0.01, respectively). One-way analysis of variance and range testing indicated a 
significant increase in plasma IR-GIP in the cold ad libitum fed animals in comparison 
to the cold pair-fed animals (p<0.01) on days 17 and 23 of the study (i. e. 10 and 15 
days after cold exposure was initiated). The raised plasma IR-GIP levels of the cold ad 
libitum fed group then fell back to levels comparable with the pair-fed group on days 30 
and 38. The warm control animals had IR-GIP concentrations intermediate to the other 
two groups until day 30. At this time, the pair-fed animals had suppressed IR-GIP 
levels in comparison with the warm controls (p<0.05). By day 38 of the study, no 
significant differences were present between any of the three groups. 
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3.5.3.3 Acute Oral Nutrient Stimulation during the process of Cold 
Acclimation; Effects on Plasma Glucose, IR-Insulin and IR-GIP 
3.5.3.3.1 Oral Glucose Tolerance Test 
This test was performed on day 21 and again on day 42 of the study, (i. e. at 2 
and 5 weeks of cold acclimation). The two tests will be considered together in order to 
illustrate differences due to the on-going process of cold acclimation. All plasma 
samples were analysed in a single assay and because control values obtained at 21 and 
42 days were similar (mean values within one standard deviation of each other) the 
control data have been pooled and are represented as one graph (Figure 3.5.4). 
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Figure 3.5.4 The Effects of the Process of Cold Acclimation on the Response 
to an Acute Oral Glucose Challenge (51.2kJ/kg body weight) 
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Animals were fast; d for 18 hours prior to the test. Values are expressed as 
mean±SEM for groups of 12 (warm control) or 7 (cold acclimated ad 
libitum fed) or 7 (cold acclimated pair fed) rats. Symbol (*) indicates a 
value significantly different from the two other treatment groups at that time 
point when assessed by one-way analysis of variance followed by Scheffe 
range test, *=p<0.05. Symbol 0 indicates a value significantly different 
from one other group at that time point when assessed by the same methods 
of analysis, 0=p<0.05. 
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Plasma glucose concentration differences between the three groups were 
overcome by an 18 hour fast. Repeated measures analysis of variance revealed that the 
differences between the groups over time were significant (p<0.01), whilst the 
differences within the groups were not. Both of the cold acclimated groups had a 
superior glucose tolerance at 30 minutes compared with the control animals (p<0.05). 
By 60 minutes this difference persisted between the 2 week cold acclimated and warm 
control rats only. The 5 week cold exposed animals had an intermediate tolerance to 
glucose at this time. Integrated glucose, IR-insulin and IR-GIP responses are given in 
Table 3.5.1. These confirm the significantly superior handling of the glucose challenge 
by the cold acclimated animals. 
Table 3.5.1 Integrated Plasma Glucose, IR-Insulin and IR-GIP Responses to an 
Oral Glucose Challenge in Wistar Rats Undergoing Cold Acclimation 
Values are expressed as mcan±SEM for groups of 7 (cold acclimated) or 12 (warm 
control) rats. Symbols (*, **) indicate values significantly different from the control 
group when assessed by one way analysis of variance followed by Scheffe range test, 
*=p<0.05; **=p<0.01. Integrated responses were calculated as described in Section 
2.9. 
Study Group Integrated Plasma Integrated Plasma Integrated Plasma 
Glucose Response IR-Insulin IR-GIP Response 
(mmol/1). hr-1 Response (pmolIl). hrl 
(nz/ml). hr-1 
Warm Control Rats 176.3 ± 15.4 91.8 ± 12.8 3579.2 ± 99.3 
2 Weeks Cold 70.7 ± 16.0 ** 129.9 ± 28.2 8203.8± 104.8 
Exposed Rats 
5 Weeks Cold 95.3 ± 25.4 69.3 ± 21.1 4657.0 ± 98.2 
Exposed Rats 
Mean fasting plasma IR-insulin concentrations were significantly lower at both 
stages of cold acclimation (p<0.05). Repeated measures analysis of variance revealed 
significant response differences between groups (p<0.05). However, within the 
groups the response over time was similar. The plasma IR-insulin response after 2 
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weeks of cold acclimation was similar to the response of warm control rats. By 5 
weeks of cold acclimation, the maximum plasma insulin concentration attained was 
significantly reduced in comparison to the warm control animals. The overall quantity 
of insulin secreted (assessed from the integrated value in Table 3.5.1) in response to the 
glucose challenge was not significantly modified in spite of this. 
Differences in basal IR-GIP values were no longer apparent after fasting the 
animals for 18 hours. The plasma IR-GIP response to the glucose challenge was 
significantly different between the groups over time (p<0.05). These differences were 
revealed to be between the warm control rats and the 2 week cold exposed rats. The 
two week cold exposed rats demonstrated a heightened IR-GIP response to the glucose 
challenge at the 60 minute time point and an augmented integrated response (p<0.05, 
Table 3.5.1). Both cold acclimated groups showed a slower return to base line values 
when compared with warm control rats. 
An oral glucose challenge during cold acclimation produced a superior glucose 
tolerance which was maintained as cold acclimation proceeded. The superior glucose 
tolerance was not due to a modified insulin response but was accompanied by an 
augmented IR-GIP response during the early stages of cold acclimation. 
3.5.3.3.2 Oral Fat Tolerance Test 
Again this test was performed after 14 and 35 days of cold exposure in order to 
investigate tolerance during, and after complete cold acclimation. Different animals from 
the same groups as previously investigated were used (Figure 3.5.5). 
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Figure 3.5.5 The Effects of the Process of Cold Acclimation on the Response 
to an Acute Oral Fat Challenge (51.2k, J/kg Body Weight) 
Animals were fasted 18 hours prior to the test. Values are expressed as 
mean±SEM for groups of 12 (warm control) or 7 (cold acclimated) rats. 
Symbol 0 indicates a value significantly different from the control value at 
that time point when assessed by a one-way analysis of variance followed by 
Scheffe range test, 0=p<0.05. 
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Plasma glucose and plasma IR-insulin concentrations showed no significant 
response to the oral fat challenge, either between or within each of the 3 study groups, 
when assessed by repeated measures analysis of variance. Plasma IR-GIP response 
likewise showed no difference in response between groups or within each group when 
assessed over time. When single time points were analysed, the rats which had been 
subjected to 2 weeks of cold exposure had a significantly greater (p<0.05) maximum 
IR-GIP response at 60 minutes when compared with warm control animals. By 5 
weeks of cold acclimation, this difference had disappeared. Integrated IR-GIP 
responses however revealed that this difference in maximum IR-GIP response had no 
significant effect on the overall IR-GIP response (Table 3.5.2). 
Table 3.5.2 Integrated Plasma IR-GIP Response to an Oral Fat Challenge in Wistar 
Rats Undergoing Cold Acclimation 
Values are expressed as mean±SEM for groups of 7 (cold acclimated), or 12 (warm 
control) rats. Integrated responses were calculated as described in Section 2.9. 
Study Group Integrated Plasma IR-GIP Response 
(mol/l). hrl 
Warnur Control Rats 1328.4 ± 676.7 
2 Weeks Cold Exposed Rats 1617.2 ± 565.2 
5 Weeks Cold Exposed Rats 1533.6 ± 1621.6 
3.5.3.4 Insulin Sensitivity Test 
This intraperitoneal challenge was performed after 42 days of cold acclimation 
in 18 hour fasted animals (Figure 3.5.6). 
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Figure 3.5.6 The Effects of Six Weeks Cold Acclimation on Insulin 
Sensitivity in \Vistar Rats 
Porcine insulin was administered in a single intraperitoneal injection at time 
0 at a dose of (IU/2ml)/kg body weight. Values are expressed as 
mean±SEM for 7 (cold acclimated) or 6 (warm acclimated) rats. Symbols 
(*, **) indicate values significantly different from control values at that time 
point when assessed by Student's unpaired t-test, *=p<0.05; **=p<0.01. 
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Repeated measures analysis of variance revealed significant differences in 
plasma glucose concentration between the two groups over time (p<0.01) with an 
interaction of environmental temperature. Fasting insulin values of the two groups 
were similar but over the following 60 minutes of the test, the cold acclimated animals 
had superior insulin sensitivities as shown by the steeper fall in plasma glucose 
concentration. Cold acclimated animals did however show a return to control plasma 
glucose concentrations 120 minutes after insulin administration. 
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3.5.3.5 The Effects of Cold Acclimation with and without Concomitant 
Hvperphagia on Brown Adipose Tissue Mass 
The results are summarised in Figure 3.5.7. Interscapular brown adipose tissue 
changes were believed to reflect changes at other brown adipose sites. The BAT was 
excised from the animals on day 42 of cold exposure. 
Figure 3.5.7 
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One-way analysis of variance of BAT mass followed by Scheffe's range test 
revealed that both cold acclimated groups of rats had significantly greater BAT masses 
than the warm control group. There was no significant difference in BAT mass 
between ad libitum fed and food restricted cold acclimated animals after 6 weeks cold 
exposure. Both cold treated groups had doubled their mass of interscapular BAT. 
The Effects of Cold Acclimation With and Without Concomitant 
Hyperphagia on Interscapular BAT Mass 
Values are mean±SEM for groups of 7 (cold ad libitum fed), 5 (cold pair fed) 
and 6 (warm control) rats. Symbol (**) indicate values significantly 
different from controls, **=p<0.01. 
  Control Rats 
Q Cold ad libitum fed rats 
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3.5.3.6 The Effects of Cold Acclimation with and without Concomitant 
Hyperphagia on Small Intestinal Entero-Endocrine Function 
Hyperphagia of 36 days duration had no significant effect on intestinal wet 
weight in the cold ad libitum fed rats (Figure 3.5.8). 
Figure 3.5.8 The Effects of Cold Acclimation With and Without Concomitant 
Hyperphagia on Small Tntestinal Wet Weight 
Values are expressed as mean±SEM for groups of 7 (cold ad libitum fed), 5 
(cold pair fed) and 6 (warm control) rats. 
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Relative intestinal weights were similar in the 3 study groups after 42 days of 
cold acclimation. The concentrations of IR-GIP and IR-GLP-1(7-36)amide have been 
calculated on ag wet weight/kg body weight basis to take into consideration the 
difference in size of the animals. 
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Figure 3.5.9 The Effects of Cold Acclimation With and Without Concomitant 
Hyperphagia on Small Intestinal IR-GIP 
Values are expressed as mean±SEM for groups of 7 (cold ad libitum fed), 5 
(cold pair fed) and 6 (warm control) rats. Symbol (0,00) indicates a value 
significantly different from the warm control group when assessed by one 
-way analysis of variance and Scheffe range test, 0=p<0.05; 00=pc0.01. 
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Six weeks of cold acclimation with unrestricted food intake had no significant 
effect on the total amount of extractable IR-GIP but did reduce the relative concentration 
of IR-GIP in the small intestine (p<0.01). Restricted feeding and cold exposure also 
significantly reduced the concentration of IR-GIP in the small intestine of the pair-fed 
  Control Rats 
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rats (p<0.01). There was no significant difference between either of the cold-treated 
groups. 
Figure 3.5.10 The Effects of Cold Acclimation With and Without Concomitant 
Hyperphagia on Small Intestinal IR-GLP-I (7-36)amide 
Values are expressed as mean±SEM for groups of 7 (cold ad libitum fed), 5 
(cold pair fed) and 6 (warm control) rats. 
500 
. t? 400 
E 
C 
M "ý 300 
.ýc 200 
Va', 
p" 100 
0 
Total Intestinal IR-GLP-1(7-36)amide 
  Control Rats 
Q Cold Ad Libitum Fed Rats 
® Cold Pair Fed Rats 
Intestinal IR-GLP-I (7-36)amide concentration 
30 
aý O 
25 
"v ý 
20 
e' p" 15 
ý--ý C1p 
a. '3 10 
va', 3 5 
CIO 
E o 
a 
U 
n 
Control Rats 
Cold Ad Libitum Fed Rats 
Cold Pair Fed Rats 
Cold acclimation in the Presence of hyperphagia had no significant influence on 
total extractable IR-GLP-1(7- 36)arnide or the relative concentration of IR-GLP-1(7- 
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36)amide in the small intestine. Again there was no significant difference between 
either cold treated group. 
3.5.4 Discussion 
Over the first 6 days of cold exposure both the pair-fed and the ad libitum fed 
rats exhibited an initial stress reaction to the change in environmental temperature from 
22°C to 4°C. The growth curve of both these groups of animals levelled off. The cold 
ad libitum fed rats responded with a rapid (49%) increase in food intake above normal. 
This subsequently increased the slope of their growth curve to mean values below, but 
statistically indistinguishable from, age-matched, warm acclimated control rats. The 
cold-exposed pair-fed rats, unable to increase food intake, exhibited retarded growth as 
their food consumption failed to meet the increased metabolic demand induced by cold 
exposure. Surprisingly, body weight changes never became negative unlike the weight 
loss observed with pair feeding in previous studies (Johnson et al., 1982; Kuroshima 
& Yahata, 1985; Puerta & Abelenda, 1987). This may be attributable to differences in 
the dietary mixture utilised in the various studies and the relatively high food intake 
recorded by the warm control animals during this study. 
Despite the differences in food intake between the two cold acclimated groups 
of rats, their relative interscapular BAT mass after 6 weeks cold exposure was 
comparatively similar. Both groups showed a mean doubling of the control values. 
This is in agreement with the findings of Kurishima & Yahata (1985) and Puerta & 
Abelenda (1987). The data supports the hypothesis that the improved cold tolerance 
upon prolonged cold exposure is related to the adaptation to the lower temperature 
rather than to an increased food intake. 
Basal plasma measurements revealed that cold acclimation produced an 
increased plasma glucose concentration that developed faster in the presence of, but 
was not dependent on, hyperphagia. The increase in glucose was apparent 2-3 weeks. 
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after cold exposure. Raised basal plasma glucose concentrations have also been 
reported by Cunningham et al. (1985). However other studies have reported no change 
from control values (Depocas & Masironi, 1960; Kuroshima et al., 1978) whilst a few 
have shown a fall in basal plasma glucose with cold acclimation (Beck et al., 1967; 
Harada et al., 1982). 
Cold stress causing hypothermia can directly influence insulin release. Several 
mechanisms for its action have been proposed, including reduced potassium 
conductance by the B cell (Dawson et al., 1986; Atwater et al., 1984) or impaired 
calcium influx (Escolar et al., 1987). In the present study, 3 days of continuous cold 
exposure significantly depressed basal insulin levels in both cold treated groups, 
suggesting an acute cold stress effect. In the pair-fed cold exposed animals, plasma 
insulin levels remained markedly suppressed throughout the study period. This is most 
probably the result of the semi-starved state of these animals. 
The cold hyperphagic animals, on the other hand, recovered normal basal 
plasma insulin levels around the same time as the hyperphagia became apparent. 
Fasting prior to the glucose challenge significantly lowered the insulin levels of these 
animals, suggesting that their insulin levels were normally dependent on the presence of 
hyperphagia. In warm acclimated animals, hyperphagia due to cafeteria feeding 
produces a hyperinsulinaernia which has been shown to be reversed by a cold 
environment (Vallerand et al., 1986). This effect was attributed to activation of the 
sympathetic innervation of the pancreas during cold exposure inhibiting insulin 
secretion. In contrast to the normal circulating basal insulin levels described in the 
present study, other workers have reported a progressive fall in pancreatic insulin 
output during cold acclimation in the presence of hyperphagia (Edwards & Howland, 
1986). In the glucose challenge test, however, there was a progressive fall in the 
insulin response, supporting the idea of changes in insulin secretory patterns to be due 
to cold acclimation rather than exposure. The increased insulin sensitivity reported in 
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the cold hyperphagic animals is well documented and believed to be due to increased 
blood flow to the tissues controlled by sympathetic stimulation (Foster & Frydmann, 
1979; Vallerand et al., 1986). 
In comparison to the food-restricted, cold-acclimated animals, basal plasma IR- 
GIP concentrations in the cold-treated hyperphagic animals showed major changes over 
the 6-week period of cold acclimation. IR-GIP concentrations in the presence of cold 
exposure and hyperphagia achieved maximum concentrations on day 17 of the study 
(10 days after cold exposure began and 4 days after food intake significantly 
increased). These raised basal levels were maintained over the next 10 days and then 
subsequently fell, despite maintenance of the hyperphagia, to concentrations 
intermediate between the warm control and pair-fed animals. The cold-exposed pair- 
fed group had consistently low plasma IR-GIP levels reflecting their semi-starved state. 
The cold hyperphagic animals demonstrated a classical adaptation response of 
an initial alarm reaction followed by a stage of resistance and finally reaching a stage of 
adaptation (Selye, 1976). In these animals it is possible that the rapid development of 
the hyperphagic condition caused an initial hyperstimulation of the K cell before 
adaptation or exhaustion of the K cell occurred. Measurements of intestinal entero- 
endocrine function in fully acclimated rats revealed that significant differences were 
present between cold acclimated and warm acclimated animals with regard to both IR- 
GIP and IR-GLP-1(7-36)amide. Hyperphagia, of 38 days' duration, in the cold ad 
libitum fed animals did not modify intestinal IR-GIP or IR-GLP-1(7-36)amide beyond 
the differences imposed by the cold treatment. Intestinal measurement revealed that the 
fall in plasma IR-GIP of the cold hyperphagic animals was not due to exhaustion of the 
K cell, but to some adaptive response. 
Both GIP and GLP-1(7-36)amide are stimulated by a mixed meal (Krevrnann et 
al., 1987). The observation that both these hormones are increased in the intestines of 
cold acclimated animals to a similar degree in spite of the differences in food 
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consumption would suggest that alternative or additional factors are mediating their 
increase. Insulin has been proposed to operate a negative feedback on GIP secretion 
(Brown et al., 1975). It may be speculated that a similar feedback mechanism could 
exist on GLP-1(7-36)amide secretion. Cold-acclimated, pair-fed animals had markedly 
reduced plasma insulin levels and the hyperphagic animals had a suppressed insulin 
response to a glucose challenge after prolonged cold exposure. Potentially the increase 
in intestinal IR-GIP and IR-GLP-1(7-36)amide could be due to modification of this 
feedback loop. 
Cold acclimation takes three weeks before the animal is completely acclimated 
(Smith & Horwitz, 1969). Insulin secretion in cold adapted animals is strongly 
opposed by sympathetic stimulation and plasma glucagon has been reported to increase 
significantly as a result. Glucagon has potentially been implicated in direct BAT 
activation (Howland, 1986) but glucagon also strongly stimulates lipolysis in white 
adipose tissue, providing the metabolic fuel necessary for BAT activity. However, in 
the presence of a reduced insulin concentration lipolysis could well proceed at a faster 
rate than necessary or desirable. GLP-1(7-36)amide has been shown to inhibit 
glucagon release (Kreymann et al., 1987) and GIP has been shown to competitively 
block glucagon stimulated lipolysis (Eben & Brown, 1976). Therefore, it could be 
speculated that these two hormones may be important in slowing the rate of lipolysis in 
the initial stages of cold exposure before BAT is capable of handling the increase in free 
fatty acids. In addition, GIP may also be involved in stimulating the increased activity 
of lipoprotein lipase (LPL) of white adipose tissue that has been reported in prolonged 
cold exposure (Deshaines et al., 1986). Increasing LPL activity in white adipose tissue 
would provide an additional source of free fatty acids. 
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GLP-1(7-36)amide also has the ability to stimulate fatty acid synthesis (Oben et al., 
1991c). The potential roles of these hormones in cold acclimation has yet to be 
elucidated but their direct biological actions on adipose tissue may well be of equal if 
not greater importance with their incretin actions under these circumstances. 
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3.6 Conclusions 
All four studies have looked at entero-endocrine function under different 
physiological situations for rats. 
The pregnancy and lactation study revealed that the hyperphagia associated with 
these states was not the only influence on IR-GIP secretion as the acute IR-GIP 
response to nutrients was not grossly modified. The intestinal concentration of IR-GIP 
and IR-GLP-1(7-36)amide was significantly influenced by pregnancy, when the 
increase in food intake was only moderately increased. The insulin resistance of 
pregnancy may possibly be influencing entero-endocrine function. Down-regulation of 
the negative feedback removing a controlling influence on the K and possibly the L cell. 
Lactation has been reported to be an insulin-sensitive situation and an increased insulin 
feedback on the K and L cell may be responsible for off-setting the increased 
stimulation of the large rise in food intake. An increased GIP and GLP-1(7-36)amide 
response during lactation would not be desirable as it could reduce the supply of 
nutrients for milk synthesis. The possibility of GIP and GLP-1(7-36)amide being 
taken up into rat milk and its possible importance in the neonatal intestine remains to be 
established. 
The ontogeny and litter size studies both indicated that the biological action of 
IR-GIP in white adipose tissue may well be of more importance than its incretin 
function during suckling. Rapid adipose deposition is essential for the rat in order to 
conserve heat loss and to provide an energy store. The importance of GLP-1(7- 
36)amide in this function has been suggested by studies in pigs. Plasma assays for 
GLP-1(7-36)amide are as yet not sensitive enough for use in rats. 
The cold acclimation study showed an adaptive response of IR-GIP to cold 
acclimation. Again this study supported the assumption that the other biological actions 
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of GIP are of importance. To date no studies have been reported investigating any 
possible direct actions of GIP or GLP- I (7-36)amide on brown adipose tissue. This is 
an area of research requiring further study. 
BAT is of course very important in neonatal life, particularly in rats. The 
increased IR-GIP response to acute challenge at this time would support the idea of a 
role for GIP and GLP- 1(7-36)amide in the activation/proliferation of BAT. 
Alternatively both hormones may have a supporting role providing, through their action 
on white adipose tissue, the necessary fuel supply for the BAT. BAT has been 
reported to shut down during lactation in mice (Trayhurn et al., 1982). The same may 
well be true for rats. This may explain the absence of a modified GIP response to the 
increased food intake at this time. 
A great deal of further work is necessary in this area. The incretin role of these 
two hormones has received most attention so far but other functions may well be of 
equal importance in physiological states. 
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Chapter 4.0 
MEASUREMENT OF BASAL AND NUTRIENT 
STIMULATED PLASMA IR-GIP AND INTESTINAL 
ENTERO-ENDOCRINE FUNCTION IN 
PATHOPHYSIOLOGICAL STATES ASSOCIATED WITH 
HYPERPHAGIA 
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The following t: o studies all 
demonstrate hyperphagic conditions where the normal 
insulin homeostasis pattern is grossly disturbed either by artificial (chemical or tumour 
induced) or spontaneous (autoimmune) means. The aims of the three studies were to 
investigate whether normal entero- endocrine K and L cell secretory functions were 
modified by the pathological conditions imposed on the animals. Each study will be 
considered separately and overall conclusions will be discussed at the end of the 
Chapter. 
4.1 The Effects of an Tnsulinoma upon Basal and Nutrient Stimulated 
Plasma IR-GIP and Intestinal IR-GIP and IR-GLP-1(7-36)amide 
4.1.1 Introduction 
The NEDH rat insulinoma has been largely exploited as a model for 
investigations into insulin secretion and biosynthesis (Flats & Swanston-Flatt, 1985). 
Subscapular transplantation of insulinoma fragments results in a highly vascularised, 
encapsulated tumour. Tumour development is associated with progressive 
hypoglycaemia, hyperinsulinaemia and hyperphagia (Flats et al., 1987). The inability 
of the animal to maintain normoglycaemia eventually culminates in neuroglycopenia. 
The aims of this study were to investigate how hyperphagia, hypoglycaemia 
and hyperinsulinaemia might influence the normal functioning of the GIP-secreting K 
cell in both the basal state and in response to acute nutrient stimulation. Small intestinal 
concentrations of IR-GIP and IR-GLP-1(7-36)amide were also measured in tumour- 
bearing and control NEDH rats for comparative purposes. 
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4.1.2 \Iethrdc 
4.1.2.1 Animals and their Treatment 
Thirty six (24 tumour bearing and 12 control) male, inbred, albino, New 
England Deaconess Hospital (NEDH) rats from the colony maintained at the University 
of Surrey Experimental Unit, were used at 8-12 weeks of age (approximately 275-3508 
body weight). Animals were caged in groups of 6 under conditions described in 
Section 2.1. Plasma measurements were performed in two studies. This was 
necessitated by the short time between transplantation and development of 
hypoglycaemia in insulinoma-bearing animals (less than three weeks following 
transplantation). It also ensured that the tests were performed on animals with similar 
sized tumours and therefore similar insulin levels. The first study investigated the 
effects of hyperphagia, hypoglycaemia and hyperinsulinaemia on GIP secretion in the 
acute and basal state. The second study looked at the effect of exogenous porcine GIP 
on insulin secretion. 
4.1.2.2 lnsulinoma Transplantation 
The time course of transplantation is outlined in Figure 4.1.1. Cryogenically 
preserved insulinonia tissue was thawed and transplanted into recipient rats on two 
occasions before use to ensure an active insulin-producing tumour for the experiment. 
Tumours were transplanted by excision of the tumour from the cadaver donor rat, 
removal of the capsule to expose the tumour and then fine mincing of the tumour, with 
a scalpel, until it could be taken up into a In-11 syringe. Recipient rats were 
anaesthetised with ether and 0.1-0.15ml of minced tumour was implanted 
subcutaneously into the subscapular region using a 16 gauge needle. 
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Figure 4.1.1 Transplantation of Tumour 
Cryogenically preserved tumour Line 17 
37°C 
Transplanted into 4 NEDH males 14 weeks old 
(0.15 ml/rat) 
19 days post transplantation 
Tumours removed from 2 rats 2 other rats 
1 died day 22 
1 died day 40 
Transplanted into 4 NEDH males 
13 weeks old 
(0.15 ml/rat) 
18 days post transplantation 
Tumours removed from 1 animal 
3 rats already dead 
Study 1 (0.1 m1/rat) n=24 
14 days post transplantation 
tumours removed from 3 rats 
Study 2 n=12 
(0.1 ml/rat) 
4.1.2.3 Experimental Procedure 
During the first study, the effects of insulinoma development on food intake and 
body weight were monitored daily. In addition to the standard pellet diet, all 
insulinorna-bearing rats received D-glucose, given in their drinking water at 10% (w/v). 
This was included from day 13 post-transplantation onwards. The aim of this was to 
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provide an easily assimilated source of carbohydrate to offset the developing 
hypoglycaemia. The survival times of the rats were recorded and the weights of the 
tumours (including capsule) noted at autopsy. 
Basal levels of glucose, IR-insulin and IR-GIP were measured in 6 insulinoma- 
bearing and 6 control rats on days 5,8,10 and 12 post-transplantation. Blood was 
sampled, between 0900-1200 hours, from the cut tail tip of non-fasted, conscious rats. 
Collection of blood and its handling has been discussed in Section 2.4.1. 
The exact nature of the provocative tests was detailed in Section 2.2. In the first 
study, an oral fat challenge (51.2kJ/kg body weight) and an oral glucose challenge 
(51.2kJ/kg body weight) were administered to two groups of insulinoma-bearing rats 
and their controls on day 14 post-transplantation. Plasma was aliquoted for the 
determination of glucose, IR-insulin and IR-GIP. 
In the second study, intraperitoneal glucose challenges were performed on day 
14 post-transplantation. Intraperitoneal glucose (51.2kJ/kg body weight) with and 
without intraperitoneal porcine GIP (50pg/kg body weight) was administered 
simultaneously in the same volume used for the oral glucose challenge. 
Because of the severity of the hyperinsulinaemia and corresponding 
hypoglycaemia of the insulinoma-bearing rats, all provocative tests were performed in 
the basal, non-fasted, state. 
On day 17 post-transplantation in study one, insulinoma-bearing rats were 
fasted and blood samples collected at 30-minute intervals for up to two hours to 
illustrate the effect of food restriction on these animals. 
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Small intestines were obtained from insulinoma-bearing and control rats of the 
second study on day 16 post-transplantation. The process of excision and subsequent 
treatment has been detailed fully in Section 2.4.2. 
4.1.3 Results 
The first casualties in the insulinoma-bearing rats were recorded on day 13 of 
both studies. Mean survival of the rats in study one was 16 ±3 days, (mean±SD for 
n=16). 
4.1.3.1 Body Weiht and Food Intake 
Body weight was recorded throughout the study. The data are presented up 
until the start of the provocative tests, (day 14). 
Figure 4.1.2 The Effects of an Insulin Secreting Tumour in NEDH Rats on 
Body Weicht 
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Values are expressed as mean±SEM for groups of 6 rats. Tumour fragments 
(0.1 ml/rat) were implanted subcutaneously in the subscapular region on 
day 0. 
Control NEDH Rats 
-t' Insulinoma Bearing NEDH Rats 
02468 10 12 14 
Days Post Transplantation 
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Repeated measures analysis of variance revealed that no significant differences 
in body weight were apparent between the insulinoma-bearing and control rats during 
the study period. Within each group over the study period body weight increased 
steadily but not significantly. 
Figure 4.1.3 The Effects of an Insulin Secreting Tumour on Food Intake in 
NEDH Rats 
Values are expressed as mean±SEM for groups of 6 rats. Tumour fragments 
(0.1 ml/rat) were implanted subcutaneously in the subscapular region on 
day 0. Symbol (**) indicate values significantly different from the control 
group, at that and subsequent time points, when assessed by repeated 
measures analysis of variance and Student's unpaired t-test, **=p<0.01. 
Control NEDH Rats 
60 Insulinoma Bearing NEDH Rats 
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Food consumption data showed significant differences between control and 
insulinoma-bearing animals over the study period, when assessed by repeated measures 
analysis of variance (p<0.01). Hyperphagia became established in the insulinoma- 
bearing animals at 10 days post-transplantation. Food consumption in the insulinoma 
rats continued to increase until day 13-14 post-transplantation. Between days 14-17, 
mean food intake was maintained at 45-50g/rat/24 hours in the insulinoma-bearing 
group. 
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4.1.3.2 Basal Levels of Plasma Glucose. IR-Insulin and IR-GIP in Insulinoma 
Bearing EDH Rats 
The regular sampling and assay of blood revealed the metabolic consequences 
of tumour development. The establishment of the tumour with its concomitant 
hyperphagia resulted in an increase in circulating plasma IR-insulin and plasma IR-GIP 
concentrations, with a precipitous fall in plasma glucose (Figure 4.1.4). 
Repeated measures analysis of variance revealed that the changes in all three 
plasma variables over time were significant (glucose, p<0.01; IR-insulin, p<0.01 ; 
IR-GIP, p<0.01). Student's unpaired t-test revealed that by 8 days post-transplantation 
the insulinoma-bearing animals had significantly elevated plasma IR-insulin levels. The 
depression in plasma glucose levels became significant two days later on day 10. 
Glucose concentrations continued to fall as plasma IR-insulin levels increased. Plasma 
IR-GIP levels were significantly elevated in the insulinoma rats on day 10 post- 
transplantation, the same day that the food intake of these animals became significantly 
increased. By the start of the provocative tests, the insulinoma-bearing rats exhibited 
marked hypoglycaemia, severe hyperinsulinaemia and hyperphagia. 
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Figure 4.1.4 The Effects of an Insulin Secreting Tumour on Plasma Glucose. 
Plasma IR-Insulin and Plasma IR-GIP in NEDH Rats 
Values are expressed as mean±SEM for groups of 6 animals. Symbols 
(*, **) indicate values significantly different from the control group when 
assessed by Student's unpaired t-test, *=p<0.05; **=p<0.01. 
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68 10 12 
Days Post Transplantation 
4.1.3-3 Acute Nutrient Stimulation Tests 
4.1.3.3.1 Oral Glucose Tolerance Test 
The responses of the two groups to this challenge are summarised graphically in 
Figure 4.1.5. 
As a result of not fasting the rats, the individual responses of the animals were 
very variable and the plasma values obtained at the zero time varied considerably 
between the insulinoma-bearing and the control rats. At all time points, the insulinoma- 
bearing animals had significantly lower plasma glucose levels and significantly higher 
plasma IR-insulin levels when compared to their controls. The incremental and 
integrated responses of the animals were calculated to aid comparison. These 
responses were calculated as described in Section 2.9. The results are summarised in 
Tables 4.1.1 and 4.1.2. 
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Figure 4.1.5 The Effects of the Oral Administration of Glucose (51.2kJ kg 
hod weiht) in Insulinoma Bearing and Control NTEDH Rats 
Values are expressed as mean±SEM for groups of 6 animals. This test was 
administered 14 days post transplantation Symbol (**) indicates values 
significantly different from control values at that time point when assessed 
by Student's unpaired t-test, **=p<0.01. 
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Table 4.1.1 Incremental Resnonses of Insulinoma Bearing and Control N"EDH Rats 
to an Oral Glucose Challenee (51.2kJ/kgbody weight) 
Values are mean±SEM for groups of 6 rats. Incremental responses were calculated as 
described in Section 2.9. Symbols (*, **) indicate values significantly different from 
control values when assessed by means of Student's unpaired t-test, *=p<0.05; 
**=p<0.01. 
Study Group Incremental Plasma Incremental Plasma Incremental Plasma 
Glucose Response IR-Insulin IR-GIP Response 
(0-30 minutes) Response (0-30 minutes) 
mmol/l (0-30 minutes) pmol/1 
n m1 
Insulinoma Bearing 
NEDH Rats 2.5 ± 0.4 * 113.3 ± 20.8 182.5 ± 29.7 
** 
Control NEDH 
Rats 4.9±0.7 5.2±0.2 118.3±29.7 
Table 4.1.2 Integrated Responses of Insulinonia Bearing Rats to an Oral Glucose 
Challenge (51.2kJ/kg body weight) 
Values are mean±SEM for groups of 6 rats. Integrated responses were calculated as 
described in Section 2.9. Symbol (**) indicates values significantly different from 
control values when assessed by means of Student's unpaired t-test, **=p<0.01. 
Study Group Integrated Plasma Integrated Plasma Integrated Plasma 
Glucose Response IR-Insulin IR-GIP Response 
(0-120 minutes) Response (0-120 minutes) 
(mmol/1). hr-l (0-120 minutes) (pmol/l). hr1 
(n ml). hrl 
Insulinoma Bearing 
NEDH Rats 17.9 ± 21.6 2420.5 ± 873.9 2200 ± 1600 
Control NEDH 
Rats 139.8 ± 30.8 125.5 ± 13.1 4100 ± 900 
The insulinoma-bearing, animals were able to respond to the oral glucose 
challenge with a significantly greater insulin response than the control rats. As a 
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consequence of their excessive insulin concentrations the incremental plasma glucose 
response was significantly attenuated. When the marked difference in basal GIP levels 
is excluded there was no difference in the GIP response of the insulinoma-bearing and 
control rats either incrementally or expressed as the integrated response. 
4.1.3.3.2 Oral Fat Tolerance Test 
The results of this test are summarised in Figure 4.1.6. 
Oral fat administration did not significantly modify plasma insulin 
concentrations in either the insulinoma-bearing or the control groups. Plasma glucose 
fell significantly, over the time course of the test, in the insulinoma animals (within 
group repeated measures analysis of variance p<0.01). Integrated responses have been 
calculated to aid comparison of the two groups; these are summarised in Table 4.1.3. 
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Figure 4.1.6 The Effects of the Oral Administration of a Corn Oil Suspension 
(51.2kJ/kgbody weight) on Insulinoma Bearing and Control 
NEDH Rats 
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Values are expressed as mean±SEM for groups of 6 animals. This test was 
performed 14 days post transplantation. Symbol (**) indicates values 
significantly different from control values at that time point when assessed 
by Student's unpaired t-test, **=p<0.01. 
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Table 4.1.3 Integrated Responses of Insulinoma Bearing and Control NEDH Rats 
to an Oral Fat Challenge (51.2kJ/kgbody weight) 
Values are mean±SEM for groups of 6 rats. Integrated responses were calculated as 
detailed in Section 2.9. Symbol (*) indicate values significantly different from 
control values when assessed by means of Student's unpaired t-test, *=p<0.05. 
Study Group Integrated Plasma Integrated Plasma Integrated Plasma 
Glucose Response IR-Insulin IR-GIP Response 
(0-120 minutes) Response (0-120 minutes) 
(mmol/l). hrl (0-120 minutes) (pmol/l). hrI 
(n ml). hrl 
Insulinoma Bearing 
NEDH Rats -31.4 ± 8.9 * -906.2 ± 649.3 11200 ± 2300 
Control NEDH 
Rats 8.4 ± 7.9 20.1 ± 23.6 3200 ± 1200 
The integrated insulin responses of the insulinoma-bearing animals were very 
variable. As a result the standard error of the response was very great and masked 
significant differences. An oral fat challenge significantly reduced the plasma glucose 
concentration of the tumour-bearing rats; the excessive insulin levels also fell during the 
test but were still extremely high. The acute plasma IR-GIP response of the 
insulinoma-bearing animals was heightened in comparison with the control rats. 
4.1.3.3.3 Inrraperitoneal Glucose Challenge Tests 
These tests were performed in study two. The basal IR-insulin levels of the 
insulinoma-bearing animals in this study were more variable than the levels seen in 
study one. The test was performed in the presence and absence of porcine GIP. 
Plasma was collected for glucose and IR-insulin assay only. 
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Figure 4.1.7 The Effects of an Insulin Secreting Tumour on the Plasma 
Glucose Response to an Intraperitoneal Glucose and GIP 
Challenge (51.2kJ and 50"1 /kg body weight respectively) in 
NEDH Rats 
Values are mean±SEM for groups of 5 rats. Symbols (*, **) indicate values 
significantly different from control values when assessed by means of 
Student's unpaired t-test, *=p<0.05; **=p<0.01. 
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For both the control and insulinoma-bearing rats glucose tolerance was 
improved in the presence of porcine GIP, significantly so for the insulinoma-bearing 
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animals (repeated measures analysis of variance p<0.01). This is confirmed by the 
significant difference in the integrated glucose responses for the insulinoma-bearing 
animals (Table 4.1.4). 
Figure 4.1.8 The Effects of an Insulin Secretin a Tumour on the Plasma 
IR-Insulin Response to an Intraperitoneal Glucose and GIP 
Challenge(51.2kJ and 50U kg body weight respectively) in 
NEDH Rats 
Values are mean±SEM for groups of 5 rats. Symbols (*, **) indicate values 
significantly different from control values when assessed by means of 
Student's unpaired t-test, *=p<0.05; **=p<0.01. 
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The improvement in glucose tolerance, for both groups, in the presence of GIP, 
was achieved by an increased peak insulin secretion. However the large individual 
variation in the insulinoma-bearing animals response masks any significant difference 
in the integrated response of these animals (Table 4.1.4). The control rats had a 
significantly greater total IR-insulin response in the presence of porcine GIP. 
Table 4.1.4 Integrated Plasma Glucose and IR-Insulin Responses of Insulinoma 
Bearing Rats and Their Controls 
Values are mean±SEM for groups of 5 rats. Integrated responses were calculated as 
described in Section 2.9. Symbol (*) indicates values significantly different from 
response to IP Glucose alone when assessed by means of Student's unpaired t-test, 
*=p<0.05. 
Study Group IP Glucose IP Glucose and 
GIP 
IP Plasma IP Plasma IR- IP Plasma IP Plasma IR- 
Glucose Insulin Glucose Insulin 
Response (0- Response (0- Response (0- Response (0- 
120 minutes) 120 minutes) 120 minutes) 120 minutes) 
(mmol/1). hr-1 (nom ml). hr1 (mmol/1). hr-1 (n ml). hrl 
Insulinoma 
Bearing NEDH 465.5 ± 49.2 3212.4 ± 1311 213.8 ± 33.2 * 1562.9 ± 2263.5 
Rats 
Control NEDH 
Rats 806.5 ± 102.9 89.3 ± 19.8 489.5 ± 71.7 170.6 ± 22.6 
4.1.3.4 The Effects of Food Withdrawal on Basal Levels of Plasma Glucose. 
IR-Insulin and IR-GIP in Insulinoma Bearing NEDH Rats 
This was performed on day 17 post-transplantation. The results are 
summarised in Figure 4.1.9. 
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Figure 4.1.9 The Effects of the Removal of the Food Supply on Insulinoma 
Bearing NEDH Rats 
Values are expressed as mean±SEM for groups of 5 rats. Symbols (*, **) 
indicate values significantly different from time 0 as assessed by Student's 
paired t-test, *=p<0.05; **=p<0.01. 
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On removal of the food supply from the insulinoma-bearing rats there was a 
rapid and significant fall in plasma glucose. This decline in plasma glucose continued 
throughout the two hours. Plasma IR-insulin concentrations declined on the removal of 
food, but the decrease in concentration was only significant after 90 minutes. The 
levels at the end of the two hour period were still exceptionally high. Plasma IR-GIP 
declined rapidly and significantly over the first hour of the experiment but after two 
hours the levels were still comparable with basal levels of the control NEDH rats. 
4.1.3.5 The Effects of an Insulin Secreting Tumour on Small Intestinal 
Entero-Endocrine Function in NEDH Rats 
Hyperphagia of six days' duration preceded the excision of the small intestines. 
The influence of the pathological condition of tumour development on intestinal wet 
weight is summarised in Figure 4.1.10. 
Figure 4.1.10 The Effects of an Insulin Secreting Tumour on Small Intestinal 
Wet Weight in NEDH Rats 
Values are expressed as mean±SEM for groups of 6 rats. Symbol (**) 
indicates a value significantly different from the control group when assessed 
by Student's unpaired t-test, **=p<0.01. 
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Actual intestinal wet weight was increased 30% in the insulinoma-bearing 
animals. Relative intestinal weight was also significantly increased in the insulinoma- 
bearing animal after 6 days of hyperphagia. Body weights were similar between the 
two groups, insulinoma-bearing animals being slightly, but not significantly, heavier 
than the control animals. 
Figure 4.1.11 The Effects of an Insulin Secreting Tumour on Small Intestinal 
IR-GIP in NEDH Rats 
Values are expressed as mean±SEM for groups of 6 rats. 
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The growth of an insulinoma together with six days of hyperphagia had no 
significant effect either on total extractable GIP content of the small intestine or its 
actual concentration (pmol/g wet weight) or its relative concentration (pmol/g wet 
weight/kg body weight). 
Figure 4.1.12 The Effects of an Insulin Secreting Tumour on Small Intestinal 
IR-GLP-1(7-36)amide in NEDH Rats 
Values are expressed as meari±SEM for groups of 6 rats. 
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Insulinoma growth and hyperphagia had no significant influence on total 
extractable IR-GLP-1(7-36)amide or its actual or relative concentration in the small 
intestine. 
4.1.4 Discussion 
The absence of a significant increase in body weight despite hyperphagia and 
hyperinsulinaemia in the insulinoma animals reflects the strong influence of malignant 
disease. By day 13, the tumour itself could account for an average 1.7% of body 
weight (as estimated an autopsy): by day 17, this had risen to 2.4%. At autopsy the 
tumours were observed to be more invasive and not as well encapsulated as previous 
studies of tumour growth would indicate (Flatt et al., 1986). The maximum insulin 
levels previously reported in this colony of rats after insulinoma transplantation was 
40ng/ml (Flats et al., 1987). Much higher values are recorded here. These 
observations together with the fact that the first mortalities occurred on day 13, rather 
than 21-22 days post-transplantation as previously reported (Flats et al., 1987) suggest 
the possibility that the growth characteristics of the tumour are gradually changing. 
Sequential plasma measurements revealed the onset of hypoglycaemia and 
hyperinsulinaemia preceded the hyperphagia that was sustained throughout the rest of 
the study. The hyperphagia was insufficient to maintain normoglycaemia in these 
animals. A two-hour withdrawal of the food supply demonstrated that it was sufficient 
to defer precipitation of a hypoglycaemic coma. Mean plasma IR-GIP levels were 
higher in the insulinoma animals when compared to the control animals from day 10 
post-transplantation onwards, when the hyperinsulinaemia was already established. 
Fasting demonstrated that regular food intake was necessary to maintain the high 
plasma IR-GIP levels. Changes in plasma IR-GIP were not reflected in intestinal 
IR-GIP measurements. It is therefore possible to suggest that the high basal IR-GIP 
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levels seen in the insulinoma-bearing animals are due to the increased, regular, food 
consumption seen in these animals. 
The basic defect in insulinomas is the reduced capacity for insulin storage 
resulting in the exocytosis of immature secretory vesicles. There is therefore a marked 
increase in circulating inactive pro-insulin which unfortunately will cross-react in the 
assay system utilised here. In human insulinomas the amount of circulating pro-insulin 
can rise to up to 80% of circulating insulin levels (Clarke & Hales, 1991). The 
measured basal insulin levels of the insulinoma-bearing rats were excessively high. 
The fact that the animals survived for a period of time with these high levels would 
suggest that a significant proportion of the insulin was inactive pro-insulin and also that 
the animals built up a degree of insulin resistance. The tumour, though self regulating, 
was sensitive to external influences. Fasting revealed that food was contributing to the 
hyperinsulinaemia. Hyperphagia was therefore offsetting the hypoglycaemic effects of 
the insulinoma but also promoting this effect by stimulating insulin secretion. 
Fasting was seen to produce a rapid deterioration in the metabolic state of the 
insulinoma-bearing animals. All provocative tests were necessarily performed in the 
fed state. This fact created experimental problems in the gavage administered tests as it 
is difficult to administer a bolus dose of a solution to an already full stomach. The 
other associated problem was the wide variation in responses to the test solutions seen 
in the animals. This is not simply a difficulty of the protocol of this experiment as the 
same problem has been reported by other workers in both animal and human studies 
(Go et al., 1979; Morgan, 1979). 
In the acute provocative oral and intraperitoneal glucose tests, the insulinoma- 
bearing animals showed a persistent depression of plasma glucose. Maximal 
concentrations achieved corresponded to only modest hyperglycaemic values in spite of 
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the large dose of glucose administered. This is due to the rapid uptake of glucose into 
the tissues stimulated by insulin. 
The greatest stimulus for IR-GIP secretion in the control rats was oral fat and 
the same was true for the insulinoma-bearing rats. The hyperinsulinaemia failed to 
prevent fat stimulated GIP secretion in a hypoglycaemic environment. This finding 
supports the results reported by Go et al. (1979) who similarly found in humans with 
insulinomas that GIP secretion in response to oral fat was not suppressed. IR-GIP 
secretion in response to fat stimulation failed to stimulate insulin secretion because of 
the hypoglycaemic environment. 
The oral glucose tolerance test produced a normal IR-GIP response and insulin 
secretion was stimulated in the insulinoma-bearing animals. The intraperitoneal tests 
revealed that the tumour could not significantly respond to glucose alone, a finding 
supported by the results of Tan et al. (1986). The tumour was however sensitive to 
GIP under the same experimental conditions. Other workers have also demonstrated 
that insulinomas are sensitive to GIP and other secretagogues, namely glucagon-like 
peptide-1 fragments, which utilise the same secondary messenger system (Tan et al., 
1986; Hatt et al., 1990). Specific GIP receptors have been reported in human 
insulinoma plasma membrane (Maletti et al., 1987). 
Intestinal measurements revealed that hyperphagia of 6 days' duration had 
caused a significant increase in relative and actual small intestinal wet weight. A similar 
finding was reported by Conlon and colleagues (1986). However, the insulinoma had 
no effect on the GIP or GLP-1(7-36)amide content of the small intestine. In contrast, 
the small intestinal content of enteroglucagon measured with N and C terminal specific 
glucagon antisera has been reported to be increased in insulinoma-bearing rats 14 days' 
after tumour transplantation (Conlon et al., 1986). The reason for this discrepancy may 
be differences in the specificity of the assay systems employed. 
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4.2 The Effects of Streptozotocin Induced Insulin Deficiency on Basal and 
Nutrient Stimulated Plasma IR-GIP and Intestinal Entero-Endocrine 
Function in Wistar Rats 
4.2.1 Introduction 
Streptozotocin is utilised as an experimental diabetogenic agent, producing 
irreversible damage to pancreatic B cells. Following acute injection there is an initial 
rise in blood sugar in the first 4 hours, followed by hypoglycaemia between 6-12 hours 
and finally permanent hyperglycaemia 24 hours post treatment (Agarwal, 1980). 
Diabetes mellitus induced by high dose streptozotocin is comparable with insulin 
dependent diabetes mellitus (IDDM) in humans (Leslie, 1983). Streptozotocin is an 
acknowledged method for inducing experimental diabetes (Agarwal, 1980; Cooperstein 
& Watkins, 1981). 
As reviewed in Section 1.6.2, there are studies indicating both increased and 
decreased IR-GIP concentrations in IDDM. Animal models of IDDM have not been 
exploited fully in this area of research (Kreymann et al., 1988). The aim of this 
investigation was to establish the function of an endocrine component of the EIA in 
hypoinsulinaemic, streptozotocin induced diabetes in rats. 
4.2.1 Methods 
4.2.1.1 Animals and their Treatment 
Twenty male, Wistar albino rats from the colony maintained at the University of 
Surrey were utilised for this study at approximately 10 weeks of age (170-190g). The 
animals were caged in groups of 3 and housed as described in Section 2.1. Food and 
water were provided ad libitcun as discussed previously, Section 2.1. 
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4.2.1.2 Experimental Procedures 
Insulin deficiency was induced in two groups of fed animals (n=6) by 
intraperitoneal administration of a streptozotocin solution (Mixed Anomers N° S-0130, 
Sigma Chemical Company, Poole, England). The streptozotocin, at a dose of 65mg/kg 
body weight, was solubilised in 0.5M citrate buffer, pH 4.5, immediately prior to 
injection. Untreated age matched rats were used as controls. 
Body weight and food intake were monitored daily. Sequential blood samples 
(200µl) were regularly taken at 0900-1200 hours from the tail tip of non-fasted 
conscious rats for plasma glucose, IR-insulin and IR-GIP analysis. At 16 days post 
streptozotocin administration, the rats were fasted for 18 hours and then subjected to an 
oral glucose tolerance test (51.2kJ/kg body weight) or an oral fat tolerance test 
(51.2kJ/kg body weight). The exact nature of these tests was described in Section 2.2. 
On day 24, the rats were fasted for 18 hours and glucose (51.2kJ/kg body 
weight) or glucose with simultaneous porcine GIP (51.2kJ/kg body weight and 
50pg/kg body weight respectively) were administered by intraperitoneal injection. 
Blood samples were collected for glucose and IR-insulin assay. 
On day 28, the rats were fasted for 18 hours and the oral glucose and oral fat 
tolerance tests were repeated in the presence of exogenous porcine insulin [(2U/ml) per 
kg body weight of monocomponent porcine insulin, Actrapid, Novo Industria, 
Copenhagen, Denmark]. On day 32, the rats were fasted for 18 hours prior to 
administration of porcine insulin either alone, at the same dose as previously used, or 
with porcine GIP (50p /kg body weight). 
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Finally, 38 days after the streptozotocin administration, both the insulin 
deficient and control rats were killed by cervical dislocation and the whole of their small 
intestines excised and treated as described in Section 2.4.2. 
4.2.3 Results 
The streptozotocin-treated rats (STZ) were tail bled 3 days after streptozotocin 
administration and the small sample of whole blood was immediately tested using a 
glucose reagent impregnated strip (Visidex Reagent Strips, Ames Division, Miles 
Laboratories Ltd., Slough). The streptozotocin -treated rats all gave blood glucose 
results in the range 6.7-11 mmol/1, indicating that hyperglycaemia was established. In 
comparison the control rats gave blood glucose values in the range (2.2-3.9 mmol/1). It 
must be noted that the reagent strips were old and it was the difference between the 
streptozotocin-treated and control groups that indicated that the animals were diabetic 
rather than the absolute glucose values. 
4.2.3.1 Body Weight and Food Intake 
The body weight results are shown up to the start of the fasting and provocative 
tests on day 15. Differences between the two groups at the start of the provocative tests 
were maintained until the study was concluded. The results are summarised graphically 
in Figure 4.2.1. 
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Figure 4.2.1 
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The streptozotocin-treated rats failed to gain weight at the same rate as the 
control rats. Repeated measures analysis of variance revealed differences both between 
and within the two groups over time were significant (p<0.01). Within the 
streptozotocin-treated group there was a wide variation in individual body weight gain, 
some animals maintaining their body weight whilst others lost weight over the study 
period. 
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Figure 4.2.2 The Effects of a Single Large Dose of Streptozotocin (65mgikg 
body weight) on Food Intake in Wistar Rats 
Values are expressed as mean±SEM for groups of 6 rats. Streptozotocin 
was administered on day 0. Symbol (**) indicates values significantly 
different from the control group at that time point when assessed by 
Student's unpaired t-test, **=p<0.01. 
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Repeated measures analysis of variance revealed that the differences in food 
intake that developed between the two groups were significant (p<0.01). The 
streptozotocin-treated rats were hyperphagic by day 7 and this hyperphagia persisted 
until the experiment was terminated, although food intake in both groups was disturbed 
by fasting and the acute test procedures. 
Fluid intake was not recorded in the study but showed a remarkable increase 
over the first four days after streptozotocin administration and a high level of intake was 
present throughout the study. 
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4.2.3.2 Basal Levels of Plasma Glucose. IR-Insulin and IR-GIP in 
Streptozotocin Treated Wistar Rats 
The regular sampling and assay of blood revealed the metabolic consequences 
of irreversible damage to the B cells. Repeated measures analysis of variance revealed 
significant changes in plasma glucose, IR-insulin and IR-GIP in the streptozotocin- 
treated group over time (p<0.01). 
Three days after streptozotocin administration plasma IR-insulin levels were 
severely suppressed and correspondingly plasma glucose levels grossly elevated in 
these animals. A significant rise in basal plasma IR-GIP concentrations was observed 
in all streptozotocin-treated animals 7 days after streptozotocin administration. The rise 
in plasma IR-GIP followed the development of the hypoinsulinaemia and 
hyperglycaemia and occurred at the same time that food intake became significantly 
increased in these animals. 
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Figure 4.2.3 
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4.2.3.3 The Effects of Food Withdrawal on Basal Levels of Plasma Glucose. 
IR-Insulin and IR-GIP in Streptozotocin Treated Wistar Rats 
Fasting of the streptozotocin-treated and control rats for 18 hours prior to the 
provocative tests helped to standardise the plasma glucose and IR-GIP levels at the start 
of these tests. The mean results of fasting are summarised in Figure 4.2.4. 
An 18 hour fast lowered the plasma glucose and IR-GIP levels in the 
streptozotocin-treated animals back to levels similar to those of the control rats. Fasting 
also lowered plasma IR-insulin concentrations in both the control and the 
streptozotocin-treated groups, however significant differences between the two groups 
persisted after the 18 hour fast. 
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Figure 4.2.4 Comparison of Plasma Glucose. IR-Insulin and IR-GIP 
Concentration in Fed and Fasted Streptozotocin Treated Diabetic 
Rats and their Controls 
Values are expressed as mean±SEM for 6 observations in fed rats and 12 
observations in fasted rats. Symbol (**) indicates values significantly 
different from the other three values when assessed by one-way analysis of 
variance followed by Scheffe's range test, **=p<0.01. Symbol 0 
indicates a value significantly different from the fasted control value, 
0=p<0.05. 
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4.2.3.4 Acute Nutrient Stimulation Tests 
4.2.3.4.1 Oral Glucose Tolerance Test 
The responses of the streptozotocin diabetic rats, acute insulin-treated 
streptozotocin diabetic rats and the control rats are summarised in Figure 4.2.5. 
Glucose tolerance was severely impaired in the streptozotocin-treated diabetic 
rats. The plasma IR-insulin response of these animals was small and insufficient to 
curtail the rise in plasma glucose. The integrated insulin response of these 
streptozotocin-treated animals was significantly reduced in comparison with the insulin 
response of the control animals, Table 4.2.1. 
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Figure 4.2.5 The Effects of the Oral Administration Of Glucose (51.2kJ/kg 
body weight) on Streptozotocin Treated Wistar Rats with and 
without Acute Insulin Treatment (2UIkgbody weight) 
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Table 4.2.1 Integrated IR-Insulin Response of Streptozotocin Treated Rats to an 
Oral Glucose Challenge (51.2kJ/k body weigbtý 
Values are mean±SEM for groups of 6 rats. Symbol (**) indicates a value 
significantly different from the control value when assessed by Student's unpaired 
t-test, **=p<0.01. Integrated response was calculated as described in Section 2.9. 
Study Group Integrated Plasma IR-Insulin Response 
(0-120 minutes) 
(n ml). hr-1 
Streptozotocin-Treated Rats 32.63 ± 8.66 ** 
Control Rats 117.96 ± 16.95 
The plasma IR-GIP response was significantly elevated above the normal 
response in the streptozotocin-treated animals. Acute administration of insulin to 
streptozotocin-treated animals immediately prior to the glucose load was sufficient to 
normalise their glucose tolerance. Plasma glucose levels in these insulin-treated 
animals actually fell significantly below control values by the end of the experiment. 
Repeated measures analysis of variance revealed highly significant differences in the 
plasma IR-GIP response of the three study groups (p<0.01). Insulin-treated 
streptozotocin diabetic animals' plasma IR-GIP response was normalised at 30 minutes 
and significantly suppressed to below control values at 60 and 120 minutes. 
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4.2.3.4.2 Oral Fat Tolerance Test 
The responses of the streptozotocin diabetic, acute insulin-treated streptozotocin 
diabetic and the control rats are summarised in Figure 4.2.6. 
Oral administration of corn oil did not modify plasma glucose or plasma IR- 
insulin concentrations in either the streptozotocin-treated or the control groups. Plasma 
IR-GIP responses were also similar over the first 60 minutes of the experiment for both 
of these groups. The tendency towards an increased IR-GIP response in the 
streptozotocin-treated animals became significant at 120 minutes. Administration of 
insulin to the streptozotocin-treated rats immediately prior to this test caused a severe 
reduction in plasma glucose levels. The plasma IR-GIP response of insulin-treated 
animals, to oral fat, was normalised. 
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Figure 4.2.6 The Effects of the Oral Administration of Corn Oil Suspension 
(51.2kJ/kg body weight) on Streptozotocin Treated Wistar Rats 
with and without Acute Insulin Treatment (2U/kg body weight) 
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4.2.3.4.3 Intraperitoneal Glucose Challenge Test 
This challenge was performed in the presence and absence of porcine GIP. 
Plasma was collected for glucose and insulin assay only. 
Figure 4.2.7 The Effects of Acute Streptozotocin Treatment in Wistar Rats on 
the Plasma Glucose Response to an Intraperitoneal Glucose 
Challenge (51.2kJ/kg body weight) with and without 
Concomitant Porcine GIP (50Ugý/kg body weight) 
Values are expressed as mearLSEM for groups of 6 rats. Symbol (**) 
indicates a significant difference when assessed by Student's unpaired t-test, 
**=P<0.01. 
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The streptozotocin-treated animals showed an impaired glucose tolerance in 
both experiments when compared with the control animals' response. Comparison 
with the results from the oral glucose challenge revealed that even though the dose of 
glucose used was the same, very different responses were observed both in the test and 
control animals. Glucose tolerance was improved for both the streptozotocin-treated 
and the control rats in the presence of porcine GIP. The improvement was far greater 
in the control animals, as indicated by comparison of integrated glucose responses, 
Table 4.2.2. 
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Figure 4.2.8 The Effects of Acute Streptozotocin Treatment in Wistar Rats on 
the Plasma IR-Insulin Response to an Intraperitoneal Glucose 
Challenge (51.2kJ/kg body weight) with and without 
Concomitant Porcine GIP (50tg/kg body weight) 
Values are expressed as mean±SEM for groups of 6 rats. Symbol (**) 
indicates a significant difference when assessed by Student's unpaired t-test, 
**=p<0.01. 
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Only the control rats showed an increased (28%) insulin response in the 
presence of exogenous GIP. The streptozotocin-treated rats were unable to increase 
their total insulin secretion above that seen with glucose alone. 
Table 4.2.2 Integrated Plasma Glucose and IR-Insulin Responses of Streptozotocin 
Treated Rats to an Tntraperitoneal Glucose Challenge (51.2kJ/kg body 
weight) with and without Concomitant Porcine GIP Administration 
5(O"e/kg body weight) 
Values are mean±SEM for groups of 6 rats. Symbol (**) indicates a value 
significantly different from the control value when assessed by Student's unpaired 
t-test, **=p<0.01. Symbol (00) indicates a value significantly different from the 
response to glucose alone, 00=p<0.01. 
Study Group IP Glucose IP Glucose + 
GIP 
Glucose IR-Insulin Glucose IR-Insulin 
Response Response Response Response 
(0-120 (0-120 (0-120 (0-120 
minutes) minutes) minutes) minutes) 
(mmol/1). hr-1 (ng/ml). hr-1 (mmol/l). hrl (n ml). hrl 
STZ Treated 
Rats 1375±88.0 33.7 15.1 1012±62.8 31.6 9.6 
** ** **, 00 ** 
Control Rats 695.5 ± 35.9 185.9 ± 13.6 416 ± 34.8 237.9 ± 19.4 
00 00 
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Figure 4.2.9 The Effects of Streptozotocin Treatment in \Vistar Rats on the 
Plasma Glucose and IR-GIP Response to an Intraperitoneal 
Insulin Challenge f(2U/ml) per kg body weightl with and 
without Concomitant Porcine GIP (5%Ig/kg_body weight) 
Values are expressed as mean±SEM for groups of 6 rats. Plasma IR-GIP 
was not measured in the group administered exogenous GIP. Symbol (**) 
indicates a significant fall from the zero value in all 3 groups **=p<0.01. 
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minutes of the test (p<0.05). Plasma IR-GIP concentrations were not markedly 
affected by insulin in either the control or streptozotocin diabetic animals. When 
porcine GIP was administered with the insulin to streptozotocin diabetic rats there was 
no significant alteration in the plasma glucose disposal rate from that seen with insulin 
alone. 
4.2.3.5 The Effects of Streptozotocin Induced Insulin Deficiency on Small 
Intestinal Entero-Endocrine Function in Wistar Rats 
Hyperphagia of 31 days' duration preceded the excision of the animals' small 
intestines. The influence of streptozotocin damage to the B cell on intestinal wet weight 
is summarised in Figure 4.2.10. 
Figure 4.2.10 
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indicate a value significantly different from the control value when assessed 
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Actual intestinal weight was significantly increased in the streptozotocin-treated 
animals. Expressed on a body weight basis to take into account the difference in size of 
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the animals, relative intestinal wet weight was significantly increased in the 
streptozotocin-treated animals. 
Figure 4.2.11 The Effects of Streptozotocin Induced Insulin Deficiency on 
Small Intestinal IR-GIP in Wistar Rats 
Values are expressed as mean±SEM for groups of 6 rats. Symbols (**) 
indicate a value significantly different from the control value when assessed 
by Student's unpaired t-test, **=p<0.01. 
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Streptozotocin-induced insulin deficiency with its concomitant hyperphagia 
resulted in an increase in the small intestinal IR-GIP content and maintained the 
concentration of IR-GIP in spite of the large increase in intestinal weight. 
Figure 4.2.12 
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Values are expressed as mean±SEM for groups of 6 rats. Symbols (*, **) 
indicate a value significantly different from the control value when assessed 
by Student's unpaired t-test, *=p<0.05; **=p<0.01. 
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Streptozotocin-induced insulin deficiency and its concomitant by perphagia 
caused a significant increase in both the relative content and concentration of intestinal 
GLP-1(7-36)amide. 
4.2.4 Discussion 
Streptozotocin induces damage to the B cells which is irreversible. The rat is a 
particularly sensitive species to the effects of this compound. Streptozotocin was 
administered in the fed state. There is some evidence that glucose may influence the 
degree of damage to the B cell. The extent of insulin deficiency induced in the treated 
animals was variable even though the streptozotocin was administered on a body 
weight basis. This may possibly be due to the influence of the nutritional state of the 
animals. The resultant condition of the animals is due almost entirely to the affinity of 
streptozotocin for the B cell. The streptozotocin-treated rats exhibited 
hypoinsulinaemia, hyperglycaemia and impaired body weight gain in spite of the 
presence of hyperphagia. Polydipsia was also noted. 
The hyperglycaemia of streptozotocin-induced diabetes is the consequence of 
the excess food consumption and insulin deficiency. Plasma IR-GIP levels were also 
elevated possibly as a result of the increased nutrient intake stimulating K cell secretion. 
The strong relationship between food intake and hyperglycaemia and enhanced K cell 
stimulation was revealed by an 18 hour fast. Fasting reduced the plasma glucose and 
IR-GIP levels back to control values. 
GIP has been shown to stimulate glucagon release under basal conditions 
(Kreymann et al., 1987). This raised the question of whether GIP could contribute to 
the hyperglycaemia through elevation of glucagon concentrations. Administration of 
exogenous porcine GIP in the fasted state with intraperitoneal insulin failed to 
influence the plasma glucose levels of the streptozotocin- treated rats compared with the 
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effects of insulin alone. In the intraperitoneal glucose challenge, the observation that 
exogenous GIP failed to improve the insulin response of the streptozotocin-treated rats 
to an intraperitoneal glucose load illustrates the grossly compromised insulin secretory 
capacity of these animals. 
The oral glucose tolerance test revealed a smaller intolerance to oral rather than 
intraperitoneal glucose. Addition of GIP to the intraperitoneal test revealed that 
differences in IR-GIP secretion could not account for the difference in glucose disposal 
rate, a finding that was also reported by Bailey and colleagues (1986b) in mice. The 
difference was explained by Bailey as most probably due to the rate of intestinal 
absorption and kidney excretion rates. 
The oral fat tolerance test revealed a greater IR-GIP response in both the control 
and streptozotocin-treated animals when compared with the response to the oral glucose 
challenge. The streptozotocin-treated animals had a significantly greater IR-GIP 
response than the control animals. This suggests a loss of negative feedback of insulin 
on IR-GIP. Administration of exogenous insulin with the oral tests returned the 
IR-GIP responses of the streptozotocin-treated animals back to lower control levels. 
This suggests that in these animals insulin has a negative feedback not just on fat 
stimulated IR-GIP secretion but also on glucose stimulated secretion. Administration 
of exogenous insulin in the fasted state failed to modify the plasma IR-GIP levels in 
either streptozotocin-treated or control rats. Insulin therefore only acts under the 
conditions of nutrient stimulation and does not have a direct, solo effect on K cell 
secretion. 
The tissue extraction and analysis revealed that the hyperphagia of the 
streptozotocin-treated animals caused an increase in small intestinal weight. This was 
most likely a secondary effect due to the increased food intake. The intestinal content 
of IR-GIP was significantly increased and the actual concentration of IR-GIP was 
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maintained in spite of the large increase in intestinal weight. The reason for this might 
be speculated to be the increased food intake causing increased nutrient stimulation of 
the K cell. IR-GLP-1(7-36)amide however was significantly increased both in terms of 
content and concentration. This may also be due to increased nutrient stimulation of the 
L cell as a result of the increased food consumption. Alternatively the deficiency of 
insulin in the streptozotocin-treated animals and the loss of body weight in these 
animals means that they were malnourished. Other products of the proglucagon 
hormone have been implicated to be involved in maintenance of the intestinal mucosa. 
Malnutrition may well have caused deleterious changes in the intestine and so the 
increase in intestinal GLP- I (7-36)amide could be a result of an increased demand for 
another product of the same prohormone. Interestingly, Kreymann et al. (1988) 
reported an insignificant increase in small intestinal GLP-1(7-36)amide in 
streptozotocin-diabetic rats 38 days post streptozotocin administration. The reason for 
this discrepancy is unknown. 
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4.3 The Effects of Autoimmune Induced Insulin Deficiency on Intestinal 
Entero-Endocrine Function in the Bio-Breeding (BB) Rat 
4.3.1 Introduction 
In 1974, spontaneous diabetes was discovered in a colony of rats maintained at 
Bio-Breeding Laboratories Ltd. Insulin deficiency in these animals results from 
massive B cell destruction mediated by an autoimmune process. The syndrome 
resembles human IDDM having its onset during the growth years and a similar 
pancreatic pathology (Bone et al., 1991). Features of the syndrome include weight 
loss, glucosuria, hyperglycaemia and hypoinsulinaemia. Unless exogenous insulin is 
administered fatalities result from severe hyperglycaemia and ketoacidosis (Nakhooda 
et al., 1977). 
The intestinal entero-endocrine function of these animals has not been reported. 
The aim of this study was therefore to measure intestinal IR-GIP and 
IR-GLP-1(7-36)amide in these animals. 
4.3.2 Methods 
4.3.2.1 Animals 
Eighteen BB(S) rats (14 males and 4 females) were obtained from Dr. A. Bone, 
Dept. of Medicine, University of Southampton. Animals were nine months of age 
upon arrival at Surrey and so their diabetes was of approximately six months' duration 
at this stage. Animals were caged in four groups of n=4 or 5, and maintained under 
normal laboratory conditions as described in Section 2.1, with food and water supplied 
ad libitum. Food intake and body weight were monitored over 24 hour periods. The 
four groups of rats were allocated different insulin therapies. All test groups received 
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exogenous insulin therapy (Ultratard Insulin, Novo, Denmark) at a dose (ranging from 
2.8-3.8U/day) sufficient to maintain or slightly increase body weight. This was 
achieved by regular monitoring of body weight and both urine and plasma for glucose 
and ketone body concentrations. One group of males (n=4) received their insulin 
therapy daily throughout the experiment. Another group of males (n=4) received the 
same dose of exogenous insulin but their insulin treatment was discontinued 4 days 
prior to the end of the experiment. The group of females (n=4) also had their insulin 
therapy withdrawn 4 days prior to the end of the experiment. The final group of males 
(n=5) who were genotyped as BB(R) i. e. resistant to the autoimmune destruction of the 
B cells, were utilised as a control group. All test groups therefore had been diabetic for 
9 months at the time of death. 
4.3.2.2 Experimental Procedure 
All animals were killed by cervical dislocation after 3 months of experimental 
monitoring. Their small intestines were excised, cleaned of extraneous material and 
treated as described previously (Section 2.4.2). 
This thesis reports only food intake and body weight measurements and the 
GIP and GLP-1(7-36)amide content of the small intestines. Body weight and food 
intake results were monitored in collaboration with Dr. C. Barnett. 
4.3.3 Results 
4.3.3.1 Body Weight, Food Intake and Plasma Glucose 
Mean body weight of the four study groups is summarised in Figure 4.3.1. 
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Figure 4.3.1 
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Body weights were similar in all male groups. Female BB(S) rats weighed 
significantly less than the male rats as expected. 
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Figure 4.3.2 
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The BB rats were clearly not hyperphagic, all test groups consumed 
significantly less food than the control animals. 
Plasma glucose levels were of the order of 14-18mmol/l in the insulin treated 
BB rats, when measured immediately before insulin injection. In those BB rats whose 
insulin therapy was withdrawn the plasma glucose levels rose from 15 to 30 mmol/l by 
day 4, indicating severe hyperglycaemia. 
4.3.3.2 Small Intestinal Entero-Endocrine Function 
Small intestinal measurements were expressed on a g/wet weight basis. 
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Figure 4.3.3 Small Intestinal Wet Weight of BB Rats with and without 
Insulin Therapy 
Values are expressed as a mcan±SEM for groups of 4-5 rats. 
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Actual intestinal wet %\, eights were very similar between the four study groups. 
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Figure 4.3.4 Small Intestinal TR-GTP of BB Rats with and without Insulin 
Thera 
Values are expressed as a mean+SEM for groups of 4-5 rats. Symbol, (0), 
indicates a value significantly different from the female and control study 
groups, 0=p<0.05. 
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Total extractable IR-GIP content of the small intestines from insulin-treated BB 
rats was significantly greater than that of the control animals. The actual concentration 
of IR-GIP in the intestines ., as similar for all four groups. 
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Figure 4.3.5 
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There were large variations in both the content and concentration of 
IR-GLP-1(7-36)amide in the small intestines of all four groups studied. No significant 
differences were observed between the groups. 
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4.3.4 Discussion 
The diabetic syndrome of BB rats has been characterised by N'akhooda et al. 
(1977). These animals show many similarities with juvenile onset diabetes (insulin 
dependent diabetes) in man. In both situations there is a genetic predisposition to 
development of the disease and the onset of visible symptoms is abrupt, often 
corresponding with the time of puberty. Features of this diabetic syndrome in both 
man and rats are weight loss, glycosuria, hyperglycaemia and hypoinsulinaemia with 
subsequent ketoacidosis which often proves fatal unless exogenous insulin is given. In 
the case of both BB rats and man, the onset of the disease is preceded by insulids. In 
clinical studies, only once has IDDM been associated with increased plasma GIP levels 
(Creutzfeldt et al., 1988). More frequently a reduced GIP response to nutrient 
stimulation has been reported in insulin dependent diabetic patients (Reynolds et al., 
1978; Krarup et al., 1983; Krarup et al., 1985). In the BB rats, the only notable 
difference was that rats maintained on insulin therapy exhibited an increase in total 
intestinal GIP. No other changes in small intestinal incretin content were observed. 
BB rats are glucose intolerant due to their severe hypoinsulinaemia. Initially it 
was believed that diabetic BB rats were hyperphagic, as is the case in streptozotocin 
diabetic rats. This however was not the case in the animals studied, due to their 
prolonged insulin treatment, even in those animals from whom the insulin treatment 
was withdrawn hyperphagia had not had time to become established. The chemically 
induced diabetes of streptozotocin diabetic rats therefore shows differences to the 
autoimmune syndrome of BB rats. Streptozotocin diabetes does not produce 
ketoacidosis and so exogenous insulin therapy is not essential to the survival of these 
rats. Small intestinal IR-GIP and IR-GLP-1(7-36)amide content were significantly 
increased in streptozotocin-treated animals contrasting with the lack of change in the BB 
rats. The streptozotocin-created animals were hyperphagic and hypoinsulinaemic (31- 
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36 days duration) in contrast to the normal level of food consumption, insulin treatment 
and short term hypoinsulinaeniia of the BB rats. 
4.4 Conclusions 
All three studies in this Chapter have investigated entero-endocrine function 
under pathologically altered insulin homeostasis conditions. 
The insulinoma study, a condition of severe hyperinsulinaemia, revealed that 
hyperphagia contributed to elevated plasma IR-GIP concentrations. Insulinomas 
suppress normal B cell function in the pancreas by production of excessive levels of 
circulating insulin. The results therefore are believed to be due to the effect of 
exogenous stimuli on the insulinorna directly. The ability of GIP to influence insulin 
secretion from the tumour under very modest hyperglycaemic conditions indicates that 
although the insulinoma is self-governing it can be influenced by external stimuli. 
The streptozotocin and BB rat studies, investigated entero-endocrine function 
under hypoinsulinaemic conditions. The BB rats were not hyperphagic, due to their 
recent or continuing insulin treatment, and there were clear differences between this 
form of spontaneous IDDM1 and that induced experimentally with streptozotocin. The 
streptozotocin study clearly demonstrated that the IR-GIP response of insulin-deficient 
animals to oral nutrients could be suppressed by simultaneously administered 
exogenous insulin. Long-term insulin therapy as administered to the BB rats and the 
absence of hyperphagia produced a normal intestinal IR-GIP and IR-GLP-1(7- 
36)amide concentration in the small intestine. 
In the insulinoma study, hyperphagia of 6 days' duration maintained the small 
intestinal content of IR-GIP and IR-GLP-1 (7 - 36)amide in the presence of a severe 
hyperinsulinaemia which h. is been shown by previous workers to suppress K cell 
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entero-endocrine secretion. Insulin resistance of the K cell may well be responsible for 
this. In the streptozotocin studs, the hyperphagia was not so severe but was 
maintained over a longer period of time (31 days). In these animals, there was an 
increase in IR-GIP and IR-GLP-1(7-36)amide content of the small intestine. This was 
believed to be the result of maintained hyperalimentation and depletion of insulin 
resulting in loss of a suppressive influence on K cell secretion. 
Both the streptozotocin and insulinoma studies support a strong relationship 
between hyperphagia and elevated plasma IR-GIP concentrations. These studies also 
illustrate the important influence of insulin feedback on GIP secreting K cell function 
and possibly also on L cell function. In contrast to human work, insulin appears to 
suppress not only fat stimulated GIP secretion but also carbohydrate stimulated GIP 
secretion in the rat. 
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Chapter 5.0 
ACUTE EFFECTS OF GIP AND GLP-1(7-36)AMIDE ON 
INSULIN SECRETION IN OBESE HYPERGLYCAEMIC 
(oh/oh) MICE 
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5.1 Introduction 
The origins and characteristics of the obese Lob/ob) mouse have been described 
by Bailey et al. (1982). This obese hyperglycaemic syndrome in mice is a recognised 
and widely utilised animal model of non-insulin dependent diabetes mellitus and obesity 
(Bailey & Flatt, 1986). In the homozygous condition, ob/2b mice exhibit an age- 
related development of hyperphagia, obesity, hyperinsulinaemia and hyperglycaemia; 
the severity of the symptoms being influenced by the genetic background. 
The evidence linking diet and the entero-insular axis with obesity-diabetes 
syndromes of rodents was reviewed in Section 1.6.2. Obese mice have been observed 
to exhibit a generalised entero-endocrine cell hyperplasia (Polak et al., 1975; Best et al., 
1977) and exaggerated plasma IR-insulin responses have been observed to GIP, 
glucagon and many other endocrine secretory products of the gastro-intestinal tract 
(Flatt & Bailey, 1982; Flatt & Bailey, 1987; Flatt et al., 1984; Bailey & Flatt, 1984). 
At present the sensitivity of the GLP-1(7-36)amide assay limits its use in 
plasma measurements of small laboratory rodents. Previous chapters have reported 
increased intestinal GLP-] (7-36)amide levels in pregnancy, streptozotocin diabetes and 
during modified neonatal feeding. In contrast, in situations of insulinoma and lactation 
no changes were observed. The parent molecule GLP-1(1-37) has been shown to have 
barely any effects on insulin secretion in ob ob mice (Bailey & Flatt, 1987). The 
rationale for this study was to evaluate the involvement of GLP-1(7-36)amide in the 
entero-insular axis and in the condition of hyperinsulinaemia. For this reason gb/. Qt 
mice were used as the chosen animal model, hyperinsulinaemia being a prominent 
feature of this syndrome. In addition the potency of GLP-1(7-36)amide was compared 
to that of GIP in order to assess whether GLP-1(7-36)amide is likely to be as potent an 
incretin in rodents as the evidence suggests it is in humans (Kreymann et al., 1987). 
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Hyperplasia of intestinal GIP secreting K cells has been reported in. Qb JQb mice 
and appears to result from hyperalimentation and impaired suppression of GIP 
secretion by insulin (Flats et al., 1983a; 1984). Intestinal enteroglucagon as determined 
by non-specific glucagon antisera has also been reported to be increased in J. Qb mice 
(Flatt et al., 1983b, Flatt et al., 1983c). Intestinal entero-endocrine function was 
therefore assessed in this study to compare the changes in GIP secreting K-cell function 
with any changes in GLP-1(7-36)amide secreting L-cell function. 
Pancreatic processing of proglucagon has been investigated in porcine, bovine, 
human and rat pancreas. The C-terminal proglucagon fragment secreted from porcine 
and human pancreas (Orskov et a!., 1986; Q rskov et al., 1987a; Kreymann et al., 
1987), is further processed in rats (Shima et al., 1987; Manaka et al., 1987) giving a 
major peak on gel filtration identical to that of synthetic GLP-1(7-37). The pancreatic 
processing of mob mice was investigated by means of gel filtration to determine if the 
C-terminal proglucagon was processed further in these animals. 
5.2 Methods 
Obese hyperglycaemic Qh oh mice (n=12, body weight 75-85g) from the colony 
maintained at the University of Aston in Birmingham were ländly donated by Dr. C. J. 
Bailey. Homozygous lean mice (±J±, n=1 1, body weight 40-50g) were used as 
controls. The origin of this colony has been described in detail elsewhere (Flatt & 
Bailey, 1981). The Aston colony is a closed non-inbred colony on a mixed genetic 
background. 
Animals upon arrival at Surrey were caged in groups of 5-6, with an equal 
distribution of the sexes between the groups and under the standard conditions outlined 
in Section 2.1. Food intake and body weight were monitored over consecutive 24 hour 
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periods prior to the start of the acute tests. Animals were fasted for 18 hours 
immediately prior to the acute tests. 
In the first provocative test, following an 18 hour fast, porcine GIP(1-42) was 
administered intraperitoneally at a dose of 40µg/kg (8.04mmol/kg) in a vehicle of 
glucose (33.1kJ/kg body weight equivalent to 2g/kg) or saline (0.9% w/v). The 
volume of the dose was standardised at 5ml/kg body weight. Blood samples (50µl) 
were obtained from the cut tail tip of the mice immediately prior to and at 5,15 and 30 
minutes following injection. Determinations of plasma glucose (5µl for obese mice, 
l0µ1 for lean mice) and IR-insulin (10µl for obese mice and 20µl for lean mice), were 
performed on individual samples as described previously (Sections 2.7 and 2.8). 
Seven days later the above experimental procedure was repeated using human 
GLP-1(7-36)amide (Bachem, Switzerland). The human GLP-1(7-36)amide was used 
at an equimolar dose to porcine GIP of 33µg/kg (8.04mmol/kg body weight) in freshly 
prepared saline or glucose vehicles. Finally, seven days later the experiment was 
repeated for a third and final time using fresh batches of the vehicles alone. 
Animals were culled by cervical dislocation. Small intestines and whole 
pancreas were dissected from the animals as described previously and individually 
frozen to -20°C prior to extraction into acid ethanol (Section 2.4.2). Small intestinal 
extracts were subsequently assayed for IR-GIP and IR-GLP-1(7-36)amide as described 
previously (Sections 2.5 and 2.6). 
In addition, pooled small intestinal and pooled pancreatic extracts were dried 
down and reconstituted in gel filtration buffer. These extracts were then subjected to 
gel filtration and the fractions collected, dried down and assayed for IR-GLP-1(7- 
36)amide content using both the G-' and the 2135 antisera. The procedures involved 
were outlined fully in Section 2.6.5. 
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5.3 Results 
5.3.1 Body Weight and Food Tntake 
Mean body weights of lean and ob/ob mice were monitored immediately prior to 
each provocative test. The results are illustrated in Figure 5.1.1. 
Figure 5.1.1 
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It can clearly be seen that the /ob mice were approximately double the weight 
of the lean mice. Within the two groups body weights continued to be static throughout 
the duration of the study. 
Body Weight of Obese Hyperglycaemic (ob/ob) and Lean (+/+) 
Mice 
Values are expressed as mean±SEM for groups of 11-12 mice. Symbol 
(**) indicates values significantly different from +/+ mice when 
assessed by Student's unpaired t-tests, **=p<0.01. 
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Figure 5.1.2 
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The obese mice were significantly hyperphagic throughout the duration of the 
study. 
5.3.2 Acute Provocative Tests 
5.3.2.1 Lean Mice 
The results of administration of the test solutions to lean mice are summarised 
graphically in Figure 5.1.3 and 5.1.4. 
Food Intake of Obese Hyperglvcaemic (ob/ob) and Lean (+/+) 
Mice 
Values are expressed as mean±SEM for groups of 11-12 mice. Symbol 
(**) indicates values significantly different from ±1 mice when assessed by 
Student's unpaired t-test, **=p<0.01. 
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Figure 5.1.3 The Effects of Acute Intraperitoneal Administration of Porcine 
GIP or Human GLP- 1 (7-36)amide in Saline on the Plasma 
Glucose and IR-Insulin Response of Homozygous Lean (+/+) 
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Values are expressed as mean±SEM for groups of 5-6 animals. Saline refers 
to the vehicle only. 
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In a saline vehicle, neither GIP nor GLP-1(7-36)amide had any significant 
effects on glucose homeostasis or plasma insulin concentrations. 
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Figure 5.1.4 The Effects of Acute Intraperitoneal Administration of Porcine 
GIP or Human GLP- I (7-36)amide in Glucose on the Plasma 
Glucose and IR-Insulin Response of Homozygous Lean (+/+) 
Mice 
Values are expressed as mean±SEM for groups of 5-6 animals. Glucose 
refers to the vehicle only. Symbols (*, **) indicate values significantly 
different between the two groups when assessed by one way analysis of 
variance and Duncan's range test, *=p<0.05, **=p<0.01. 
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In a `lucose vehicle, both GIP and GLP-1(7-36)amide were seen to 
significantly improve glucose tolerance and insulin secretion. Integrated plasma 
glucose and IR-insulin responses in the presence of glucose are tabulated in Table 5.1. 
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The integrated results confirm the improvement in glucose tolerance and insulin 
secretion in the presence of GIP and GLP-1(7-36)amide. GIP caused over a four-fold 
increase in mean plasma insulin concentration and GLP-1(7-36)amide a five-fold 
increase. There was no significant difference in the degree of stimulation by the two 
hormones. 
Table 5.1 Integrated Plasma Glucose and IR-Insulin Res nses of Lean 
Homozygous (+/+) Mice in Response to Intraperitoneal Administration 
of Porcine GTP or Human GLP-l(7-36)amide 
Values are expressed as mcan±SEM for groups of 5-6 animals. Symbol (**) 
indicates a value significantly different from the two other groups when assessed by 
one way analysis of variance and Duncan's range test, **=p<0.01. 
Nature of Provocative Test Integrated Plasma Glucose Integrated Plasma IR-Insulin 
Response Response 
(mmol/l). hrl (n ml). hrl 
IP Glucose 53.13 ± 3.88 ** 2.75 ± 1.24 ** 
IP Porcine GIP 
and Glucose 31.46 ± 2.35 11.76 ± 1.80 
IP Human 
GLP-1(7-36)amide 22.27 ± 3.24 14.03 ± 2.05 
and Glucose 
5.3.2.2 Obese Mice 
The results of administration of the test solutions to obese mice are summarised 
graphically in Figure 5.1.5 and 5.1.6. 
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Figure 5.1.5 The Effects of Acute Intraperitoneal Administration of Porcine 
GIP or Human GLP- I (7-36)amide in Saline on the Plasma 
Glucose and IR-Insulin Response of Obese Hyperglycaemic 
(ob/ob) Mice 
Values are expressed as mcan+SEM for groups of 5-6 animals. Saline refers 
to the vehicle only. 
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As with the lean mice, at basal plasma glucose concentrations neither GIP nor 
GLP-1(7-36)amidc had any significant effect on plasma IR-insulin levels. 
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Figure 5.1.6 The Effects of Acute Intraperitoneal Administration of Porcine 
GIP or Human GLP- I (7-36)amide in Glucose on the Plasma 
Glucose and TR-Tnsulin Response of Obese Hyrgl, aemic 
(ob/ob) Mice 
Values are expressed as mean±SEM for groups of 5-6 animals. A symbol 
(*) indicates a value significantly different from the two other groups when 
assessed by one-way analysis of variance and Duncan's range test, *=p<0.05. 
A symbol (p) indicates a value significantly different from the control group 
when assessed by one-way analysis of variance and Duncan's range test, 
o=p<0.05. 
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In the presence of glucose, both GIP and GLP-1 significantly improved glucose 
tolerance and increased insulin secretion. Since both hormones were administered at 
equimolar doses it can be seen from the integrated insulin responses (Table 5.2) that the 
two hormones were approximately equipotent in their actions. Porcine GIP caused an 
average 2.6 fold increase in plasma insulin concentration and GLP-l(7-36)amide a 3.4 
fold increase. 
Table 5.2 Integrated Plasma Glucose and IR-Insulin Responses of Obese (ob/ob) 
Mice in Response to Intraperitoneal Administration of Porcine GIP or 
Human GLP-] (7-36)amide 
Values are expressed as mcan±SEM for groups of 5-6 animals. Symbol (**) 
indicates a value significantly different from the two other groups when assessed by 
one way analysis of variance and Duncan's range test, **=p<0.01. 
Nature of Provocative Test Integrated Plasma Glucose Integrated Plasma IR-Insulin 
Response Response 
(mmol/l). hrl (n ml). hrl 
IP Glucose 83.79 ± 3.37 ** 37.72 ± 9.47 ** 
IP Porcine GIP 
and Glucose 55.21 ± 4.01 97.02 ± 8.00 
IP Human 
GLP-1(7-36)amide 56.92 ± 4.78 127.40 ± 7.47 
and Glucose 
5.3.3 Small Intestinal Entero-Endocrine Function 
Small intestinal wet weights of lean and ob/Qb mice are summarised in Figure 
5.1.7. 
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Figure 5.1.7 
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The actual intestinal wet weight of ob ob mice was significantly increased in 
comparison to the lean animals. 
Small Intestinal Wet Weight of Lean (+/+) and Obese (ob/ob) 
Mice 
Values are expressed as mean±SEM for groups of 8 lean and 10 obese mice. 
Symbol (**) indicates a value significantly different from lean animals when 
assessed by Student's unpaired t-test, **=p<0.01. 
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Figure 5.1.8 Small Intestinal IR-GIP of Lean (+/+) and Obese (ob/ob) Mice 
Values are expressed as mean±SEM for groups of 8 lean and 10 obese mice. Symbol (**) indicates a values significantly different from lean animals 
when assessed by Student's unpaired t-test, **=p<0.01. 
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Obese hyperglycaemic ob gb) mice showed a highly significant increase in 
small intestinal content and concentration of IR-GIP when compared to lean (±J±) mice. 
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Figure 5.1.9 Small Intestinal IR-GLP-1(7-36)amide of Lean (+/+) and Obese 
(ob/ob) Mice 
Values are expressed as mean±SEM for groups of 8 lean and 10 obese mice. 
Symbol (**) indicates a value significantly different from lean animals when 
assessed by Student's unpaired t-test, **=p<0.01. 
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The changes apparent in intestinal IR-GIP in obese mice were also present in 
IR-GLP-1(7-36)amide content and concentration. The actual content and concentration 
of IR-GLP-1(7-36)arnide was si 2nificantly increased in obese mice. 
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5.3.4 Gel Filtration of Obese (ob/ob) Small Intestine and Pancreatic Extracts 
5.3.4.1 Pancreatic Tissue Extracts 
The results of measuring IR-GLP-1(7-36)amide in pancreatic extracts of obese 
mice using both the G2 and the 2135 antisera are illustrated in Figure 5.1.10. 
Figure 5.1.10 
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It can clearly be seen that the non-specific 2135 antiserum detected more IR- 
GLP-1(7-36)amide than the G2 antiserum. Gel filtration of extracts was carried out to 
determine the molecular weight profile of the immunoreactive material. The results of 
the gel filtration are illustrated in Figures 5.1.11 and 5.1.12. 
Total Pancreatic IR-GLP-1(7-36)amide Content of Obese 
(ob/ob) Mice 
Values are expressed as mean±SEM for groups of 10 obese mice. 
IR-GLP-1(7-36)amide content was measured with the G2 and the 2135 
antisera. Symbol (**) indicates a value significantly different from the 
result with the other antiserum when assessed by Student's paired t-test, 
* *=p<0.01. 
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Figure 5.1.11 Gel Filtration Profile of Pancreatic IR-GLP- I (7-36)amide 
Extracts of Obese (ob/ob) Mice With Antiserum 2135 
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Vo is the void volume of the column; CC is the elution maximum of 
cytochrome C; GLP-1(7-36)amide is the elution maximum of a human 
standard preparation previously run through the column; B 12 is the elution 
maximum of cyanocobalamin. Kav was defined in Chapter 2,2.6.6 
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Figure 5.1.12 Gel Filtration Profile of Pancreatic IR-GLP-1(7-36)amide 
Extracts of Obese (ob/ob) Mice With Antiserum G2 
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Vo is the void volume of the column; CC is the elution maximum of 
cytochrome C; GLP-1(7-36)amide is the elution maximum of a human 
standard preparation previously run through the column; B 12 is the elution 
maximum of cyanocobalamin. Kav was defined in Chapter 2,2.6.6. 
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Gel filtration of obese mouse pancreatic extracts by Sephadex G-50 and 
detection of immunoreactivity by Antiserum 2135 revealed a major form of GLP-1-like 
immunoreactivity at the position of synthetic GLP-1(7-36)amide (Kav 0.477-0.489). 
Antiserum G2 also detected an immunoreactive peak at this position, but the peak was 
far smaller than that detected by Antiserum 2135. In addition two minor 
immunoreactive peaks were detected by Antiserum 2135, one being located close to the 
void volume and the other at 0.30 Kav, corresponding to a molecular weight of 
approximately 10000 daltons. Both of these minor peaks were absent from detection 
by Antiserum G2. Basal immunoreactivity levels were also detected to be higher when 
measured by Antiserum 2135. 
5.3.4.2 Small Intestinal Tissue Extracts 
The results of measuring IR-GLP-1(7-36)amide in gel filtration fractions of 
small intestinal extracts of mob mice using both the G2 and the 2135 antisera are 
illustrated in Figures 5.1.13 and 5.1.14. 
Both Antisera 2135 and G2 detected a single peak of immunoreactivity which 
eluted at the position of synthetic GLP-1(7-36)amide. The concentrations of IR-GLP- 
1(7-36)amide detected by the two antisera were very similar. Antisera 2135 detected 
approximately 10-15% more immunoreactivity per fraction tube than antisera G2 
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Figure 5.1.13 Gel Filtration Profile of Small Intestinal IR-GLP-1(7-36)amide 
Extracts of Obese (ob/ob) Mice With Antiserum 2135 
Vo is the void volume of the column; CC is the elution maximum of 
cytochrome C; GLP-1(7-36)amide is the elution maximum of a human 
standard preparation previously run through the column; B12 is the elution 
maximum of cyanocobalamin. Kav was defined in Chapter 2,2.6.6. 
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Figure 5.1.14 Gel Filtration Profile of Small Intestinal IR-GLP-1(7-36)amide 
Extracts of Obese (ob/ob) Mice With Antiserum G2 
Vo is the void volume of the column; CC is the elution maximum of 
cytochrome C; GLP-1(7-36)amide is the elution maximum of a human 
standard preparation previously run through the column; B 12 is the elution 
maximum of cyanocobalamin. Kav was defined in Chapter 2,2.6.6. 
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5.4 Discussion and Conclusions 
The obese hyperglycaemic (ob/ob) mice demonstrated a marked hyperphagia 
and increased body weight in comparison to the lean ( -±/±) control animals. 
Fasting the 
oyQb animals for 18 hours lowered their plasma glucose levels and reduced their 
hyperinsulinaemia but the fast was insufficient to return their plasma insulin and 
glucose profile back to the normal control values. 
The Qob mouse has been shown to exhibit markedly raised plasma GIP 
concentrations (Flatt et al., 1983a). This increase in plasma GIP contributes to the 
hyperinsulinaemia of these animals (Flatt et a!., 1984). An exaggerated insulin 
secretion in response to exogenous porcine GIP has previously been reported in Aston 
mob mice (Flats et al., 1984). 
In the present study, acute administration of GIP or GLP-1(7-36)amide in 
saline revealed the importance of glucose in modulating the responsiveness of the B 
cells to the two hormones. Both GIP and GLP-1(7-36)amide showed no effects on 
glucose homeostasis or insulin secretion in the presence of normoglycaemia. In the 
presence of a modest hyperglycaemia both GIP and GLP-1(7-36)amide were seen to be 
capable of augmenting insulin secretion in both the lean and the &Qb animals. This 
confirms the observation of Fridolf et al. (1990b) that GLP-1(7-36)amide stimulates 
insulin secretion in mice. The potency of both hormones when assessed by the 
magnitude of the increase in insulin stimulation was greatest in the lean animals. Since 
obese mice are known to demonstrate increased circulating levels of GIP possible down 
regulation of the GIP receptors on the B cells or reduced storage capacity for insulin 
within the B cells may account for the reduced sensitivity of their B cells. 
The infusion of exogenous GLP-1(7- 36)amide in man has been shown to elicit 
a greater insulin response than GIP at post prandial concentrations (Kreymann et al., 
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1987). In the present study equimolar doses of GIP and GLP-1(7-36)amide were 
administered at a dose known to produce a physiological increase in plasma IR-GIP 
(Flatt et al., 1984). In man GLP-1(7-36)amide has been shown to be four times as 
potent as GIP on a molar basis (Kreymann et al., 1987). This difference in potency 
was not detectable in this present study. The half life of exogenous GIP inJ. Qh mice 
is known to be short, approximately 15 minutes (Platt et al., 1984) as opposed to 30 
minutes in humans (Kreymann et al., 1987). The half life of GLP-1(7-36)amide in 
humans is known to be significantly shorter than that of GIP (Kreymann et al., 1987). 
In rats the half life of GLP-1(7-36)amide has been reported to be approximately 4.5 
minutes (Ruiz-Grande et al., 1990) supporting a faster turnover of this hormone 
compared with GIP. It can be speculated that the same is also true for &_b mice and 
if this is so increased turnover of GLP-1(7-36)amide may account for the similar 
potency of the two gut hormones. 
Hyperplasia of intestinal mucosa K cells has been noted in mob mice (Flatt et 
al., 1983a). Increased intestinal GIP concentration has also been reported and is 
believed to result in part from hyperalimentation and impaired suppression of GIP 
secretion by insulin (Flats et al., 1983a, 1984). In the present study the increase in 
intestinal GIP content and concentration was noted. Similar results were also obtained 
for IR-GLP-1(7-36)amide and this raises the question of whether the changes in 
IR-GLP-1(7-36)amide are also partially the result of hyperalimentation and impaired 
suppression by insulin or whether another mechanism is operating on the control of L 
cell secretion. The increase in intestinal IR-GLP-1(7-36)amide in ob/, ob mice would 
suggest that the plasma levels of this hormone are also likely to be elevated. Elevated 
plasma levels of GIP and GLP-1(7-36)amide may therefore contribute to the severe 
hyperinsulinaemia of ob/oh mice by stimulation of the B cell. Additionally in rats 
receiving prolonged nutrient infusion, hyperinsulinaemia was promoted in part by a 
suppression of insulin receptor binding, prolonged exogenous GIP infusion further 
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suppressing receptor activity (Baer and Dupre, 1985). This may therefore offer another 
mechanism by which GIP promotes the hyperinsulinaemia of mob mice. 
The A cells of the pancreas and the L cells of the intestinal mucosa have 
identical mRNA's coding for preproglucagon. However it is believed that these cells 
differ in their post translational enzymic processing (Mojsov et al., 1986). It has been 
reported that most of the GLP- I -like immunoreactivity in human pancreatic extracts co- 
elutes with GLP-2-like immunoreactivity in a 10000 dalton molecular weight fragment, 
the so called C-terminal fragment (Uttenthal et al., 1985; George et al., 1985). These 
results have been confirmed in porcine pancreas extracts (Holst et al., 1987). In rats 
however the major fraction of GLP- I -like immunoreactivity elutes at the position of 
synthetic GLP-1(1-37), (Shima et al., 1987; Manaka et al., 1987). The results from 
the gel filtration of oh oh mice pancreatic extracts suggest that these mice, like rats, 
show further processing of the C-terminal fragment. The GLP-1-like immunoreactivity 
measured is mainly of the 1-37 or even the 7-37 form as only a small proportion cross 
reacts with the G2 antisera which is specific for the 36-amide forms of the molecule. 
The function of the GLP-1-like immunoreactivity released from the pancreas is 
unknown but the level is far lower than that detected in the intestine. 
In the intestine of oh oh mice the major form of GLP-1 like immunoreactivity is 
the 36-amide form. Gel filtration of ob 2b intestines and detection of filtration products 
with non-specific glucagon antiserum has revealed that mob mice intestine contains 
large amounts of low molecular weight glucagon like immunoreactivity (GLI) (Flats er 
al., 1983b; Flatt et al., 1983c). This agrees with the high concentration of IR-GLP- 
1(7-36)amide detected in oh Qh intestines in this study. 
In conclusion GLP- l (7- 36)amide is a potent incretin in mice. Demonstration of 
its release in response to nutrient stimulation is therefore necessary to support the 
potential incretin role of endogenous GLP-1(7-36)amide in rodents. 
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Chapter 6.0 
EFFECTS OF VARIOUS SUGARS ON THE IN-VITRO 
SECRETION OF IR-GIP AND IR-GLP-1(7-36)AMIDE 
Page 24, 
6.1 Introduction 
GLP-1(7-36)amide is a polypeptide secreted from mucosal L-cells located 
mainly in the distal small intestine and colon (Kreymann et al., 1988). 
IR-GLP-1(7-36)amide has been shown to be released into the plasma in response to an 
oral glucose load or a mixed meal and to stimulate insulin release (Kreymann et al., 
1987). GLP-1(7-36)amide has therefore been proposed to be an important 
physiological incretin in man (Kreymann et al., 1987). An understanding of the 
mechanism of stimulus-secretion coupling for this hormone is an important step in the 
demonstration that this hormone is a true incretin that qualifies the criteria outlined in 
Section 1.2.3. 
GIP is an acknowledged incretin in man, rodents and other animals (Jones et 
al., 1987; Kreymann et al., 1987; Flatt et al., 1984). It is secreted by mucosal K-cells 
located primarily in the proximal small intestine (Bloom and Polak, 1981). An 
intestinal perfusion technique has revealed that IR-GIP secretion is stimulated by 
actively absorbed sugars (Sykes et al., 1980) and fats (Kwasowski et al., 1985). A 
perfusion technique for the assessment of IR-GLP-1(7-36)amide stimulus-secretion 
coupling would be very difficult in rodents with the very low circulating levels of this 
hormone and the necessarily large amounts of plasma required to measure the hormone. 
A recent intestinal perfusion study in dogs revealed that IR-GLP-1(7-36)amide 
secretion could be stimulated by certain saccharides via a "glucose sensor" without 
absorption of the sugar being a prerequisite for secretion (Shima et al., 1990). 
The aim of this study was to investigate the effects of sugars with different 
mechanisms of absorption on the secretion of GLP-1(7-36)amide by using an in-vitro 
system. As a control measurement, to demonstrate the suitability of this system for 
such a procedure, IR-GIP secretion to the various stimuli was also evaluated. The 
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advantage of an in-vitro system, apart from the cost, is that the prepared intestine is 
completely denervated and so the mechanism of stimulation is solely hormonal. 
6.2 Methods 
6.2.1 Animals and their Housing Conditions 
Fifty two male, Wistar albino rats of 200-250g body weight were used in this 
study. The origin of these animals and their housing conditions were described in 
Section 2.1. All animals were fasted for 18 hours (overnight), prior to the experimental 
procedure. 
6.2.2 Experimental Design 
6.2.2.1 Reagents 
All chemicals unless otherwise stated were obtained from BDH Chemicals Ltd., 
Poole, Dorset. 
Krebs Saline: 
Krebs saline perfusion medium was used as the perfusate and also as a control 
incubation solution. The perfusion fluid consisted of a mixture of 0.154M solutions of 
the following salts mixed in the volumes indicated in the right hand column of Table 
6.1. 
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Table 6.1 The Constituents of Krebs Saline Perfusion Medium 
Salt Solution Volume to be Mixed 
0.154M (0.90%) NaCl 100 
0.154M (1.15%) KCI 4 
0.154M(2.11%) KH-)P04 I 
0.154M (3.82%) MgSO4 1 
0.154M (1.30%) NaHCO3 21 
The perfusion solution was adjusted to pH 7.2-7.3 and gassed with 
95% 02 /5% C02 for a minimum of 20 minutes prior to use. 
Sugar Solutions Tested: 
The following test solutions were freshly prepared in Krebs saline perfusion 
medium; 
1 25mM ß-D-Glucose 
2 25mM f3-D-Galactose 
3 25mM (3-D-Fructose 
4 25mM Lactose 
5 25mM Sucrose 
6 25mM Maltose 
7 10mM ß-D-Glucose 
8 25mM ß-D-Glucose + 2.5mM Phloridzin (Sigma Chemical Co. Ltd., 
London) 
The control was the saline perfusion medium alone. Each sugar solution was 
gassed with 9>1c 02 /5 Tc CO? for a minimum of 10 minutes prior to use. All solutions 
were maintained at approximately 4°C prior to incubation with the evened gut sacs. 
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6.2.2.2 Experimental Procedure 
The evened gut sac technique of Wilson & Wiseman (1954), was used for this 
study. This method was reviewed by Madge (1975). 
Rats were killed by cervical dislocation and the abdomen opened by midline 
incision. The small intestine was cut at the ileo-caecal junction and the final 15cm 
length of distal small intestine removed. The mesentery was carefully removed from 
the intestine. The intestinal lumen was flushed out with 0.9% NaCI to clean it of 
adhering food debris. The isolated intestine was placed in a dish of ice cold gassed 
perfusion medium. All subsequent manipulations of the tissue were carried out at 4°C. 
A 12cm glass rod with an indentation 1cm from one end was gently inserted 
into the intestine and a ligature tied around the intestine to secure it on the indentation in 
the rod. The intestine was carefully everted by rolling the intestine over its invaginated 
end. The evened intestine was then cut just below the ligature and slid off the rod into 
a 50cm3 flask of oxygenated perfusion medium at 4°C. The tissue was allowed to rest 
in this medium for 10 minutes with constant gassing. 
After resting the intestine was cut into two lengths (transversely) in order to 
make two gut sacs. One end of an intestinal length was tied off by a thread ligature 
which was left untrimmed. The sac was lifted by means of this ligature in order to 
drain the contents of the sac. A second ligature was placed around the other end of the 
drained sac. Through a blunt needle fresh perfusion medium was injected until the sac 
was just distended. The ligature was tightened and the needle withdrawn and finally 
the sac was tied off. 
Each prepared sac was checked for leakage and placed in an incubating flask 
(50cm3) containing 25m1s of an incubating sugar solution or 25mis of the perfusion 
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medium alone (control). The flask was gassed for 2 minutes with 95% 02 /517c C02 
and then sealed and mechanically shaken in a preheated water bath (37°C), for the 
required length of time. Table 6.2 gives the range of solutions, the incubation times 
looked at and the number of gut sacs per treatment used in this study. 
Table 6.2 Protocol of the Study 
Incubation Solution Incubation Time Number of Gut Sacs 
Krebs Saline 0 8 
Krebs Saline 15 8 
Krebs Saline 30 8 
25mM Glucose 0 8 
25mM Glucose 15 8 
25mM Glucose 30 8 
10mM Glucose 15 8 
25mM Galactose 15 8 
25mM Fructose 15 8 
25mM Maltose 15 8 
25 mM Sucrose 15 8 
25mM Lactose 15 8 
25mM Glucose +2.5mM 
Phloridzin 
15 8 
An incubation time of zero was achieved by preparing the sac as normal and not 
incubating in the shaking water bath but proceeding with the next step immediately. At 
the end of the incubation the sac was removed from the flask by the handling of the 
untrimmed ligature and washed by dipping through ice-cold perfusion medium. The 
sac was drained and the mucosal surface gently blotted dry on filter paper prior to 
weighing the gut sac. The serosal fluid was then drained out into a test tube by holding 
the sac vertically and snipping it immediately above the bottom ligature. The drained 
sac was then reweighed. Both ligatures and the excess intestinal tissue were cut off as 
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close as possible to the point of tie and the sac reweighed. The sac was then dried at 
80°C overnight and reweighed. For each sac the serosal fluid weight, effective weight 
of fresh tissue and the dry weight of tissue were recorded. The serosal fluid weight 
was obtained from the weight of the intact sac minus the weight of the drained sac. The 
effective weight of fresh tissue was taken as the weight of the sac after removal of the 
ligatures. Dry weight of tissue was taken as the weight of fresh tissue after drying. 
The serosal fluid collected was immediately aliquoted for IR-GLP-1(7-36)amide 
assay (50µ0), and IR-GIP assay (100µl). Aprotinin 600 KIU/ml in phosphate buffer 
(0.04M, pH 6.5), was added to the aliquots for GLP-1(7-36)amide assay. All aliquots 
and excess serosal fluid was immediately frozen to -20°C and maintained at this 
temperature until assayed at a later date. 
6.2.3 RIA Procedure 
With the in-vitro gut sac method substances transferred from the incubating 
(mucosal) fluid to the serosal fluid (the fluid within the sac) cannot be transported 
away. This raised several questions about the suitability of this procedure to look at 
GIP and GLP-1(7-36)amide secretion; would glucose absorbed by the sac interfere 
with the assay procedure and what would be the effects of Krebs saline on the assay? 
Since the GIP and GLP-1(7-36)amide assays are virtually identical in protocol these 
potential problems were investigated in the GLP-1(7-36)amide assay. 
The influence of glucose on the GLP-1(7-36)amide standard curve was 
investigated by preparing a range of GLP-1(7-36)amide standards (50-1500pmolJl), in 
phosphate buffer (pH6.5,0.04M), containing glucose at concentrations of 10mmol/l, 
25mmol/l, 50mmol/l and 100mmo1/1. The result was that standard curves prepared in a 
glucose solution up to 50mmol/1 were indistinguishable from the normal assay standard 
curve. 
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The influence of the perfusion medium on the GLP-1(7-36)amide assay was 
investigated by substituting 100µ1 of perfusion medium for 1OOµ1 of assay buffer in the 
NSB, zero and standards tubes on day 1 of the assay. The perfusion medium 
influenced the assay binding. The standard curves in both the GLP-1(7-36)amide and 
the GIP assays were therefore run in the presence of perfusion medium. In the case of 
the GLP-1(7-36)amide assay 50µl, and in the case of the GIP assay 100µl. In addition 
the GIP assay was run with a human GIP standard rather than a porcine GIP standard 
simply for reasons of availability. The porcine GIP assay has been shown to be unable 
to distinguish human GIP standards from porcine GIP standards (Dr L. M. Morgan 
personal communication). Serial dilutions of a gut sac serosal fluid sample showed 
parallelism with the standard curve obtained. 
6.3 Results 
6.3.1 The Influence of Incubation Time on Gut Sac IR-GIP and 
IR-GLP- l (7-36)amide Content 
The results were calculated on ag dry weight basis. The results are 
summarised in Figures 6.1.1 and 6.1.2. 
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Figure 6.1.1 
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The Effect of Incubation Time on the Content of IR-GIP in the 
Serosal Fluid of Gut Sacs 
Values are mean ± SEM for groups of 8 gut sacs (4 animals). Symbols 
(*, **) indicate values significantly different from the control (saline) values 
at that incubation time, *=p<0.05; **=p<0.01. 
r 
Incubation Time (minutes) 
  Saline Perfusate 
rd 25mM Glucose 
A clear relationship was observed between the length of the incubation period 
and the amount of IR-GIP in the serosal fluid of the gut sacs incubated in a glucose 
solution. The amount of accumulated IR-GIP increased significantly at each incubation 
time for those sacs incubated in a glucose solution, (p<0.01 for 0-15 minutes and 
p<0.05 for 15-30 minutes). An incubation period of 15 minutes was decided upon for 
subsequent experiments. 
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Figure 6.1.2 
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Incubation Time (minutes) 
  Saline Perfusate 
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No clear relationship was observed between the length of the incubation period 
and the content of IR-GLP-1(7-36)amide in the serosal fluid. In addition, there was no 
significant difference in the IR-GLP-1(7-36)amide content of the serosal fluid between 
those sacs incubated in the saline perfusate and those incubated in 25mM glucose. 
6.3.2 The Influence of Various Sugars on Gut Sac IR-GIP Content 
The results are summarised in Figure 6.1.3. 
The Effect of Incubation Time on the Content of 
IR-GLP-1(7-36)amide in the Serosal Fluid of Gut Sacs 
Values are mean ± SEM for groups of 8 gut sacs (4 animals). 
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Figure 6.1.3 The Effects of Various Sugars on Gut Sac IR-GIP Content 
Values are mean ± SEM for groups of 8 gut sacs (4 animals). Symbol 
(**) indicates a value significantly greater than control (saline) values when 
assessed by one-way analysis of variance followed by Duncan's range test, 
**=p<0.01. 
  Krebs Saline 
2.0 10mM Glucose 
® 25mM Glucose 
0 25mM Glucose + 2.5mM Phloridzin 
1.5 Q 25mM Fructose 
'aý   25mM Galactose 
3 
C7 
1.0 
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Only glucose, at both a IOmM and 25mM concentration, and galactose 
significantly increased IR-GIP content of the gut sacs above the control (saline) 
content. The addition of 2.5mM phloridzin to the 25mM glucose solution reduced the 
IR-GIP content of gut sacs incubated in this solution until the IR-GIP content was no 
longer significantly increased above the IR-GIP content of saline incubated sacs. A 
lactose incubation solution had least effect on IR-GIP accumulation in the serosal fluid 
of the gut sac. 
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Figure 6.1.4 The Effects of Various Sugars on Gut Sac 
IR-GLP-I (7-36)amide Content 
Values are mean ± SEM for groups of 8 gut sacs (4 animals). Symbol (0) 
indicates a value significantly greater than the lactose incubated value when 
assessed by one-way analysis of variance followed by Duncan's range test, 
p=p<0.05. 
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The only significant difference was between the lactose and galactose incubated 
sacs. For all the other incubation solutions the amount of IR-GLP-1(7-36)amide in the 
serosal fluid did not vary significantly. Saline stimulated a higher mean accumulation 
of IR-GLP-1(7-36)amide than all the sugars with the exception of galactose. 
Phloridzin had no observable effect on glucose stimulation of IR-GLP- 1(7-36)amide 
secretion. 
6.4 Discussion 
With an in vivo intestinal perfusion system there is an unlimited supply of 
oxygen (from the abdominal aorta) and energy (in the form of blood glucose and 
nutrients absorbed from the intestinal lumen) to the tissues. The in-vitro system is 
limited by the short supply of oxygen and energy available but it does have the 
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advantage that substances transferred across the intestinal wall cannot be transported 
away. The two gastrointestinal hormones of interest to this study were measured in the 
serosal fluid of the gut sacs, not the incubation medium. Any hormone released into 
the mucosal fluid (incubating solution) would be diluted below the detection limit of the 
assays. A study investigating the release of glucagon-like i. mmunoreactivity (GLI), in 
the perfused jejunum of rats demonstrated that the eluate from the lumen of the jejunum 
showed only a slight increase in GLI concentration during the perfusion (W6jcikowski 
et al., 1985). Therefore any loss of IR-GIP or IR-GLP-1(7-36)amide into the 
incubating solution in this study can be assumed to be minimal. 
The gut sacs utilised in this study were prepared from the terminal ileum region 
of the small intestine. The reason for this is that this area of the intestine is a site of 
high GLP-1(7-36)amide concentration as assessed by tissue extraction methods 
(Kreymann et al., 1988). Since the main aim of this study was to investigate 
GLP-1(7-36)amide secretion, an area of tissue rich in this hormone was therefore 
necessary. The main area of distribution of GIP is the duodenum and jejunum but in 
rodents the concentration of extractable IR-GIP is still high in the ileum (Ponter et al., 
1990). This area of tissue was therefore suitable for the assessment of secretion of 
both hormones. 
The stimulus-secretion coupling of the GIP secreting K cell was investigated by 
Sykes and colleagues (1980). They reported that the sugars glucose, galactose, 
maltose and sucrose, among others, could stimulate IR-GIP release. The GIP secreting 
monosaccharides - and in the case of disaccharides their monosaccharide hydrolysis 
products - were concluded to be those sugars that were actively transported across the 
mucosal cell bnish border into the mucosal cell. 
In this present study only glucose and galactose stimulated a significantly 
greater IR-GIP accumulation within the gut sac than saline. Glucose and galactose 
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share a common sodium dependent carrier protein which possesses a lower Km for 
glucose than galactose (Crane, 1965; 1968). Galactose stimulated a greater mean 
increase in IR-GIP accumulation within the gut sac (a 4.7 fold increase), than glucose 
(a 4 fold increase) at the same concentration. This reflects the preference of the carrier 
protein. Active transport is an energy requiring process and this is why the incubation 
period was limited to 15 minutes for the comparison of the various sugars. The 
transport system was aided by the high concentration of sodium ions in the perfusion 
medium. Reducing the concentration of glucose in the incubation medium from 25mM 
to 10mM had no significant effect on the accumulation of IR-GIP in the serosal fluid. 
This suggests that the gut sacs were incubated in an excess glucose solution at 25mM 
and active transport by the carrier system was near saturation at 10mM glucose 
concentration. Phloridzin, a ß-D-glucoside, competitively inhibits the sodium 
dependent carrier protein. Addition of phloridzin to a 25mM glucose solution 
significantly reduced the accumulation of IR-GIP within the serosal fluid. This 
confirms the findings of Sykes et al. (1980). 
Hydrolysis of disaccharides to constituent monosaccharides is carried out by 
specific enzymes situated close to the luminal side of the brush border. The 
observation that insignificant accumulation of IR-GIP occurred in those sacs incubated 
in disaccharide solutions may be explained by the low levels of disaccharidases present 
in the terminal ileum. The optimal location of sugar absorptive capacity being the 
jejunum and proximal ileum (Alpers, 1987). Lactose was the least stimulatory 
disaccharide sugar investigated. This may well be because lactase levels are very low 
in the intestinal mucosa of the mature rat (Rubino et al., 1964). Fructose uses a 
separate carrier system than glucose and the observation that it failed to stimulate IR- 
GIP secretion is in agreement with the findings of Sykes et al. (1980). 
The stimulus-secretion coupling of IR-GLP-1(7-36)amide is not so straight- 
forward. No clear relationship between the incubating sugar solution and the amount 
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of IR-GLP-1(7-36)amide released was observed. The control saline perfusion medium 
appeared to be one of the most successful stimuli for IR-GLP-l(7-36)amide 
accumulation in the serosal fluid. A study investigating GLI release, by a perfusion 
protocol, has reported that hypotonic solutions, especially water, stimulated GLI 
release in the plasma (Matsuyama et al., 1981). If the saline results are ignored in the 
statistical evaluation of the experiment, then galactose stimulated accumulation of 
IR-GLP-1(7-36)amide is significantly greater (p<0.05), than the results obtained with 
25mM glucose or 25mM glucose and phloridzin, or lactose or fructose in the incubation 
medium. Shima and co-workers (1990) reported an increased secretion of GLP-1(7- 
36)amide in the presence of sugars that activated a sensor without being metabolised. 
In the case of disaccharides the disaccharides themselves not their constituent 
monosaccharides stimulated GLP-1(7-36)amide release. However the standard 
deviation of the response of individual animals in this study was extremely large. In 
the present study there was a trend towards an increased IR-GLP-l(7-36)amide 
accumulation with increasing incubation time in the presence of glucose. 
Several earlier workers investigated nutrient stimulation of GLI using non- 
specific N-terminal directed glucagon antisera reported GLI was modulated by a 
number of dietary factors including glucose and fat (Read et al., 1984; Unger et al., 
1968; Ohnede et al., 1975). A study which investigated release of GLI in rats by an 
intestinal perfusion system did show an increase in plasma GLI, as detected by a non- 
specific glucagon antiserum (Wojcikowski et al., 1985). The perfusion was 
continuous and a biphasic GLI response was seen with peak plasma GLI concentration 
being recorded seventy minutes after the start of the perfusion. In contrast, Shima et al. 
(1990), recorded their response over fifteen minute following a ten minute control 
period. The rate of perfusion was not reported by Shima et al. (1990). Glucose failed 
to stimulate GLI release from cultured foetal intestinal cells in the absence of a 
physiological concentration of insulin (Brubaker, 1987). 
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A recent study investigating oral nutrient stimulation of IR-GLP-1(7-36)amide 
secretion in man using the Surrey antisera revealed only a very modest (in the order of 
10 pmol/1) and transient increase in the plasma concentration of GLP-1(7-36)amide. 
The fasting range of the hormone was 14-17pmolfl and following individual nutrient 
stimulation this maximally increased to 23±1.3pmol/1 with fat (Elliott et al., 1991). 
These observations suggest that GIP may represent the principal component of the 
entero-insular axis in both man and animals. 
6.5 Conclusions 
The in-vitro technique of gut sacs largely confirmed the findings of workers 
who had used the intestinal perfusion technique to investigate stimulus-secretion 
coupling for GIP. The results for GLP-1(7-36)amide secretion were however not as 
anticipated. No sugar solution significantly altered the secretion of this hormone from 
the basal secretion seen with saline and the individual variation in accumulated levels in 
the serosal fluid was greater than the variation in GIP. The evidence presented here 
would suggest that possibly GLP-1(7-36)amide is not an incretin and the observation 
by Shima et al. (1990) that metabolism is not necessary for stimulation may suggest 
that a nervous mechanism of stimulation exists. In man, a peak IR-GLP-1(7-36)arnide 
concentration is seen 30 minutes after an oral glucose load (Kreymann et al., 1987). 
For a hormone located mainly in the distal ileum and colon this is a very rapid response 
as transit time through the small intestine in fasted humans is very variable, between 30 
and 140 minutes being required for complete passage through the small intestine 
(Caride et al., 1984). 
To conclude, the in vitro technique of gut sac nutrient incubation failed to 
support the assumption of nutrient directly stimulating IR-GLP-1(7-36)amide release 
from the small intestine. 
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Chapter 7.0 
OVERALL CONCLUSIONS 
Page 2ý9 
As reviewed in Section 1.6, short term dietary change can influence GIP 
secretion in both man and animals. GIP and GLP-1(7-36)amide are considered 
currently to be the most potent incretin candidates. A wide study of the influence of 
hyperphagic conditions on the secretion of these two hormones was therefore 
undertaken in order to gain a better understanding of the relationship between the 
stimulus for and the secretion of these two hormones. In this thesis a range of 
physiological and pathological states have been investigated; all were believed to be 
characterised by a change in dietary consumption. In the case of the BB rats this was 
shown to be a false assumption, but the information obtained in the study of a 
spontaneous diabetic state was of value when compared with the information obtained 
with the chemically induced (streptozotocin) diabetic state. To review, the 
physiological and pathological states investigated were: 
1. Pregnancy, a physiological condition of increased food consumption in rats in 
order to meet the nutritional demands of the growing foetus. 
2. Lactation, a physiological condition of markedly increased food consumption as 
milk must meet all the nutritional requirements of the suckling neonates. 
3. Foetus to neonate transition, a physiological time of sudden changes in nutrient 
supply. The timing of the supply changes from continuous to intermittent, and 
the nature of the supply also changes abruptly. In addition, the increasing 
nutritional requirements for growth have to be met. The ontogeny of GIP and 
GLP-1(7-36)amide at this time were investigated as were the influences of over 
and undernutrition during the suckling period. The importance of the maternal 
nutrient supply to the hyperinsulinaemia of the foetus during late gestation was 
also evaluated. 
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4. Cold acclimation, a physiological condition where food consumption was 
increased to meet the energy requirements of non-shivering thermogenesis. 
5. Insulinoma, a short-term pathological condition that eventually culminates in 
severe hypoglycaemia. An increased food consumption was essential to 
counteract the hyperinsulinaemia and delay the neuroglycopenia. 
6. Streptozotocin-induced diabetes, a pathological chemically induced insulin 
deficient condition where an increased food consumption is a characteristic of 
the hypoinsulinaemic-hyperglycaemic condition. 
7. Spontaneous insulin-dependent diabetes in the BB rat, a pathological condition 
where insulin therapy is essential to survival. 
8. Obese hyperglycaemic (oh Job) mice, a pathological condition characterised by 
hyperinsulinaemia, hyperglycaemia, obesity and an increased food 
consumption. 
In most of these studies a degree of hyperphagia was observed. Hyperphagia 
was defined as a sustained, significant increase in food consumption. The underlying 
cause of the hyperphagia was not investigated. The control of energy balance is 
thought to be regulated by a large number of neural, metabolic and endocrine factors 
(Williams & Bloom, 1989; Williams et al., 1991; Williams, 1990). The hypothalamus 
is involved in the regulation of energy balance and three nutritional balance regulating 
areas have been identified; the ventromedial nucleus, the paraventricular nucleus and the 
lateral hypothalamic area. However, other hypothalamic regions also influence 
appetite. Several neuropeptides which have been located within (but not exclusively) 
the hypothalamus have been identified OVilliams et al., 1991). Interaction of these 
peptides with insulin status in the control of feeding behaviour and energy expenditure 
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has been suggested (Williams et al., 1991). The insulin status of the animals studied in 
this thesis ranged from the excessive levels seen in the insulinoma-bearing animals to 
the deficient levels seen in the streptozotocin diabetic animals. The potential 
hypothalamic changes in the animals studied may therefore be very important in 
regulating the degree of hyperphagia observed which varied from a maximum 1.5-fold 
increase in food consumption in pregnant rats to a 3.6-fold increase in lactating rats. 
Can a relationship between hyperphagia and IR-GIP concentration and IR- 
GLP-1(7-36)amide concentration be confirmed? 
7.1 Hyperphatgia and IR-GIP 
When considering the plasma concentrations of this hormone, with the 
exception of the pregnant animals, an increased basal plasma IR-GIP concentration was 
seen in all hyperphagic animals. Where an 18 hour fast was imposed prior to acute 
tests, this significantly reduced the elevated plasma IR-GIP level towards normal 
(control) fasting values, confirming that hyperphagia is in part responsible for the 
increase in plasma IR-GIP concentration. The absence of a change in plasma IR-GIP 
concentration in the pregnant animals may well be due to the slow development of the 
hyperphagia in these animals. In the physiological studies investigated, the influence of 
hyperphagia on the acute response of IR-GIP to nutrient stimulation was not grossly 
modified during pregnancy or lactation and was only significantly modified in 
overnourished neonatal rats and after two weeks cold acclimation (but only to glucose 
stimulation) returning to normal after five weeks cold acclimation. During neonatal 
overnutrition, the acute IR-GIP response to an oral glucose tolerance test was 
significantly increased but was normalised three weeks after weaning. In the 
pathological states of insulinoma and streptozotocin, an increased plasma IR-GIP 
response to acute nutrient stimulation was again observed. The insulinoma animals 
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showed a heightened IR-GIP response to a corn oil suspension test and the 
streptozotocin animals showed a heightened response to a glucose test. 
A relationship between hyperphagia and intestinal IR-GIP content was also 
present in both physiological and pathological states. Overnutrition during the suckling 
period revealed that after weaning, plasma and intestinal GIP levels were normalised, 
indicating no long-term effect of hyperphagia on entero-endocrine function. In some 
studies IR-GIP content of the small intestine was increased, in other studies only the 
concentration of IR-GIP was altered, and in others both parameters were affected by 
hyperphagia. The insulinoma-bearing animals were the only study population that did 
not show a significant increase in intestinal GIP content or concentration. However, 
these animals were only hyperphagic for six days and so the increased stimulation of 
the K cells was only short term, the very high levels of GIP secretion seen may well 
have limited cellular GIP storage. In addition, these animals had very high circulating 
insulin levels. The lack of effect of hyperphagia on intestinal IR-GIP may therefore be 
due to the rapid progression of these animals to a severe metabolic state. 
It would appear that hyperphagia causes increased stimulation of the entero- 
endocrine K cell, resulting in increased IR-GIP secretion. In the majority of the 
physiological studies, hyperphagia did not overstimulate the K cell as there was no 
heightened acute IR-GIP response to a specific nutrient load in the pregnant, lactating 
and five weeks' cold-acclimated animals. The exceptions to this were the two-week 
cold-acclimated and the overnourished suckling rats. Other workers have suggested 
rapid stimulatory effects of increased food consumption on IR-GIP secretion (Section 
1.6). This may be so, as in the studies reported here, basal plasma IR-GIP levels 
increased rapidly following the onset of the hyperphagia in all but the pregnant animals. 
However the influence of hyperphagia in physiological conditions appears not to be 
permanent. Reversal of the hvperphagia restored normal IR-GIP concentrations in the 
small intestine and plasma of overnourished suckling rats three weeks after weaning. 
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In the hyperphagic pathological states of insulinoma and streptozotocin 
diabetes, the acute IR-GIP response to specific nutrient loads was significantly 
increased. Interpretation of these findings is complicated by the altered insulin status of 
these animals. The influence of insulin status on IR-GIP secretion will be discussed 
later in this Chapter (Section 7.3). 
7.2 Hyperphagia and IR-GLP-1(7-36)amide 
A relationship between hyperphagia and intestinal IR-GLP-1(7-36)amide is not 
so clear. An increased IR-GLP- 1(7-36)amide content and/or concentration of the small 
intestine was observed in the hyperphagic pregnant, lactating, cold acclimated, 
neonatally overnourished and streptozotocin diabetic rats studied. However the 
concentration of small intestinal IR-GLP- 1(7-36)amide was not significantly modified 
during lactation in spite of the presence of a severe hyperphagia. In addition, the 
undernourished suckling neonatal rats also demonstrated a persistent increase in IR- 
GLP-1(7-36)amide content and concentration in their small intestines. Hyperphagia 
and semi-starvation therefore had a similar influence on the entero-endocrine L cell. 
The L cell in addition to secreting GLP-1(7-36)amide also secretes GLP-2, glicentin 
and oxyntornodulin. Glicentin and oxyntomodulin are often referred to by the old 
fashioned term enteroglucagon (Kreymann & Bloom, 1991). Enteroglucagon has been 
implicated in the control of intestinal growth (Section 3.3.4). The increase in IR-GLP- 
1(7-36)amide content of the intestine in undernourished and hyperphagic animals may 
therefore be the result of increased requirements for other hormones sequenced on the 
same proglucagon molecule. Certainly enteroglucagon itself may well be of importance 
during hyperphagia as increased wet weight of the small intestine was noted in all 
hyperphagic animals. 
Chapter 6.0, the in vitro gut sac studs', raised questions about the mechanism of 
stimulus-secretion coupling for GLP-1(7-36)amide. Simple sugars were shown to 
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directly stimulate IR-GIP release from the gut sac but not IR-GLP- 1 (7- 36)amide release 
under the same conditions. The experimental procedure employed was very simple and 
straight forward and it is tentatively concluded that this hormone is not a true incretin 
hormone when assessed by the criteria listed in Table 1.1, Section 1.2.3. To support 
the theory that hyperphagia stimulates increased secretion of an entero-endocrine 
hormone would require the demonstration of nutrient stimulated secretion of the 
hormone. Glucose stimulation had no effect on GLP-1(7-36)amide secretion in vitro; 
further research in this area is required. 
7.3 The Effect of Insulin on IR-GTP Secretion 
The importance of insulin in the control of IR-GIP secretion was revealed by 
the contrasting pathological states of excessive and deficient insulin secretion, namely 
the insulinoma and streptozotocin diabetic studies. The insulinoma study revealed that 
in a hyperinsulinaemic environment fat stimulated acute IR-GIP secretion was 
maintained. This is believed to be due to insulin resistance, down regulation of the K- 
cell receptors for insulin. The streptozotocin study illustrated the contrasting situation 
of a loss of insulin feedback suppression on IR-GIP secretion and synthesis. 
Administration of exogenous insulin with a nutritional stimulus partially restored the 
feedback control on GIP secretion. It was clearly demonstrated that this feedback only 
acted in the presence of post-prandial nutrient levels in plasma. Both glucose and fat 
stimulated GIP secretion were seen to be suppressible by insulin. 
7.4 The Role of GIP and GLP- l (7-3f )amide in the EIA 
Both GIP and GLP-1(7-36)amide were shown to be potent stimulators of 
insulin secretion in mob and lean mice. From this it can be speculated that both are 
potent stimulators of the B-cell in rodents per se. GIP is a true incretin, being 
stimulated by the absorption of nutrients (Section 1.3.5). GLP-1(7-36)amide has also 
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been shown to be stimulated by nutrients (Section 1.4.6); however, doubt has been cast 
on whether the stimulus for secretion is direct nutrient stimulation of the L-cell. As 
discussed previously the importance of insulin feedback on GIP secretion was revealed 
by hypoinsulinaemic diabetes. In this situation increased plasma and intestinal GIP 
levels results from the hyperphagia and loss of insulin suppression. Long-term 
administration of insulin therapy to BB rats showed that intestinal GIP and GLP- 1 (7- 
36)amide concentrations can be normalised. 
In the ontogeny study, a maintained increase in intestinal GIP and GLP-1(7- 
36)amide concentrations was observed in the first few days of extrauterine life. Insulin 
concentrations at the time were low yet normoglycaemia was preserved. The 
importance of direct actions of GIP and GLP-l (7-36)amide in adipose tissue 
metabolism at this time has been suggested. Additional support for this theory comes 
from the increased adiposity of rats overnourished during the suckling phase. The 
importance of this effect during cold acclimation was also suggested as a means of 
providing fuel for brown adipose tissue. Both GIP and GLP-1(7-36)amide were 
shown to have no effect on insulin secretion when administered under normoglycaemic 
conditions to doh and lean mice. However, GIP secretion has been shown to be 
stimulated by oral fat (Kwwwasowski et al., 1986) and more recently GLP-1(7-36)amide 
has also been shown to be stimulated by oral fat alone in man (Elliott et al., 1991). 
The biological actions of these hormones at this time may therefore be on fat 
metabolism. The evidence for a role of these hormones in influencing the degree of 
adiposity is encouraging but is not complete (Sections 1.3.9 and 1.4.9). This proposed 
role for GIP and GLP-1(7-36)amide complements the incretin role of these peptides. 
They are thus capable of controlling plasma glucose post-prandially through 
augmentation of insulin secretion and enhancement of the effect of insulin on fatty acid 
synthesis from glucose. Independently GIP and GLP-1(7-36)amide have been shown 
to have effects on de novo fatty acid synthesis in vitro (Sections 1.3.9 and 1.4.9). 
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Increased nutrient absorption due to hyperphagia has been shown to stimulate 
increased GIP secretion. Fasting revealed the importance of the contribution of 
hyperphagia to the elevated levels of GIP seen in the studies reported here. Intestinal 
GLP-1(7-36)amide concentrations were not always elevated in hyperphagic animals, 
therefore the true nature of the stimulus for secretion is unknown. In the lactating rats 
insulin status was not modified. The rapid glucose disposal, due to milk production 
ensured that the increased plasma GIP levels did not augment insulin secretion. 
The progressive hyperphagia of pregnancy and the physiological 
hyperinsulinaemia counteracted each other to maintain normal plasma GIP levels. In 
the ob/ob mice the hyperinsulinaemia is progressive and more severe. Changes in 
plasma GIP levels have been shown to mirror changes in plasma insulin. Both GIP 
and GLP-1(7-36)amide were potent stimulators of insulin secretion and would 
contribute to the hyperinsulinaemia. Together with insulin, GIP and GLP-1 contribute 
to adipose tissue lipogenesis. In doh mice as the hyperinsulinaemia worsens, insulin 
resistance ensues. Insulin hypersecretion initially feeds back on GIP but as 
hyperinsulinaemia proceeds resistance causes reduced feedback on the K cell, therefore 
perpetuating the cycle of increased food intake, causing increased stimulation of the 
entero-insular axis, and thus promoting increased insulin secretion. Prolonged 
stimulation of adipose tissue by entero-endocrine hormones and insulin leads to excess 
fat deposition i. e. obesity. The importance of these hormones on adipose tissue 
metabolism is an important area of future research and offers an additional mechanism 
by which components of the entero-insular axis may contribute to obesity and non- 
insulin dependent diabetes syndromes. 
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